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Abstract
Sodium-taurocholate co-transporting polypeptide (NTCP, SLC10A1) is the
central bile acid uptake transporter on the basolateral membrane of hepatocytes.
Pharmacological inhibition of NTCP is also being used to treat Hepatitis B and D,
and NTCP transports a variety of drugs including cholesterol-lowering statins.
Despite these crucial roles, limited knowledge exists regarding the effects of
genetic variation in SLC10A1 on bile acid and rosuvastatin transport.
To address this, we characterized activity and protein expression of
genetically variant SLC10A1 in vitro. Seven SLC10A1 genetic variants displayed
robust reductions in NTCP-mediated transport of taurocholic acid and
rosuvastatin and virtually absent NTCP protein expression at the plasma
membrane. In silico tools were employed to assess their performance to predict
deleterious function, however these did not generate robust enough predictions
to replace in vitro studies.
To elucidate the in vivo effects of targeted Slc10a1 disruption, serum bile
acid composition and hepatic, renal, and ileal gene expression were assessed in
male Slc10a1-/- mice. Conjugated serum hypercholanemia and absence of
Oatp1a1 (Slco1a1) mRNA were observed in a subset of Slc10a1-/- mice.
Additional changes in gene mRNA expression and mouse necropsy studies
suggest these mice were unable to thrive as a result of nutrient malabsorption
and disrupted nuclear receptor signaling.
Sex-related differences were evaluated in serum bile acid composition and
hepatic gene expression in Slc10a1-/- mice. No important sex-related differences
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were observed in serum bile acid composition. Oatp1a1 mRNA was nearly
undetectable in both male and female hypercholanemic mice. Sex associated
differences in hepatic gene expression in control and normocholanemic Slc10a1/- mice

were consistent with literature, however these sex-specific differences

were reversed for certain bile acid genes in hypercholanemic mice.
These findings identify novel loss of function genetic variants in the
SLC10A1 gene in vitro. Additionally, our studies in Slc10a1-/- mice provide
evidence of altered nuclear receptor signaling that may have important
implications on bile acid physiology and drug response.

Keywords
Na+-taurocholate co-transporting polypeptide (NTCP), SLC10A1, bile acids, bile
acid transporters, drug transporters, hepatic uptake transport, rosuvastatin,
Slc10a1-/- mice, genetic variation
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Summary for Lay Audience
Bile acids are important in digesting food but also play important roles in
liver and intestinal health. Genetic changes that affect bile acid movement
throughout the gastrointestinal tract can therefore have important implications on
health and disease. Specifically, proteins located on the outer membranes of
cells in the liver and intestine act as entry and exit points for the movement of bile
acids through these tissues. These proteins are called transporters and are also
involved in cellular entry and exit of drugs in clinical use. Of importance to this
thesis is the commonly prescribed drug rosuvastatin, known by its brand name
Crestor™. The ability of rosuvastatin to enter into liver cells is important for its
cholesterol-lower capabilities. Therefore, in addition to transporter proteins being
important in gastrointestinal health, they are important in drug response. Genetic
changes that affect transporters can decrease entry of rosuvastatin into the liver,
thereby reducing its cholesterol-lowering benefit. Moreover, reduced entry of
rosuvastatin into the liver increases rosuvastatin concentrations in the blood,
which has been associated with the adverse drug event of muscle pain and
weakness.
Limited information is available regarding the effects of genetic variation in
a specific transporter protein that is expressed on the outer cellular membrane of
liver cells. This thesis aimed to gather information related to bile acid and drug
transport into the liver by using cellular and mouse models to study the effects of
genetic changes in our transporter protein of interest. Results from these studies
indicate that previously untested genetic changes in our transporter protein result
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in reduced protein function and expression, reflected by reduced transport of a
bile acid and of the drug rosuvastatin. Furthermore, we genetically disrupted our
transporter of interest in mice and identified important changes in bile acid
physiology and signaling. We did not observe any differences in rosuvastatin
concentrations in the blood or livers of these genetically modified mice, as
additional transport proteins are sufficient to maintain rosuvastatin uptake into the
liver.
Taken together, these studies used cellular and animal models to identify
important effects of genetic changes in our transporter protein. Future studies
should assess these effects in humans to determine the overall clinical relevance
of our findings. These studies will help contribute to better understanding bile
acid transport, signaling, and drug response.
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1

Introduction
1.1

The Liver

The liver is responsible for many integral homeostatic and physiological
functions. The liver is a bidirectional biological filter; it filters blood from the portal
circulation as well as from the systemic circulation. The portal vein and the
hepatic artery supply hepatocytes with blood. The portal vein carries nutrients,
xenobiotics, and toxins absorbed from the gastrointestinal tract. The hepatic
artery stems from the lungs and delivers oxygen to the liver. The hepatic veins
are responsible for draining blood from the liver into the inferior vena cava, thus
reaching the systemic circulation (Nagy et al., 2020). The filtration achieved by
the liver is an active process, where many exogenous substances are
metabolized and subsequently excreted. The biliary system is a main component
of the liver. The biliary system removes hydrophobic substances including bile
acids, drugs, and metabolites from hepatocytes by draining into the gallbladder
followed by secretion into the intestinal lumen and fecal excretion (Nagy et al.,
2020). A gross overview of these important structures in hepatic anatomy are
depicted in Figure 1.1.
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Liver

Portal vein
Gallbladder

Hepatic artery

Bile duct
To duodenum
Figure 1.1. Liver anatomy
The liver is a large gastrointestinal organ with a variety of physiological functions. Blood is
delivered to the liver via the hepatic artery and is drained from the liver via the portal vein.
Endogenous and exogenous compounds extracted from the blood into the liver can be excreted
into the bile, which is stored in the gallbladder. Upon hormonal signaling, the contents of the
gallbladder are released into the duodenum, which is the proximal segment of the small intestine.
From the duodenum, compounds can be reabsorbed or will be subject to fecal excretion. This
diagram was adapted from Servier Medical Art (https://smart.servier.com).
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The liver is composed of several cell types including two main epithelial
cells: hepatocytes and bile duct cells, also known as cholangiocytes (Müsch and
Arias, 2020). Hepatocytes are parenchymal cells of the liver and account for 7080% of liver’s mass. Hepatocytes are responsible for bile formation. They secrete
and extract a variety of molecules from the blood into the liver and vice versa
(Müsch and Arias, 2020). Cholangiocytes are located in the biliary tree and form
tube-like networks responsible for draining hepatocytes and maintaining bile flow.
Cholangiocytes are polarized epithelial cells capable of altering bile composition
and mediating hepatic tissue repair.
The functions of hepatocytes and cholangiocytes are dependent on
supporting cells such as the endothelial cells, myofibroblasts, and immune cells.
Sinusoidal endothelial cells are characterized by distinctive fenestrae that
promote exposure of hepatocytes to substances in the blood for extraction. Also
located within the sinusoids are various subpopulations of myofibroblasts which
provide mechanical support and are reservoirs for growth factors, cytokines, and
vitamins. Various immune cells including Kupffer cells, hepatic stellate cells, and
dendritic cells are present within the liver to defend against pathogens and help
filter blood. The organization of the hepatocytes, liver sinusoids with fenestrated
endothelial cells, and afferent and efferent vessels allow for very efficient
exchange between the blood and hepatocytes (Nagy et al., 2020). An overview
of the cellular organization of hepatocytes and cholangiocytes is depicted in
Figure 1.2.

3

Hepatocyte
Kupffer cell
Sinusoid
Bile canaliculus

Cholangiocyte
Branch of
hepatic artery
Bile duct

Branch of portal vein

Figure 1.2. Organization of hepatocytes and cholangiocytes within the liver
Hepatocytes are the most prominent functional cells of the liver and conduct a variety of
metabolic functions. The liver sinusoids provide blood to hepatocytes. Sinusoids are vascular
channels that receive blood from branches of the hepatic artery. Hepatocytes are in direct contact
with endothelial cells that line the liver sinusoids, and this proximity to blood allows movement of
compounds from the blood into hepatocytes and vice versa. The portal vein drains blood from the
liver. Bile canaliculi are important, tube-like structures that collect bile into the bile ducts.
Cholangiocytes are the main cell types within the bile canaliculi and bile ducts. Kupffer cells are
immune cells within the liver. This diagram was adapted from Servier Medical Art
(https://smart.servier.com).
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1.2

Organization, architecture, and cell biology of

hepatocytes
Hepatocytes fulfill the majority of liver functions, including metabolism of
macronutrients and drugs, as well as cholesterol and bile acid synthesis and
excretion (Trefts et al., 2017). Hepatocytes are large, polarized polygon-shaped
cells with several distinct surfaces. The hepatocyte is characterized by three
separate membrane regions: the basolateral domain, the lateral domain, and the
bile canalicular domain. The basolateral domains of portal hepatocytes are in
contact with the vasculature of the liver sinusoids, allowing for exchange of
endogenous and exogenous compounds between the blood and hepatocytes.
The lateral domain is the least complex and contains a variety of junction
proteins for cell-cell adherence and gap junctions that permit the intercellular
transfer of small molecules and communication signals (Nagy et al., 2020). The
lateral membrane domains of adjacent hepatocytes are discontinuous to allow
the formation of a bile canalicular domain. Canalicular domains connect a
network of hepatocytes to form bile canaliculi, which are small tube-like
structures that empty bile from hepatocytes into a series of progressively larger
ducts (Müsch and Arias, 2020). The bile canalicular membrane domains contain
transport proteins that actively secrete bile acids, phospholipids, cholesterol,
drugs, and metabolites from hepatocytes into the biliary network.
Microtubules, microfilaments, and motor proteins are essential for cell
polarity and protein trafficking; their regulation dictates protein sorting and
delivery to apical and basolateral domains (Kumar et al., 2020). The selective
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absorption and secretion exhibited by hepatocytes is dependent on cell polarity.
Although hepatocytes exhibit a unique multipolar phenotype, they express similar
polarization complexes observed in monopolar epithelial cells. Therefore, these
same polarization mechanisms may be regulated in a distinctive manner within
hepatocytes (Müsch and Arias, 2020).

1.3

Physiological roles of bile acids

Bile acids, cholesterol and phospholipids are key components of bile. The
biosynthesis of bile acids represents a major mechanism of cholesterol turnover,
and secretion of bile acids from hepatocytes regulates bile flow. The most wellknown role of bile acids is to facilitate digestion in the gut. They also regulate
metabolic functions through nuclear receptor and G protein-coupled receptormediated signaling in the enterohepatic system. Bile acids are amphipathic
molecules and contain hydrophobic and hydrophilic faces. The hydrophobic
region aids in cholesterol and fat emulsification in the gut, assisting digestive
enzymes in nutrient extraction for subsequent absorption. The hydrophilic region
increases bile acid solubility (de Aguiar Vallim et al., 2013).
Bile acids undergo enterohepatic circulation, which is an efficient type of
recycling. A postprandial rise in fat and amino acids within the intestinal lumen
stimulates duodenal endocrine cells to secrete the hormone cholecystokinin.
Cholecystokinin signals to contract the smooth muscle cells surrounding the
gallbladder, causing release of gallbladder contents. Cholecystokinin is also
responsible for relaxation of the sphincter of Oddi, which controls bile release
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from bile ducts into the duodenum (Otsuki, 2000). Following their secretion into
the intestine, most bile acids are actively reabsorbed in the terminal ileum and
secreted into the systemic circulation for redistribution to the liver and uptake into
hepatocytes. About 95% of the bile acid pool is recycled through enterohepatic
circulation, and the rest is excreted (Li and Chiang, 2020).

1.4

Primary bile acid synthesis

In hepatocytes, cholesterol is catabolized in a multistep fashion which
includes hydroxylation and reduction to form bile acids. There are two main
pathways of bile acid production: the classical pathway and the alternative
pathway (Li and Chiang, 2020).
The rate-limiting and initiating enzyme in the classical pathway is
cholesterol 7α-hydroxylase (CYP7A1), found in the endoplasmic reticulum of
hepatocytes. CYP7A1 catalyzes hydroxylation of cholesterol at the C-7α position
to form 7α-hydroxycholesterol (Myant and Mitropoulos, 1977). Subsequently, one
of two primary bile acids, cholic acid (CA) or chenodeoxycholic acid (CDCA), will
be produced. Production of CA is mediated by sequential hydroxylation via
microsomal sterol 12α‐hydroxylase (CYP8B1) and mitochondrial sterol 27hydroxylase (CYP27A1). Alternatively, CYP27A1 will produce CDCA when
CYP8B1 metabolism does not occur. The activity of CYP8B1 therefore influences
the ratio of CA:CDCA in the bile acid pool, where increased CYP8B1 activity will
yield increased concentrations of CA. Within peroxisomes, CA and CDCA will be
conjugated to taurine or glycine prior to secretion across the bile canalicular
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membrane. The alternative bile acid synthesis pathway is achieved by
hydroxylation through CYP27A1 and oxysterol and sterol 7α-hydroxylase
(CYP7B1). The key enzymes involved in the alternative and classical pathways
of bile acid synthesis are presented in Figure 1.3.
Of note, the classical pathway is under tight control by bile acid-mediated
nuclear receptor signaling, whereas the alternative pathway is constitutively
active, independent of bile acid signaling. The alternative pathway is especially
important in neonates which do not express CYP7A1 until weaning, whereas the
classical pathway is the predominant cascade for bile acid production in adults
(Li and Chiang, 2020).
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Figure 1.3. Primary bile acid synthesis
Within hepatocytes, the classical primary bile acid synthetic pathway is initiated in liver
microsomes of the endoplasmic reticulum, where cholesterol 7α hydroxylase (CYP7A1)
hydroxylates cholesterol to form 7α-hydroxycholesterol. Hydroxylation by microsomal sterol 12αhydroxylase (CYP8B1) and subsequently mitochondrial CYP27A1 will yield cholic acid (CA),
whereas metabolism by CYP27A1, bypassing CYP8B1, yields chenodeoxycholic acid (CDCA).
Within peroxisomes, bile acid CoA:amino acid N-acyltransferase (BAAT) amidates CA and CDCA
with glycine or taurine to form glycocholic acid (GCA) taurocholic acid (TCA),
glycochenodeoxycholic acid (GCDCA) and taurochenodeoxycholic acid (TCDCA). The alternative
pathway is independent of CYP7A1 and mainly produces CDCA through CYP27A1 followed by
CYP7B1.
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1.5

Secondary bile acid synthesis

Subsequent to bile release into the small intestine, primary bile acids are
modified by gut microbiota to produce secondary bile acids. Bile salt hydrolase
hydrolyzes the amide bond that links taurine or glycine to the bile acid, thus
reverting conjugated bile acids to their unconjugated forms. In the colon,
hydroxysteroid dehydrogenase partially dehydroxylates unconjugated CA and
CDCA to form secondary bile acids deoxycholic acid (DCA) and lithocholic acid
(LCA), respectively (Ridlon et al., 2006). The most abundant secondary bile acid
is DCA, whereas LCA is only present in trace amounts. Secondary bile acid
synthesis is presented in Figure 1.4.
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Figure 1.4. Formation of secondary bile acids
Conjugated primary bile acids GCA, TCA, GCDCA, and TCDCA that were synthesized in the liver
are released into the small intestine. Within the intestine, microbiota produce bacterial enzymes
called bile salt hydrolases (BSHs), which deconjugate primary bile acids to their unconjugated
forms, CA and CDCA. Microbiota also produce hydroxysteroid dehydrogenases (HSDHs) which
partially dehydroxylate unconjugated primary bile acids to form the secondary bile acids
deoxycholic acid (DCA), lithocholic acid (LCA) and ursodeoxycholic acid (UDCA). Deoxycholic
acid is produced from cholic acid, and LCA and UDCA are formed from CDCA.
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1.6

Bile acid detoxification

Bile acid detoxification occurs through sulfation and hydroxylation within
hepatocytes. Metabolism via sulfation and/or hydroxylation increases the
hydrophilicity of bile acids and promotes their excretion. The majority of bile acids
excreted in the feces are mainly unconjugated, as bacterial hydrolases
deconjugate bile acids in the colon. Although minimal urinary bile acid excretion
occurs under physiological conditions, sulfation is upregulated under high bile
acid conditions and promotes urinary excretion (Li and Chiang, 2020). Under
physiological conditions, glucuronidation is a negligible mechanism of bile acid
detoxification. However, glucuronidation may become a more prominent mode of
bile acid metabolism and excretion during cholestasis (Javitt, 2002).

1.7

Transporters maintain enterohepatic circulation of

bile acids
The vast majority of bile acid circulation through the enterohepatic system
is dependent on transporter proteins expressed at the plasma membranes of
hepatocytes and enterocytes. Two types of transporters are involved in this
process: solute carrier transporters and ATP-binding cassette (ABC)
transporters. Solute carrier (SLC) transporters can be classified as either Na+dependent or Na+-independent. ABC transporters utilize ATP hydrolysis to
harness energy for the translocation of a substrate against its concentration
gradient (Giacomini et al., 2010).
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The secretion of bile acids from hepatocytes into the bile canaliculi is
mediated by ABC transporters. The major canalicular membrane transporter for
canalicular bile acid efflux is the bile salt export pump (BSEP, encoded by the
ABCB11 gene). Also on the canalicular membrane, multidrug resistanceassociated protein 2 (MRP2, encoded by the ABCC2 gene) can transport bile
acids but plays a more important role in sulfated bile acid export (Dawson et al.,
2009).
As bile acids flow through the intestine, active reuptake occurs in the ileum
through the apical sodium-dependent bile acid transporter (ASBT, encoded by
the SLC10A2 gene), which is a Na+-dependent SLC transporter. On the
basolateral membrane of enterocytes, efflux of bile acids into portal blood is
facilitated by the Na+-independent SLC transporter heterodimer organic solute
transporter αβ (OSTα and OSTβ, encoded by the SLC51A and SLC51B genes,
respectively) and the ABC transporter, multidrug resistance-associated protein 3
(MRP3, encoded by gene ABCC3) (Dawson et al., 2009).
Once secreted into the blood, bile acids recirculate to the liver where they
are taken up at the basolateral membrane of hepatocytes. The central hepatic
bile acid uptake transporter is the SLC transporter Na+-taurocholate cotransporting polypeptide (NTCP, encoded by the SLC10A1 gene), which
preferentially transports conjugated bile acids. Additionally, organic anion
transporting polypeptides (OATPs, gene family SLCO) are important Na+independent SLC bile acid uptake transporters on the basolateral membranes of
hepatocytes. Organic anion transporting polypeptides involved in bile acid uptake

13

from the sinusoidal blood into hepatocytes are OATP1B1 (encoded by the
SLCO1B1 gene) and OATP1B3 (encoded by the SLCO1B3 gene) (Dawson et
al., 2009).
The aforementioned transporters maintain enterohepatic circulation under
physiological conditions. However, under cholestatic conditions, altered nuclear
receptor signaling promotes hepatocellular bile acid efflux to prevent toxic bile
acid buildup. In this case, hepatic expression of bile acid transporters OSTαβ and
multidrug resistance-associated protein 4 (MRP4, encoded by gene ABCC4) 4
(MRP3 and MRP4, genes ABCC3 and ABCC4) at the basolateral membrane of
hepatocytes, which are not typically abundant in liver under physiological
conditions, are induced (Halilbasic et al., 2013). A graphical depiction of bile acid
transporters in the enterohepatic system is presented in Figure 1.5.

14

Figure 1.5. Transporters in bile acid enterohepatic circulation
Uptake transporters are shaded light blue and efflux transporters are shaded pink. Subsequent to
bile acid synthesis and conjugation in hepatocytes, bile acids are secreted into bile canaliculi by
ATP-dependent transporters, bile salt export pump (BSEP) and multidrug resistance-associated
protein 2 (MRP2). Bile acids concentrate in the gallbladder, are released upon hormonal signaling
to aid in emulsification of dietary lipids and are largely reabsorbed in the terminal ileocytes by the
apical sodium-dependent bile acid transporter (ASBT). Bile acids are secreted into portal
circulation by organic solute transporters (OST)α/β and MRP3. Bile acids can then recirculate to
the liver for uptake by Na+-taurocholate co-transporting polypeptide (NTCP) or the sodiumindependent organic anion transporting polypeptides OATP1B1 and OATP1B3 on the basolateral
membranes of hepatocytes. Hepatic efflux of bile acids into sinusoidal blood is mediated by
MRP3. Under pathological conditions including hepatic cholestasis, MRP4 and OSTαβ are
upregulated to aid in secreting bile acids from hepatocytes into the blood.
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1.8

Pathology associated with disruption of bile acid

transport and synthesis
Bile acid synthesis and transport are tightly regulated to avoid bile acid
accumulation; when this homeostasis is disrupted, cholestasis can ensue.
Cholestasis is a chronic liver condition characterized by bile acid accumulation in
the liver and/or elevated bile acids in the serum. It is characterized by decreased
bile flow and can result from genetic variation in bile acid transporters, biliary
obstruction, or autoimmune-mediated destruction of bile ducts. Cholestasis can
progress to fibrosis, cirrhosis, and liver failure. Chronic cholestasis is a common
cause of liver transplantation and has been associated with increased incidences
of hepatocellular and cholangiocellular carcinomas (Wikström Shemer et al.,
2015).
Dysregulation of bile acid signaling can also mediate serum
hypercholanemia. Hypercholanemia is characterized by excessive accumulation
of bile acids in the blood, causing itching and fat malabsorption, and can be an
indicator of liver pathology (Neale et al., 1971; Luo et al., 2018). Genetic variation
that alters bile acid transport or synthesis can result in serum hypercholanemia
(Carlton et al., 2003; Vaz et al., 2015; Deng et al., 2016). Implications of serum
hypercholanemia include increased incidence of cholelithiasis, known as
gallstone formation, due to impeded bile flow (Fisher and Yousef, 1973).
Elevated serum bile acids may also be indicative of decreased intestinal bile
acids, which is linked to fat malabsorption, decreased absorption of fat-soluble
vitamins, and failure to thrive (Carlton et al., 2003).
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1.9

Nuclear receptors in bile acid homeostasis

Nuclear receptors are key transcription factors that modify the expression
of their target genes. Nuclear receptors are generally activated upon binding of
ligands or through post-translational modification and recruitment of
transcriptional co-factors. A variety of nuclear receptors including farnesoid X
receptor (FXR, encoded by gene NR1H4), pregnane X receptor (PXR, encoded
by gene NR1I2), vitamin D receptor (VDR, encoded by gene NR1I1), and
constitutive androstane receptor (CAR, encoded by gene NR1I3) are directly or
indirectly responsive to bile acids and initiate signaling to regulate bile acid
synthesis, transport, and detoxification (Claudel and Trauner, 2020). These
pathways are not only involved in bile acid metabolism but also drug metabolism,
and their regulation contribute to overall liver functions. Dysregulation of these
nuclear receptors subsequent to altered bile acid signaling can result in liver
pathology or adverse drug events (Li and Chiang, 2013). A brief overview of the
interplay between bile acids, nuclear receptors, and liver functions including bile
acid and drug metabolism is presented in Figure 1.6.
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Figure 1.6. Interplay between bile acids, nuclear receptor regulation, and bile acid and
drug metabolism.
Bile acids are ligands for nuclear receptors. Bile acids bind directly to FXR, PXR and VDR, and
indirectly to CAR, to elicit nuclear receptor signaling that regulates the various phases of drug
metabolism and bile acid metabolism. Moreover, the nuclear receptor target genes involved in
these processes also regulate processes that control downstream nuclear receptor signaling.
This dynamic process is involved in the major metabolic functions of the liver, including lipid,
glucose, and energy metabolism and drug disposition. Ultimately, dysregulation of these
processes can affect liver health, contributing to disease such as cholestatic insult or metabolic
conditions, and can affect the handling and response to drugs. Adapter from Li & Chiang (Li and
Chiang, 2013).
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Farnesoid X receptor is mainly expressed in hepatocytes and enterocytes
(Li and Li, 2017), and bile acids are the central ligands for FXR activation
(Makishima et al., 1999). Farnesoid X receptor can function as a heterodimer
with retinoic acid receptor α (RXRα, gene NR2B1). Upon activation, the FXRRXRα complex binds to FXR response elements to induce transcription of target
genes (Claudel and Trauner, 2020). Farnesoid X Receptor can also bind to DNA
as a monomer to either repress (Claudel et al., 2002) or stimulate (Barbier et al.,
2003) gene transcription. FXR response elements are typically located within two
kilobases of transcriptional start sites of genes involved in fatty acid, lipid, steroid,
and bile acid metabolism (Chong et al., 2010). Genetic defects in FXR are
associated with a severe form of inherited cholestasis known as progressive
familial intrahepatic cholestasis (Gomez-Ospina et al., 2016), and can predispose
pregnant women to intrahepatic cholestasis of pregnancy (Van Mil et al., 2007).
Similar to FXR, nuclear receptors PXR, CAR, and VDR are expressed in
the liver and intestine and form heterodimers with RXR (Baes et al., 1994; Jones
et al., 1998; Kliewer et al., 1998). Bile acid structure dictates their efficacy for
nuclear receptor activation. The most potent activator of FXR is CDCA, followed
by DCA, CA, and LCA. The most efficacious ligand for the activation of both
PXR and VDR is LCA. Bile acids do not directly bind to or activate CAR. As the
master regulator of bile acid homeostasis, FXR is imperative in the regulation of
bile acid synthesis, oxidation, conjugation, and transport. Additionally, PXR,
CAR, and VDR play important roles in bile acid oxidation (phase I metabolism),
conjugation (phase II metabolism), and transport (phase III metabolism) (Li and
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Chiang, 2013). A summary of how FXR activates its target genes is presented in
Figure 1.7. Specific FXR, PXR, VDR, and CAR target genes of relevance to this
thesis are presented in Table 1.1.
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Figure 1.7. FXR binds to response elements in target genes to induce their transcription
When FXR is activated by bile acids, it can heterodimerize or act as a monomer to bind DNA
response elements upstream of its target genes. The response element for FXR is an inverted
nucleotide repeat. Once FXR binds to this recognition sequence, transcriptional activator proteins
will initiate the FXR response by recruiting and stabilizing transcriptional machinery so that RNA
polymerase II can enhance the transcription of the target gene.
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Table 1.1. Nuclear receptors and their target bile acid-related genes
Human
Gene
SLCO1B1
SLCO1B3

Human
Protein
OATP1B1
OATP1B3

NTCP

Mouse
Gene
Slco1b2
Slco1b2
Slco1a1
Slco1a4
Slc10a1

Mouse
Protein
OATP1B2
OATP1B2
OATP1A1
OATP1A4
NTCP

Tissue(s)
Liver
Liver
Liver
Liver
Liver

SLC10A1
ABCC3
ABCC4
SLC51A/B

MRP3
MRP4
OSTαβ

Abcc3
Abcc4
Slc51a/b

MRP3
MRP4
OSTαβ

ABCB11
ABCC2

BSEP
MRP2

Abcb11
Abcc2

SLC10A2

ASBT

CYP7A1
NR0B2
FGF19

CYP7A1
SHP
FGF19

Membrane
localization
Basolateral
Basolateral
Basolateral
Basolateral
Basolateral

Function
Uptake
Uptake
Uptake
Uptake
Uptake

Major regulatory
nuclear receptor
FXR, SHP, HNF4α
FXR, SHP, HNF4α
PXR, CAR
PXR, CAR
FXR, SHP, HNF4α

Liver, intestine Basolateral
Liver
Basolateral
Liver, Intestine Basolateral

Efflux
Efflux
Efflux

CAR, PXR, VDR
CAR
FXR

BSEP
MRP2

Liver
Liver

Canalicular
Canalicular

Efflux
Efflux

FXR, CAR, PXR

Slc10a2

ASBT

Intestine

Uptake

FXR, SHP

Cyp7a1
Nr0b2
Fgf15

CYP7A1
SHP
FGF15

Hepatic
Hepatic
Intestine, liver

Apical
Endoplasmic
reticulum
Cytosolic
Cytosolic

Synthesis
Regulation
Regulation

FXR, SHP
FXR
FXR, SHP

Adapted from Li & Chiang and Halilbasic et al. (Halilbasic et al., 2013; Li and Chiang, 2013).
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The nuclear receptor regulation of bile acid transport is a complex
process. In addition to the nuclear receptors already described, the nuclear
receptors peroxisome proliferator activator α (PPARα, encoded by gene NR1C1),
liver X receptor (LXR, encoded by gene NR1H3), glucocorticoid receptor (GR,
encoded by gene NR3C1), estrogen receptor, and hepatocyte nuclear factors 1α,
3β, and 4α (HNF1α, HNF3β, and HNF4α , encoded by genes HNF1A, HNF3B,
and NR2A1, respectively) contribute to regulating bile acid transporters to
maintain enterohepatic circulation (Halilbasic et al., 2013).

1.10

FXR regulation of bile acid synthesis and transport

Bile acid synthesis is largely controlled by CYP7A1. The CYP7A1
promoter contains two bile acid response elements (BAREs), BARE-1 and
BARE-2 which are regulated by transcription factors. In humans and mice,
transcriptional coactivators HNF4α and liver-related homolog 1 (LRH-1, encoded
by gene NR5A2) bind to BARE-1 to induce CYP7A1. Hepatocyte nuclear factor
4α and LRH-1 are thought to be constitutively active in hepatocytes to control
basal expression of CYP7A1. Bile acids mediate negative feedback regulation of
their own synthesis. Through binding to HNF4α and LRH-1, bile acids prevent
CYP7A1 transcription. However, the fundamental mechanism of CYP7A1
repression is attributed to bile acid-mediated activation FXR.
There are two major inhibitory pathways that act through FXR to repress
CYP7A1 when intracellular concentrations of bile acids rise (Li and Chiang,
2020). One pathway originates in enterocytes, where bile acids directly bind to
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FXR, and activated FXR binds an FXR response element in the fibroblast growth
factor 19 (FGF19) gene. The mouse ortholog of FGF19 is Fgf15. Fibroblast
Growth Factor 19/FGF15 is released from enterocytes for circulation to the liver,
where it binds to the fibroblast growth factor receptor 4 (FGFR4) located on the
basolateral membrane of hepatocytes. This event recruits the co-receptor βKlotho, and the activated FGFR4-β-Klotho complex initiates a cascade to signal
through c‐Jun N terminal kinase (Holt et al., 2003) and induces the orphan
nuclear receptor, small heterodimer partner (SHP, gene NR0B2) (Inagaki et al.,
2005).
The second homeostatic pathway governed through FXR occurs within
hepatocytes, where bile acids bind and activate FXR which promotes the
transcription of SHP. SHP is a transcriptional co-repressor that inhibits bile acid
synthesis. Specifically, SHP indirectly represses CYP7A1 gene transcription by
inhibiting HNF4α and LRH-1 at the protein level (Goodwin et al., 2000). However,
under physiological conditions, bile acid concentrations within hepatocytes may
not be sufficient to elicit FXR activation. Importantly, studies showed that infusing
taurocholic acid into the duodenum caused inhibition of bile acid synthesis,
whereas intravenous taurocholic acid infusion did not. This suggests that
intestinal signaling through FXR and FGF19 may be the rate-limiting mechanism
driving this negative feedback loop, rather than hepatic bile acid concentrations
(Pandak et al., 1995; Li and Dawson, 2019).
Bile acid secretion into the canaliculi and bile acid reuptake in the ileum
are two driving forces of bile acid enterohepatic circulation. After bile acids are
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synthesized in hepatocytes, FXR induces BSEP transcription through direct
binding to the FXRE in the BSEP promoter, leading to enhanced bile acid
secretion across the canalicular membrane (Ananthanarayanan et al., 2001). Bile
acid mediated FXR activation inhibits the transcription of NTCP via SHP (Denson
et al., 2001). In enterocytes, FXR activation similarly inhibits bile acid uptake by
inhibiting ASBT gene transcription (Neimark et al., 2004), possibly via SHP.
Furthermore, FXR directly induces bile acid efflux genes OSTα and OSTβ (Lee et
al., 2006) by binding directly to their promoters. In response to high bile acid
concentrations, the overall regulation of transporters favours a decrease in
intracellular bile acid concentrations. This is achieved by the upregulation of
efflux transporters and the downregulation of uptake transporters and genes
involved in bile acid synthesis. The regulatory pathways governed by FXR
activation in enterocytes and hepatocytes are shown in Figure 1.8.
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Figure 1.8. FXR regulation of bile acid synthesis and transport
In enterocytes, bile acids bind and activate farnesoid X receptor (FXR), which stimulates
production of fibroblast growth factor 19 (FGF19, FGF15 in mice). FGF19 travels to hepatocytes
where it binds to the fibroblast growth factor receptor 4 (FGFR4), which signals to induce SHP.
SHP protein interferes with coactivators of CYP7A1 to inhibit CYP7A1 transcription. Also, within
enterocytes, FXR activation directly induces organic solute transporters αβ (OSTαβ) and FXR
inhibits apical sodium-dependent bile acid transporter (ASBT) via SHP. In hepatocytes, FXR
activation directly induces bile salt export pump (BSEP) and multidrug resistance-associated
protein 2 (MRP2) on the bile canalicular membrane. On the hepatic basolateral membrane,
OSTαβ and MRP4 are typically not expressed abundantly, but can become upregulated upon
FXR activation. FXR also induces SHP to inhibit bile acid uptake by Na+-taurocholate cotransporting polypeptide (NTCP) and organic anion transporting polypeptides OATP1B1 and
OATP1B3 at the basolateral membrane of hepatocytes.
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1.11

Role of bile acid transporters in statin transport

In addition to their roles in enterohepatic circulation of bile acids, many of
these transporters are also important in the disposition of xenobiotics including
statins. Statins are lipid-lowering drugs that competitively inhibit 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in
cholesterol synthesis in hepatocytes (Istvan, 2002). Statins are often prescribed
to hypercholesterolemic patients to prevent cardiovascular disease, providing
their primary therapeutic benefit by reducing total and low-density lipoprotein
cholesterol in the plasma (Collins et al., 2016).
Importantly, transporters also regulate statin pharmacodynamics. Efficient
uptake into hepatocytes is imperative for therapeutic efficacy (Rocha et al.,
2018). Decreased hepatic uptake of statins can result in increased systemic
concentrations, which has been associated with elevated risk of the most
common statin-induced adverse event, myopathy (Tomaszewski et al., 2011;
Nigam, 2015). A high degree of interindividual variability in plasma statin
concentrations has been documented. Variability up to 45-fold has been
observed in patients taking the same dose of atorvastatin or rosuvastatin
(DeGorter et al., 2013).
There are various statins on the market, all of which maintain the same
therapeutic effect and share similar pharmacophore structures that mimic HMGCoA. Statins are amphiphilic and differ in ring structures attached to the
pharmacophore, which change their chemical properties and determine their
hydrophilicity. Statins with more hydrophobic properties are atorvastatin,

27

simvastatin, fluvastatin, and lovastatin, whereas rosuvastatin, pitavastatin, and
pravastatin are more hydrophilic (Fong, 2014). Statins are administered orally
and exhibit rapid intestinal absorption. Hydrophobic statins are capable of plasma
membrane diffusion, whereas hydrophilic statins are highly dependent on
transporters for their absorption (Schachter, 2005).

1.12

Rosuvastatin transport and genetic variation

Rosuvastatin displays high selectivity for hepatocytes and, due to its
minimal metabolism, is not prone to cytochrome P450-mediated drug-drug
interactions (Cheng-Lai, 2003). Due to its low passive membrane permeability,
rosuvastatin disposition is nearly entirely dependent on uptake and efflux
transporters. In vitro, hepatic uptake transporters OATP1B1, OATP1B3,
OATP2B1, and NTCP can transport rosuvastatin (Ho et al., 2006; Kitamura et al.,
2008; Choi et al., 2011; Bi et al., 2013). In human hepatocytes, OATP1B1 and
OATP1B3 mediate high affinity and capacity rosuvastatin transport, accounting
for approximately 55% of rosuvastatin uptake, whereas NTCP shows high
capacity but lower affinity and is responsible for up to 35% of hepatic
rosuvastatin uptake (Ho et al., 2006; Bi et al., 2013). In vitro and in vivo studies
provide evidence that bile canalicular efflux transporters breast cancer resistance
protein (BCRP, gene ABCG2) and MRP2 mediate biliary secretion of
rosuvastatin (Kitamura et al., 2008; Hu et al., 2010; DeGorter et al., 2013).
Genetic polymorphisms in hepatic uptake transporters and bile canalicular
efflux transporters have been associated with altered plasma rosuvastatin
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concentrations. Variability up to 45-fold was observed in plasma statin
concentration between patients taking the same dose. This study identified
genetic variants in SLCO1B1 and ABCG2 that decrease statin transport by
OATP1B1 and BCRP, respectively, and are associated with increased plasma
rosuvastatin concentrations (DeGorter et al., 2013). The low degree of
metabolism and high degree of facilitated and active transport of rosuvastatin
implies that variation in other rosuvastatin transporters, such as NTCP, might
also play a role in the observed interpatient variability in plasma statin
concentrations.

1.13

Na+-taurocholate co-transporting polypeptide

(NTCP, SLC10A1)
NTCP is a key bile acid transporter located on the basolateral membrane
of hepatocytes. Conjugated bile acid uptake from the blood into hepatocytes is
largely mediated by NTCP (Hagenbuch et al., 1991; Hagenbuch and Meier,
1994). NTCP works by secondary active transport, faciliting the symport of one
bile acid molecule per two sodium ions (Weinman, 1997; Anwer and Stieger,
2014).
Genetic variation resulting in deficient NTCP expression and/or activity
can result in serum hypercholanemia (Vaz et al., 2015; Mao et al., 2019). Over
the past five years, various case reports of NTCP deficiency in humans have
been published. Individuals deficient in NTCP present with elevated bile acids in
the serum, which is most prominent in pediatric subjects (Vaz et al., 2015; Liu et
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al., 2017; Qiu et al., 2017). In some NTCP deficient mice and humans, serum bile
acids normalization occurs over time. This is thought to occur via compensation
of bile acid uptake by other transporters, including hepatic OATPs. However, in
some subjects, serum hypercholanemia persist into adulthood (Deng et al., 2016;
Liu et al., 2017; Mao et al., 2019). Although serum hypercholanemia does not
cause the progressive liver damage seen with intrahepatic cholestasis, serum
cholestasis affects the enterohepatic circulation of bile acids. Vitamin D
deficiency and decreased bone mineral density have been reported in individuals
with homozygous loss of function genetic variation in SLC10A1 (Liu et al., 2017),
which may indicate reduced bile acid secretion into the gut.
In Slc10a1-/- mice, serum hypercholanemia and altered bile acid
transporter expression has been observed in some but not all animals
(Slijepcevic et al., 2015). It remains unclear why certain mice appear near-normal
in terms of bile acid physiology, whereas others are severely impacted by the
disruption of Slc10a1.
NTCP is also the receptor for the entry of hepatitis B and D viruses into
hepatocytes (Yan et al., 2012), and the NTCP-specific inhibitor, Bulevirtide
(formerly Myrcludex B), has recently been approved for the treatment of Hepatitis
B and D. Clinical trials have shown no serious acute adverse events with
Myrcludex B administration (Blank et al., 2016; Bogomolov et al., 2016).
However, serum bile acids, particularly conjugated species, were significantly
elevated in individuals administered the NTCP inhibitor. Due to the detergent
properties of bile acids and their ability to digest cellular membranes causing
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toxicity, long-term implications of persistent serum hypercholanemia are
unknown and warrant further investigation (Blank et al., 2018).

1.14

Rare genetic variation and next-generation

sequencing
Next-generation sequencing (NGS) is a powerful tool that provides the
opportunity for the discovery of common as well as rare variants. However,
elucidating functional effects of rare variants, particularly with regard to drug
response, lack thereof, or adverse drug events (ADEs), remains a major challenge.
Costs of genome sequencing have declined exponentially over the past
decade, with the current average cost of sequencing one human genome at
approximately $1,000 US dollars, compared to over $100,000 in 2009 (Hayden,
2014). This has fostered rapid uptake of genomic sequencing for both research
and clinical purposes. However, the rate at which we are discovering variants far
exceeds our ability to characterize their function, let alone understand their clinical
relevance.
The abundance of rare variants has been confirmed by numerous studies
characterizing large genomic datasets from initiatives including The 1000
Genomes Project (Genomes Project et al., 2012) and the Exome Aggregation
Consortium (ExAC) (Lek et al., 2016), the latter combining sequencing data of
more than 60,000 individuals. A high prevalence (97.5%) of very rare variation was
discovered in 628 known drug-target genes, leading researchers to predict that
approximately 80% of patients may harbour a variant that affects a gene involved
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in response to commonly prescribed drugs (Scharfe et al., 2017). A recent study
noted high frequencies of rare variants in genes of drug transporters belonging to
the solute carrier (SLC) superfamily, where 99.8% of single nucleotide variants
were found to be rare (Schaller and Lauschke, 2019).
Despite the sustained reduction in cost, genome-wide sequencing of larger
patient populations remains challenging for most research institutions due to the
increased cost, time, data storage capacity, and bioinformatics pipelines required
to carefully analyze the vast number of data generated while ensuring assay
quality and technical as well as clinical validity of detected variants (DePristo et al.,
2011; Rehm et al., 2013; Richards et al., 2015). Alternatively, targeted exome
sequencing panels focus on a small number of genes of interest (100) but can
also target specific noncoding regions of known functional relevance. Such gene
panels generally facilitate “deeper” sequencing with a higher read coverage, also
known as read depth, and therefore sequencing data can be interpreted with
greater confidence (Gulilat et al., 2019).
In comparison to more cost-effective array-based genotyping platforms
focused on common variation with established functional effects, targeted nextgeneration sequencing allows for the discovery of novel, mostly rare genetic
variation. Consequently, sequencing data can be utilized to assess specific
genotypes that may be clinically actionable or to perform a more comprehensive
pharmacogenetic analysis for subsequent research. While increasingly robust
sequencing technologies have identified many rare and very rare genetic variants,
most remain of unknown functional and clinical significance. Currently,
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computational (in silico) and in vitro approaches are employed as the first steps in
defining which variants have altered function such that rigorous in vivo testing can
be pursued to determine potential clinical implications in disease and
pharmacotherapy.

1.15

Computational prediction of rare variant function

A variety of computational algorithms have been developed and optimized
to predict whether genetic variants will affect the function of a given protein.
Variants predicted to have an altered function are classified as deleterious or
damaging, and those predicted to maintain physiological function are classified as
benign or tolerated. These in silico prediction tools are especially important for the
classification of rare variants, where population scale and genome-wide
association studies (GWAS) are often underpowered to associate rare variation to
drug-associated phenotypes such as toxicity (Speed et al., 2012; Visscher et al.,
2017).
Commonly used algorithms for variants in coding regions of the genome
base their predictions on evolutionary conservation and/or amino acid
physicochemical properties (Grantham, 1974; Cooper et al., 2005; Kumar et al.,
2009; Adzhubei et al., 2010). Other in silico tools aggregate prediction scores from
multiple algorithms to generate one ensemble prediction score in an attempt to
improve their predictive accuracy (Kircher et al., 2014; Ioannidis et al., 2016).
While the open-access nature of such prediction tools allows easy access
to score variants of interest, predictions from different tools often produce
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conflicting results: one tool may classify a variant as deleterious when another tool
may predict no functional effect, thus classifying the same variant as tolerated or
benign. Though some of these differences may be expected given the diverse
methodologies employed by each algorithm to derive their respective scores, such
conflicting and potentially incorrect results undoubtedly degrade the confidence in
these algorithms for variant interpretation (Han et al., 2017; Gulilat et al., 2019).
Particularly, if such functional predictions lack the required sensitivity (proportion
of true positives that are correctly identified by a score) and specificity (proportion
of true negatives correctly identified by a score) to forecast functionality of a
particular variant, they cannot be trusted clinically.
One well-known caveat of applying these in silico tools to predict functional
effects of variations in drug transport or metabolism genes, known as
pharmacogenes, is that most algorithms are trained using data on evolutionary
conservation and disease. Typically, genetic variants in pharmacogenes are not
associated with disease; they display lower evolutionary conservation in contrast
to disease-associated genes which are under higher evolutionary pressure to
retain endogenous function (Fujikura et al., 2015; Lauschke et al., 2017; Zhou et
al., 2018; Schaller and Lauschke, 2019). Recently, an in silico tool was specifically
optimized using drug transport and metabolism data. Overall, this algorithm
showed more accurate predictions for functional effects in pharmacogenes
compared to conventional in silico tools developed based on sequence homology
and disease (Zhou et al., 2019).
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2
2.1

Rationale, Specific Aims, Hypotheses

Thesis Rationale

NTCP (SLC10A1) is central to the hepatic uptake of conjugated bile acids
(Dawson et al., 2009). Genetic disruption of NTCP function can result in serum
hypercholanemia (Vaz et al., 2015; Deng et al., 2016; Liu et al., 2017; Qiu et al.,
2017), which may alter nuclear receptor signaling and gene expression. Further,
the additional roles of NTCP in hepatic of uptake rosuvastatin (Ho et al., 2006; Bi
et al., 2013), and hepatitis B and D viruses (Yan et al., 2012) underline its
importance in drug transport and disease. Despite these important physiological
roles, limited data exist regarding the effects of genetic variation in SLC10A1 on
bile acid dynamics and rosuvastatin transport. The goals of this study are to
assess in vitro and in vivo effects of genetic disruption of SLC10A1 on bile acid
and rosuvastatin transport.

2.2

Governing hypothesis

Genetic variation in NTCP (SLC10A1) decreases hepatic bile acid and
rosuvastatin uptake

2.3

Specific Aim 1

A. To test the functional effects of uncharacterized genetic variants in
SLC10A1 on NTCP transport activity and protein expression in vitro
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B. To determine the performances of in silico algorithms to predict the
effects of genetic variation on NTCP-mediated transport activity

Rationale: Many studies have characterized the transport activity and protein
expression of genetically variant forms bile acid transporters OATP1B1 and
OATP1B3 (Tirona et al., 2001; Schwarz et al., 2011; DeGorter et al., 2012),
however, few studies have done so for NTCP. In vitro characterization is an
important step in understanding which variants may be critical to study in vivo.
Genetic variation in SLC10A1 is rare, thus in silico prediction presents an
attractive approach to prioritize variants for subsequent in vitro characterization.
My hypothesis is that genetic variation in SLC10A1 will decrease
taurocholic acid and/or rosuvastatin transport in vitro. Additionally, I
hypothesize that common in silico tools will accurately predict deleterious
NTCP-mediated transport of the endogenous substrate and that the
pharmacogenetic-optimized tool will accurately predict NTCP-mediated
transport of rosuvastatin.

2.4

Specific Aim 2

A. To examine bile acid composition and expression of genes involved
in bile acid synthesis and transport in Slc10a1-/- mice
B. To determine hepatic uptake of rosuvastatin in Slc10a1-/- mice
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Rationale: Although NTCP is an important rosuvastatin transporter in vitro, the
importance of NTCP to rosuvastatin uptake in vivo has not been assessed.
Additionally, limited data exist regarding effects of Slc10a1 disruption in a mouse
model (Slijepcevic et al., 2015; Mao et al., 2019). My hypothesis is that
Slc10a1-/- mice are unable to compensate for disrupted Slc10a1, resulting in
serum conjugated hypercholanemia and an altered hepatic gene
expression. Additionally, I hypothesize that the liver-to-serum rosuvastatin
concentration ratios will be decreased in Slc10a1-/- mice.

2.5

Specific Aim 3

To investigate sex-related differences in bile acid composition and
expression of bile acid synthesis and transporter genes in Slc10a1-/- mice

Rationale: Sex-related differences in bile acid synthesis and transport have been
described in humans and animals (Phelps et al., 2019). Moreover, female mice
may be more susceptible to persistent hypercholanemia (Mao et al., 2019),
however sex-related differences have not been extensively investigated in
Slc10a1-/- mice. My hypothesis is that female Slc10a1-/- mice will display
increased serum bile acid concentrations and hepatic Cyp7a1 mRNA
expression.
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3

In vitro functional characterization and in silico prediction of rare
genetic variation in the bile acid and drug transporter, Na+taurocholate co-transporting polypeptide (NTCP, SLC10A1)
(Russell et al., 2020)

Adapted & reprinted with permission from: Russell LE, Zhou Y, Lauschke VM,
Kim RB. 2020. In vitro functional characterization and in silico prediction of rare
genetic variation in the bile acid and drug transporter, Na+-taurocholate cotransporting polypeptide (NTCP, SLC10A1). Mol Pharm 17(4):1170-81. Copyright
2020 American Chemical Society.
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3.1

Introduction

Bile acids are essential to digestion and absorption of dietary lipids, fatsoluble vitamins, and xenobiotics (Hofmann and Mysels, 1992; Chiang, 2013).
Importantly, bile acids serve as key signaling molecules. The direct binding of
bile acids to nuclear receptors such as farnesoid X receptor regulates expression
of a medley of genes involved in bile acid biosynthesis and transport (Makishima
et al., 1999; Tu et al., 2000). Bile acid homeostasis is maintained by membranebound transporters which facilitate enterohepatic recycling and prevent toxic
intracellular and extracellular bile acid accumulation (Hofmann, 1999; Dawson et
al., 2009). Bile acid transporters are also involved in the disposition of drugs
including the cholesterol-lowering drug rosuvastatin (McTaggart et al., 2001;
Martin et al., 2003; Ho et al., 2006; DeGorter et al., 2013). Rosuvastatin exerts its
effect in the liver by preventing the conversion of 3-hydroxy-3-methylglutaryl-CoA
to mevalonate, the rate-limiting step in cholesterol biosynthesis. Due to the
hydrophilic nature of rosuvastatin, this statin is dependent on drug transporters
for optimal hepatic uptake, a prerequisite for therapeutic benefit at its site of
action (McTaggart et al., 2001; Martin et al., 2003).
First cloned from rat liver in 1991 and from human liver in 1994, Na+taurocholate co-transporting polypeptide (NTCP, SLC10A1) is a key hepatic bile
acid uptake transporter that also mediates transport of substrate drugs from the
sinusoidal blood into hepatocytes (Hagenbuch et al., 1991; Hagenbuch and
Meier, 1994; Ho et al., 2006). NTCP is the only sodium-dependent bile acid
transporter in the liver and is localized exclusively to the basolateral membrane
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of hepatocytes (Hagenbuch and Meier, 1994; Anwer and Stieger, 2014). NTCP
uses secondary active transport to symport one bile acid molecule per two ions
sodium from portal blood into the liver (Weinman, 1997; Anwer and Stieger,
2014). NTCP favors uptake of conjugated bile acids, can be inhibited or induced
by a number of clinically used drugs, and is thought to contribute to up to 35% of
hepatic rosuvastatin uptake (Meier et al., 1997; Kim et al., 1999; McTaggart et
al., 2001; Martin et al., 2003; Ho et al., 2006).
Given the central role of NTCP in the maintenance of bile acid homeostasis,
clinical cases of variation inducing complete deficiency of NTCP-mediated bile
acid transport are extremely rare. However, a few causative genetic variants
have been observed in greater abundance in East Asian or African American
populations (Ho et al., 2004; Pan et al., 2011; Cunningham et al., 2019). NTCPdeficient individuals present with persistent elevations in serum bile acid
concentrations, particularly of the conjugated nature (Vaz et al., 2015; Deng et
al., 2016; Liu et al., 2017; Qiu et al., 2017). Additionally, NTCP deficiency may be
associated with deficits in bone mineral density and fat-soluble vitamins due to
impaired absorption at the intestine (Vaz et al., 2015; Deng et al., 2016; Liu et al.,
2017). Studies of NTCP deficiency in knockout mouse models report marked
elevations in serum bile acid concentrations along with dysregulated expression
of bile acid transporters and increased serum concentrations of sulfated bile
acids (Slijepcevic et al., 2015; Slijepcevic et al., 2017; Mao et al., 2019). More
recently, NTCP was identified as a receptor for the entry of Hepatitis B and D
viruses (HBV and HDV) into hepatocytes (Yan et al., 2012; Ni et al., 2014). Since
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then, there has been growing interest in studying genetic influences on HBV and
HDV infection.
Next-generation sequencing (NGS) has revealed vast amounts of rare
variation in the human genome. Most of these genetic variants remain of
uncertain clinical significance (Nelson et al., 2012; Fujikura et al., 2015). Solute
carrier (SLC) transporters were found to be among the gene families with most
variations, with each individual harbouring on average 30 genetic variants in the
SLC superfamily (Schaller and Lauschke, 2019). It is expected that rare variants
in genes involved in absorption, distribution, metabolism, and excretion (ADME)
of drugs account for 30-40% of genetically induced adverse drug events (Kozyra
et al., 2017). A major challenge with genomic datasets at present is the inability
to interpret which rare variants may be clinically important, as classical functional
assays in vitro are not feasible for the large number of rare variants that continue
to be discovered (Lauschke and Ingelman-Sundberg, 2019; Lauschke et al.,
2019; Zhou et al., 2019). Various algorithms have been developed to predict the
consequences of genetic variation for which no functional data exist. However,
different in silico algorithms often generate conflicting results (Gulilat et al.,
2019). Moreover, most algorithms have been trained using evolutionary
conservation and disease and thus are often poor predictors of functional
variation related to drug transport or metabolism (Zhou et al., 2018).
Due to the vital roles of NTCP in bile acid homeostasis, statin transport, and
HBV and HDV infection and treatment, functional characterization of rare
SLC10A1 variants may help identify genetic variants that increase susceptibility

52

to disease and/or adverse drug events. Furthermore, comparing observed
transport in vitro to in silico predicted function will help elucidate the relevance of
using in silico tools to predict rare SLC10A1 variation. In the present study, we
assessed 35 previously uncharacterized, rare, missense SLC10A1 variants by
determining in vitro expression, cellular localization and transport of the
endogenous substrate taurocholic acid (TCA) and the xenobiotic substrate
rosuvastatin. We also compared the in silico scores with the observed functional
effects in vitro to assess the performances of seven algorithms to predict TCA
and rosuvastatin uptake by genetically variant NTCP.

53

Methods & Materials

3.2
3.2.1

Materials

[3H]-Taurocholic acid (20 Ci/mmol) was purchased from American Radiolabeled
Chemicals (St. Louis, MO). Taurocholic acid, rosuvastatin, and d6-rosuvastatin
were purchased from Toronto Research Chemicals (Toronto, ON). All other
chemicals, unless otherwise stated, were obtained from Millipore Sigma (St.
Louis, MO).

3.2.2

Identification of single nucleotide variants in SLC10A1

The Ensembl Genome Browser (https://www.ensembl.org, accessed February
2019) was used to identify rare, missense genetic variants in SLC10A1. For this
study, a rare variant was defined as displaying a minor allele frequency (MAF)
<0.5%. Additional variants were identified from targeted next-generation
sequencing of 235 local patients on heterogeneous pharmacotherapy regimens
at London Health Sciences Centre, Canada (Gulilat et al., 2019). The genomics
component of our study was approved by the Research Ethics Board of Western
University, London, Canada (Appendix C). All subjects provided written informed
consent. The DNA from patients was sequenced on the basis of having an
adverse drug reaction or having measured drug concentrations outside of the
expected range as identified by therapeutic drug monitoring. ClinVar
(https://www.ncbi.nlm.nih.gov/clinvar/) and Single Nucleotide Polymorphism
(https://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi)
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databases from the National Centre for Biotechnology Information as well as the
Online Mendelian Inheritance in Man (https://omim.org/) database were searched
for publications that assessed SLC10A1 variant function. Variants for which no
data were found for taurocholic acid uptake, rosuvastatin uptake, or protein
expression were deemed novel for the purpose of this study and were selected
for characterization in vitro.

3.2.3

In silico functional prediction of genetic variants in NTCP

Using the Ensembl Genome Browser database (https://ensembl.org), in silico
functional prediction scores for genetic variants of SLC10A1 were obtained from
the following tools: Combined Annotation-Dependent Depletion (CADD) (Kircher
et al., 2014), Sorting Intolerant From Tolerant (SIFT) (Kumar et al., 2009),
PolyPhenotyping-2 (PolyPhen-2) (Adzhubei et al., 2013), Mutation Assessor
(Reva et al., 2007), Rare Exome Variant Ensemble Learner (REVEL) (Ioannidis
et al., 2016), and MetaLR (Meta Logistic Regression) (Dong et al., 2015). One
additional in silico algorithm optimized for pharmacogenes, further referred to as
ADME-optimized, was independently employed to generate predictive scores for
SLC10A1 variants (Zhou et al., 2019). For ease of interpretation, predictions for
functional impact of genetic variants were classified under one of two categories:
deleterious (D) or tolerated (T). To classify variants as deleterious, the following
threshold values were used: SIFT < 0.05, CADD > 20, and > 0.5 for PolyPhen-2,
Mutation Assessor, REVEL, MetaLR, and ADME-optimized. Variants with SIFT >
0.05, CADD < 20, and scores < 0.5 for PolyPhen-2, Mutation Assessor, REVEL,
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MetaLR, and ADME-optimized were classified as tolerated (T). An overview of
methodologies used by individual tools to generate their predictions is presented
in Table 3.1.
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Table 3.1. In silico tools used to predict effects of SLC10A1 genetic variation on NTCP
protein function
Tool

Acronym definition

Main prediction parameter(s) Genomic region(s) Publication

SIFT

Sorting Intolerant From
Tolerant

Sequence homology

Coding

2009. Kumar et al.,
Nat Protocols

Mutation
Assessor

NA

Sequence homology

Coding

2007. Reva et al.,
Genome Biol

PolyPhen-2

PolyPhenotying
version 2

Sequence homology, amino
acid physicochemical
properties

Coding

2013. Adzhubei et al.,
Curr Pro Hum Genet

Meta LR

Meta Logistic
Regression

Ensemble method including
inputs from 14 tools

Coding

2015. Dong et al.
Hum Mol Genet.

CADD

Combined AnnotationDependent Depletion

Ensemble method including
inputs from 63 tools

Conding and
noncoding

2014. Kircher et al.,
Nat Genet

REVEL

Rare Exome Variant
Ensemble Learner

Ensemble method including
inputs from 13 tools

Coding

2016. Ioannidis et al.,
Am J Hum Genet

ADMEoptimized

Absorption, Distribution, Ensemble method including
Metabolism, Excretion
inputs from 5 tools

Coding

2019. Zhou et al.,
Pharmacogenomics J
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3.2.4

Wild type and variant plasmid construction

The open reading frame of SLC10A1 was amplified by PCR from cDNA of pooled
healthy human liver samples obtained through the Liver Tissue Cell Distribution
System (Minneapolis, MN; funded by National Institutes of Health Contract
N01DK70004/HHSN267200700004C) using primers listed in Table 3.1 (NTCP F
and NTCP R). The PCR product was subcloned into the pCR2.1-TOPO cloning
plasmid (Thermo Fisher Scientific). The NTCP open reading frame was then
transferred to the pEF6/V5-His-TOPO expression plasmid (Thermo Fisher
Scientific). Missense mutations were introduced using site-directed mutagenesis
(QuikChange II, Agilent Technologies, Cedar Creek, TX). The stop codon of
NTCP was mutated to ensure the translation of the V5 tag for subsequent
analysis of protein expression. Constructs were verified using dideoxy
sequencing at Robarts Research Institute. Primer pairs for mutating the stop
codon and for creating each of the missense variants are listed in Tables 3.2 &
3.3.
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Table 3.2. Primers used to clone NTCP and create variants
Wild Type
NTCP

Nucleotide
Change
NA
NA

Forward or
Reverse?
Forward
Reverse

A3T

c.7G>A

Forward
Reverse

ATTGCCCTTATGGAGACCCACAACGCGTCTG
CAGACGCGTTGTGGGTCTCCATAAGGGCAAT

R21C

c.61C>T

Forward
Reverse

CCAACTTTGGCAAGTGCCCCACAGACCTGGC
GCCAGGTCTGTGGGGCACTTGCCAAAGTTGG

V29I

c.85G>A

Forward
Reverse

CCTGGCACTGAGCATCATCCTGGTGTTC
GAACACCAGGATGATGCTCAGTGCCAGG

M39T

c.116T>C

Forward
Reverse

GTTGTTCTTCATCACGCTCTCGCTGGGC
GCCCAGCGAGAGCGTGATGAAGAACAAC

S41L

c.122C>T

Forward
Reverse

CATGTTGTTCTTCATCATGCTCTTGCTGGGCTGCAC
GTGCAGCCCAGCAAGAGCATGATGAAGAACAACATG

K52N

c.156G>C

Forward
Reverse

GTTCAGCAAGATCAACGCTCACTTATGGAAGC
GCTTCCATAAGTGAGCGTTGATCTTGCTGAACT

A64T

c.190G>A

Forward
Reverse

GGGCTGGCCATCACCCTGGTGGCAC
GTGCCACCAGGGTGATGGCCAGCCC

P73T

c.217C>A

Forward
Reverse

CAGTATGGCATCATGACCCTCACGGCCTTTG
CAAAGGCCGTGAGGGTCATGATGCCATACTG

I88T

c.263T>C

Forward
Reverse

AGGTCTTCCGGCTGAAGAACACTGAGGCACTGG
CCAGTGCCTCAATGTTCTTCAGCCGGAAGACCT

I93V

c.277G>A

Forward
Reverse

CATTGAGGCACTGGCCGTCTTGGTCTGTGGCTGC
GCAGCCACAGACCAAGACGGCCAGTGCCTCAATG

L138P

c.413T>C

Forward
Reverse

GCCTCTCCTCCCGTACATCTACTCC
GGAGTAGATGTACGGGAGGAGAGGC

I159M

c.477C>G

Forward
Reverse

GCCCTATAAAGGCATGGTGATATCACTGGTCC
GGACCAGTGATATCACCATGCCTTTATAGGGC

T171I

c.512C>T

Forward
Reverse

GGTTCTCATTCCTTGCATCATAGGGATCGTCCTCA
TGAGGACGATCCCTATGATGCAAGGAATGAGAACC

R180Q

c.539G>A

Forward
Reverse

CGTCCTCAAATCCAAACAGCCACAATACATGCGC
GCGCATGTATTGTGGCTGTTTGGATTTGAGGACG

M184T

c.551T>C

Forward
Reverse

ATCCAAACGGCCACAATACACGCGCTATGTCATCA
TGATGACATAGCGCGTGTATTGTGGCCGTTTGGAT

V187L

c.559G>C

Forward
Reverse

CAATACATGCGCTATCTCATCAAGGGAGGG
CCCTCCCTTGATGAGATAGCGCATGTATTG

G190E

c.569G>A

Forward
Reverse

GCGCTATGTCATCAAGGAAGGGATGATCATCATTC
GAATGATGATCATCCCTTCCTTGATGACATAGCGC

Primer name

Oligonucleotide
ATGGAGGCCCACAACGCGTCTGC
CCAGGCCACCAGGGGAAGGGCTAG
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Table 3.3. Primers used to clone NTCP and create variants continued
G191R

Nucleotide
Change
c.571G>A

Forward or
Reverse?
Forward
Reverse

I195L

c.583A>C

Forward
Reverse

GGAGGGATGATCATCCTTCTCTTGTGCAGTG
CACTGCACAAGAGAAGGATGATCATCCCTCC

V200M

c.598G>A

Forward
Reverse

ATTCTCTTGTGCAGTATGGCCGTCACAGTTC
GAACTGTGACGGCCATACTGCACAAGAGAAT

V202I

c.604G>A

Forward
Reverse

CTTGTGCAGTGTGGCCATCACAGTTCTCTCTGCC
GGCAGAGAGAACTGTGATGGCCACACTGCACAAG

L205F

c.613C>T

Forward
Reverse

GGCCGTCACAGTTTTCTCTGCCATCAATGTGGGG
CCCCACATTGATGGCAGAGAAAACTGTGACGGCC

I232T

c.695T>C

Forward
Reverse

CCTCCTCCCTGATGCCTTTTACTGGCTTTCTGCTG
CAGCAGAAAGCCAGTAAAAGGCATCAGGGAGGAGG

F234L

c.702T>G

Forward
Reverse

GCCTTTTATTGGCTTGCTGCTGGGTTATGTTC
GAACATAACCCAGCAGCAAGCCAATAAAAGGC

S241F

c.722C>T

Forward
Reverse

GGGTTATGTTCTCTTTGCTCTCTTCTGCC
GGCAGAAGAGAGCAAAGAGAACATAACCC

R249W

c.745C>T

Forward
Reverse

CTGCCTCAATGGATGGTGCAGACGCAC
GTGCGTCTGCACCATCCATTGAGGCAG

R252S

c.754C>A

Forward
Reverse

CAATGGACGGTGCAGAAGCACTGTCAGCATGGAG
CTCCATGCTGACAGTGCTTCTGCACCGTCCATTG

R252C

c.754C>T

Forward
Reverse

CAATGGACGGTGCAGATCGACTGTCAGCATGGAG
CTCCATGCTGACAGTCGATCTGCACCGTCCATTG

T258S

c.773G>C

Forward
Reverse

CGCACTGTCAGCATGGAGAGTGGATGCCAAAATGTCC
GGACATTTTGGCATCCACTCTCCATGCTGACAGTGCG

I279T

c.836T>C

Forward
Reverse

CCACCTGAAGTCACTGGACCACTTTTC
GAAAAGTGGTCCAGTGACTTCAGGTGG

Q293E

c.877C>G

Forward
Reverse

CCTCTACATGATTTTCGAGCTTGGAGAAGGGC
GCCCTTCTCCAAGCTCGAAAATCATGTAGAGG

M319I

c.957G>A

Forward
Reverse

TCAAGACTCCCAAGGATAAAACAAAAATAATCTACACAGCTGCC
GGCAGCTGTGTAGATTATTTTTGTTTTATCCTTGGGAGTCTTGA

E328K

c.982G>A

Forward
Reverse

CAGCTGCCACAACTGAAAAAACAATTCCAGGAGCT
AGCTCCTGGAATTGTTTTTTCAGTTGTGGCAGCTG

E328Q

c.982G>C

Forward
Reverse

GCTGCCACAACTGAACAAACAATTCCAGGAGC
GCTCCTGGAATTGTTTGTTCAGTTGTGGCAGC

E342K

c.1024G>A

Forward
Reverse

GCACCTACAAAGGGAAGGACTGCTCCCCT
AGGGGAGCAGTCCTTCCCTTTGTAGGTGC

Mutate stop
codon

c.1047G>C

Forward
Reverse

CCCCTTGCACAGCCTACAAGGGCAATTCTGC
GCAGAATTGCCCTTGTAGGCTGTGCAAGGGG

Primer name

Oligonucleotide
GCGCTATGTCATCAAGGGAAGGATGATCATCATTC
GAATGATGATCATCCTTCCCTTGATGACATAGCGC
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3.2.5

Transient expression of NTCP in cultured cells

Transient transfection was performed in human embryonic kidney 293 type T
(HEK293T) cells, obtained from American Type Culture Collection (Manassas,
VA). HEK293T cells were cultured in Dulbecco’s Modified Eagle’s Medium
(MEM) (Thermo Fisher Scientific, Grand Island, NY) supplemented with 10%
FBS and 2 mM L-glutamine (Thermo Fisher Scientific) at 37C and 5% CO2. For
transport experiments and protein analysis, HEK293T cells were seeded at 2.0 x
105 cells/well on 12-well plates coated with poly-D-lysine-hydrobromide. After 24
hours, Lipofectamine 3000 (Thermo Fisher Scientific) diluted in Opti-MEM
medium (Thermo Fisher Scientific) was used to transiently transfect 1 g per well
of empty vector cDNA (control) or plasmid containing NTCP cDNA inserts, wild
type (WT) or variant. Cells were cultured for 16 hours prior to transport and
protein assays. An overview of cloning, transfection, and transport assays is
depicted in Figure 3.1.
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Figure 3.1. An overview of cloning, transfection, and transport experiments
Human NTCP was cloned from healthy hepatic tissue. 2. The NTCP open reading frame was
ligated into the pEF-V5-His/TOPO expression vector, and site-directed mutagenesis was used to
introduce missense mutations into the plasmid. 3. Vector control (pEF empty vector) or pEFNTCP (pEF with the NTCP open reading frame, wild type or mutant, inserted) was transiently
transfected into human embryonic kidney 293 type T (HEK293T) cells using Lipofectamine 3000,
a lipid reagent that coats the DNA plasmid with lipids, creating a positive charge surrounding the
plasmid DNA which is then attracted to the plasma membrane of cells for fusion and uptake of the
DNA. 4. Transfected cells were incubated with a specified concentration of radiolabelled [ 3H]
taurocholic acid (TCA) or unlabelled rosuvastatin. 5. At a specified timepoint, cells were washed
with phosphate buffered saline to remove media containing the substrate, and cells were lysed for
measurement of taurocholic acid uptake using liquid scintillation spectrometry or rosuvastatin by
liquid chromatography tandem mass spectrometry (LC-MS/MS).
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3.2.6

Single timepoint in vitro transport of taurocholic acid and
rosuvastatin

For taurocholic acid (TCA) uptake, cells were incubated with 5 µM taurocholic
acid supplemented with [3H]-taurocholic acid for 5 min to yield 100,000
disintegrations per minute (DPM) per dose (400 L). Transport was quenched by
washing wells 3x with 1 mL ice-cold 1x PBS. Cells were lysed in 1% SDS in
water (v/v), and uptake was assessed using liquid scintillation spectrometry (TriCarb 3900TR; Perkin Elmer, Waltham, MA).
For rosuvastatin uptake, transfected cells were incubated with 1 µM rosuvastatin
for 5 min, washed 3x with 1 mL ice-cold 1x PBS, and lysed in 400 L ice-cold
acetonitrile supplemented with the internal standard d6-rosuvastatin. Cell lysates
were centrifuged at 10,000 x g for 10 min at 4ºC to pellet cell debris. The
supernatant was diluted in H2O supplemented with 0.1% formic acid (2:1 v/v).
The concentration of rosuvastatin was quantified based on a previously reported
method (DeGorter et al., 2013). Solutes were separated by reversed-phase
chromatography on a Hypersil GOLD C18 column (50 × 3 mm, 5 μm;
ThermoFisher Scientific) with 0.1% formic acid/water and acetonitrile solvent
gradient. After electrospray ionization, mass spectrometric detection (TSQ
Vantage) was performed in positive mode with transitions 482.1 → 258.2 m/z for
rosuvastatin and 488.0 → 264.3 m/z for d6-rosuvastatin. Calibration curves were
linear with rosuvastatin concentrations between 0 and 1000 ng/mL. Inter-day
assay accuracy and precision were 5.8% and 8.9%, respectively, and the lower
limit of quantitation was 1 ng/mL.
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Cellular uptake was corrected for protein content per well as determined by the
Pierce Bicinchoninic Acid (BCA) Protein Assay Kit (Thermo Fisher Scientific).
Passive diffusion was accounted for by determining the difference in uptake
between cells transfected with WT or variant NTCP plasmids and empty vectortransfected cells. For single time-point transport experiments, cellular uptake was
normalized to uptake by WT NTCP-transfected cells (% WT). Experiments were
performed in duplicate on three to four experimental days (n=3-4).

3.2.7

Characterization of transport kinetics

Three variants were selected for kinetic analysis based on the results from the
single time point uptake assays. These include one variant that displayed
substrate specificity (NTCP G191R) and two variants with reduced transport
activity for TCA and rosuvastatin (NTCP R21C and K52N). To determine the
transport kinetics for taurocholic acid and rosuvastatin uptake, a timepoint of 2
was selected based on linear substrate uptake at this timepoint. Uptake of 0.5, 1,
2, 5, 10, 20, 50, and 100 M taurocholic acid and 1, 2, 5, 10, 20, 50, 100, and
200 M rosuvastatin were assessed at 2 min. Michaelis-Menten nonlinear curvefitting was performed with GraphPad Prism 6 (GraphPad, San Diego, CA) to
determine the maximal uptake velocity (Vmax) and the concentration at which halfmaximal uptake occurred (Km). Cellular uptake was corrected for protein content
per well as determined by the Pierce BCA Protein Assay Kit (Thermo Fisher
Scientific). Passive diffusion was accounted for by determining the difference in
uptake between cells transfected with WT or variant NTCP plasmids and empty
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vector-transfected cells. For kinetic experiments, the rates of substrate uptake
were calculated by determining picomoles of substrate transported per milligram
of protein per well per minute (pmol/mg protein/min). Experiments were
performed in duplicate on 3 experimental days (n=3).

3.2.8

Western blot analysis

Transfected HEK293T cells were lysed in Pierce IP Lysis Buffer (Thermo Fisher
Scientific) and 15 g protein/well, as quantified using a BCA assay (Thermo
Fisher Scientific), were separated by SDS-PAGE using 10% NuPAGE Bis-Tris
gels (Thermo Fisher Scientific). Gels were transferred to polyvinylidene difluoride
membranes and probed with antibodies. The loading control was probed first by
incubating membranes for 16 hr at 4C with rabbit polyclonal anti-Na+/K+-ATPase
antibody (Cell Signaling Technology, Danvers, MA; catalogue number 3010S)
diluted 1:1000 in TBS-T (20mM Tris, 150mM NaCl, 0.1% Tween 20, pH 7.4).
Membranes were washed with 1x TBS-T for 10 min, 3x, at room temperature
prior to a 1 hr incubation at room temperature with horseradish peroxidaselabeled anti-rabbit antibody (Cell Signaling Technology, Danvers, MA).
Membranes were washed with 1x TBS-T for 10 min, three times, and the loading
control was visualized by enhanced chemiluminescence (Amersham ECL Select;
GE Healthcare, Mississauga, ON). Subsequently, to probe for NTCP expression
using an antibody for the V5 tag, membranes were incubated for 1 hr at room
temperature with mouse monoclonal anti-V5 antibody (Thermo Fisher; catalogue
number R960-25), diluted 1:5000 in 1x TBS-T. The anti-V5 antibody was
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selected to probe for NTCP expression due to the lack of a high-affinity NTCP
antibody. Blots were washed with 1x TBS-T for 10 min, 3x, prior to incubation
with horseradish peroxidase-labeled anti-mouse antibody (Bio-Rad, Hercules,
CA) for 1 hr at room temperature. Blots were washed with 1x TBS-T at room
temperature for 10 min, 3x, and expression of the V5 was visualized using
enhanced chemiluminescence (Amersham ECL Select; GE Healthcare,
Mississauga, ON). Western blots for HeLa cells were performed as stated above,
with the exception of the use of a β-actin antibody (sc-1615-HRP, Santa Cruz
Biotechnology, Dallas, TX) at 1:1000 dilution in TBS-T to probe the loading
control.

3.2.9

Cell surface biotinylation

Plasma membrane protein expression was carried out for SLC10A1 variants that
displayed reduced substrate transport or reduced NTCP protein expression in
whole-cell lysates. HEK293T cells were transfected as previously described for
transport experiments. Sixteen hours post-transfection, cells were washed with
1x PBS. Cells were treated with membrane impermeable biotinylating reagent,
Sulfo-NHS-SS-Biotin (EZ-Link, Thermo Fisher Scientific) at 0.5 mg/mL/well in 1x
PBS supplemented with 100 M CaCl2 and 2.12 mM MgCl2 (PBS/Mg/Ca), and
were rocked gently for 1 hr at 4C. Cells were washed 3x with 1 mL PBS/Mg/Ca
supplemented with 50 M glycine (PBS/Mg/Ca/glycine) and then incubated with
1 ml PBS/Mg/Ca/glycine, rocking at 4C. After 20 min, cells were washed with
PBS/Mg/Ca and lysed in 700 L radioimmunoprecipitation (RIPA) buffer (10 mM
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Tris, 150 mM NaCl, 1.27 mM EDTA, 0.1% (w/v) SDS, and 10% (v/v) Triton X100), supplemented with protease inhibitor cocktail. After sonication and 10,000 x
g centrifugation for 5 mins at 4C, 80 L Streptavidin Agarose Resin (Thermo
Fisher Scientific) was added to 600 L cell lysate. Samples were mixed on an
end-over-end rocker for 1 hr at room temperature, centrifuged at 10,000 x g for 3
min, and the supernatants were discarded. The pellets were washed three times
with ice-cold RIPA buffer, and biotinylated proteins were released by incubating
each sample with 100 L 4x Lithium Dodecyl Sulfate (LDS) Sample Buffer
(NuPAGE, Thermo Fisher Scientific) supplemented with 5% (v/v) 2mercaptoethanol, mixing on an end-over-end rocker for 30 min at room
temperature. Samples were centrifuged and the supernatants were subject to
Western blot analysis as described above.

3.2.10

Cell surface deglycosylation assay

Protein deglycosylation was performed in HEK293T cell lysates enriched for the
plasma membrane fraction using the biotinylation method previously described.
Deglycosylation was achieved using the Glycoprofile II Enzymatic in-Solution NDeglycosylaion Kit. The kit protocol was modified as described below. Ten µg of
HEK293T plasma membrane protein fraction were added to tubes containing
22.5 µL RNase B standard solution (22.5 µg/µL w/v) and 10 µL 1x reaction
buffer. One µL aliquots of the denaturant solution containing 2% octyl B-D
glycopyranoside with 100 mM 2-mercaptoethanol were added to the solution
containing plasma membrane cell fractions and RNase B. One µL H2O was
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added to the control sample, and 1 µL PNGase F enzyme at 500 units of
enzyme/mL was added to the experimental sample. Samples were mixed by
vortexing and were incubated at 37°C for 1 hr. Samples were allowed to cool and
were subsequently subjected to SDS-PAGE and Western blotting for NTCP
protein expression using the V5 epitope tag as previously described.

3.2.11

Immunofluorescence confocal microscopy

HEK293T cells were plated on lysine-coated 4-well culture slides at 2.0x105 cells
per 1.7cm2 well (2.35x104 cells/mm2) and were transiently transfected with
plasmids encoding V5-tagged WT or variant NTCP. Culture slides were washed
with room temperature 1x PBS, fixed in 4% paraformaldehyde for 10 min,
permeabilized with 0.3% Triton X-100 in 1x PBS for 10 min, and washed in 1x
PBS for 5 min. Slides were then blocked with 2% bovine serum albumin (BSA) in
1x PBS for 2 hr. Slides were incubated with mouse monoclonal anti-V5 diluted
1:2000 in 2% BSA/PBS for 1 hr at room temperature, then subjected to three, 5
min washes in 1x PBS supplemented with 0.05% Tween-20 (PBS-T). Slides
were incubated with secondary Alexa 488-conjugated goat anti-mouse antibody
diluted 1:1000 in PBST for 30 min at 37C and were kept covered from light for
subsequent steps. Slides were washed for 5 min, 3x, with 1x PBS-T. All liquid
was removed from slides and a culture slide tool was used to remove culture
slide walls. One drop of VECTASHIELD (Vector Labs, Burlington, Canada)
mounting medium containing DAPI nuclear stain was added to each section of
interest. A Corning No.1 (22x50 mm) cover glass was sealed over the regions of
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interest. The samples were visualized using a TSC-SP8 confocal microscope by
Leica Microsystems (Wetzlar, Germany). A 63x objective lense with oil
immersion was used, and samples were observed at 405 nm using a 50 mW
diode laser and 488 nm using a 20 mW optically pumped semiconductor laser for
DAPI and V5-NTCP, respectively.

3.2.12

Predictive performance of in silico tools

Receiver operating characteristic (ROC) curves were generated to analyze the
performance of algorithms to predict observed TCA and rosuvastatin uptake.
Variants defined as tolerated in vitro were those with > 25% WT substrate
uptake. Variants with < 25% WT uptake activity were defined as deleterious.
Prediction scores from in vitro tolerated variants were compared to prediction
scores from in vitro deleterious variants using ROC curves generated using
GraphPad Prism 6. Area under the curve for receiver operating characteristic
curves (AUCROC) was used as a measure of predictive performance. Sensitivity
was determined by the true positive (TP) rate. True positives reflect variants with
deleterious transport in vitro that were predicted to be deleterious by the in silico
tool. False negatives (FN) are defined as having deleterious transport in vitro but
predicted tolerated by the in silico tool. Specificity was determined by calculating
the true negative (TN) rate. True negatives have no effect on transport activity in
vitro and were predicted to be tolerated by the in silico tool. False positives (FP)
are variants that display no change in transport activity in vitro yet are predicted
deleterious by the in silico tool.
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𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =

Σ 𝑇𝑃

𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =

Σ 𝑇𝑃+Σ 𝐹𝑁

Σ 𝑇𝑁
Σ 𝑇𝑁+Σ 𝐹𝑃

Σ : Sum, TP: true positive, FN: false negative

3.2.13

Predicted structures of NTCP

The 2D predicted membrane topologies of NTCP were visualized using the web
application Protter (Omasits et al., 2014). The 3D predicted structure of NTCP
was generated using Phyre2 (Kelley et al., 2015) and visualized using PyMOL
(version 1.7.4, Schrödinger, LLC). Regions involved in sodium- and bile acidbinding were identified by previous biochemical studies of NTCP (Hallen et al.,
2002; Mareninova et al., 2005).

3.2.14

Statistics

To determine statistical significance between transport activities for WT NTCP
and wild type NTCP expressing the V5 epitope, unpaired, two-tailed Student’s t
tests were performed. One-way ANOVA with Dunnett’s multiple comparisons
tests were used to determine statistical differences between the transport
activities of WT and variant NTCP. One-way ANOVA with Dunnett’s multiple
comparisons tests were also used to determine statistical differences in Michaelis
Menten Km and Vmax values between transport activities of WT and variant NTCP.
For in silico predictive algorithm performance, Mann-Whitney tests were used to
determine statistical differences AUCROC values, sensitivities, and specificities of
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the various in silico predictions. Statistical significance was set at P < 0.05. All
statistical analyses were performed using GraphPad Prism 6 (La Jolla, CA).
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3.3
3.3.1

Results
Identifying SLC10A1 variants

A total of 35 uncharacterized SLC10A1 variants were identified for
functional assessment. Thirty-one missense variants were identified using the
Ensembl Genome Browser (http://ensembl.org) with filters set to identify rare,
missense variants (< 0.5% minor allele frequency). Four additional variants were
identified by next-generation sequencing of 235 patients from London Health
Sciences Centre, Canada. All variants were scored for their predicted
deleteriousness using in silico algorithms (Table 3.4).
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Table 3.4. SLC10A1 variants for in vitro characterization and in silico prediction
NTCP (SLC10A1 ) variant information
Nucleotide AA
rs ID
change
change ID
rs201910047 c.7G>A
A3T
E
rs200758433 c.61C>T
R21C E
rs148905100 c.85G>A
V29I
E
rs536458730 c.116T>C M39T E
rs111885789 c.122C>T S41L
N
rs569402278 c.156G>C K52N
E
rs202018997 c.190G>A A64T
E
rs763683476 c.217C>A P73T
N
rs148467625 c.263T>C I88T
E
rs200105842 c.277G>A I93V
E
rs543063679 c.413T>C L138P E
rs144006534 c.477C>G I159M E
rs202007233 c.512C>T T171I E
rs571796903 c.539G>A R180Q E
rs766070047 c.551T>C M184T N
rs199771927 c.559G>C V187L E
rs553948182 c.569G>A G190E E
rs202246109 c.571G>A G191R E
rs145747967 c.583A>C I195L
E
rs202213974 c.598G>A V200M E
rs146868379 c.604G>A V202I E
rs142448421 c.613C>T L205F N
rs190268737 c.695T>C I232T E
rs139931299 c.702T>G F234L E
rs150579813 c.722C>T S241F E
rs76966244
c.745C>T R249W E
rs141269120 c.754C>A R252S E
rs141269120 c.754C>T R252C E
rs541801766 c.773G>C T258S E
rs72547507
c.836T>C I279T E
rs189313778 c.877C>G Q293E E
rs149272163 c.957G>A M319I E
rs571658472 c.982G>A E328K E
rs571658472 c.982G>C E328Q E
rs375849915 c.1024G>A E342K E

in silico predictions
MAF
(%)
0.005
0.009
0.007
0.003
0.055
0.005
0.004
0.001
0.119
0.033
0.002
0.001
0.002
0.01
0.001
0.001
0.02*
0.003
0.001
0.022
0.007
0.001
0.021
0.028
0.001
0.2*
0.02*
0.02*
0.001
0.014
0.017
0.019
0.002
0.002
0.004

SI
T
D
T
D
D
D
D
D
T
T
D
D
T
D
T
T
T
D
T
D
T
D
T
D
D
D
D
D
D
D
D
T
D
D
T

PP
T
D
T
D
D
D
D
D
T
T
D
D
T
D
T
T
T
D
T
D
T
D
T
D
T
D
D
D
D
D
D
T
D
T
T

MA
T
D
T
D
D
D
D
D
D
T
D
T
T
D
T
D
D
D
D
D
D
D
T
D
D
D
D
D
D
D
D
T
D
D
T

CA
T
D
T
D
D
D
D
D
T
T
D
T
T
D
T
T
T
D
T
D
T
D
T
D
D
D
D
D
D
D
D
T
D
D
T

RE
T
T
T
D
D
T
D
D
T
T
D
T
T
T
T
T
T
D
T
T
T
T
T
T
T
D
D
D
D
T
T
T
T
T
T

LR
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
D
D
D
D
T
T
T
T
T
T

AD
T
D
T
D
D
D
D
D
T
T
D
D
T
T
T
T
T
D
T
D
T
D
T
D
D
D
D
D
D
D
D
T
T
T
T

Acronyms and short forms: rs ID, reference single nucleotide polymorphism identification; AA,
amino acid; ID, identification; E, Ensembl genome browser; N, or next-generation sequencing;
MAF, minor allele frequency; SI, Sorting Intolerant From Tolerant (SIFT); PP, PolyPhenotyping
Version 2 (PolyPhen-2); MA, Mutation Assessor; CA, Combined Annotation-Dependent Depletion
(CADD); RE, Rare Exome Variant Ensemble Learner (REVEL); LR, Meta Logistic Regression
(MetaLR); AD, Absorption Distribution Metabolism Excretion (ADME) pharmacogeneticsoptimized algorithm; T, tolerated; D, deleterious. Minor allele frequencies were obtained from the
Exome Aggregation Consortium (ExAC) database (http://exac.broadinstitute.org/) except where
denoted by *, where frequency was determined using the 1000 Genomes database.
Classifications by these algorithms were simplified to tolerated (T) for variants predicted to have
no functional consequence and deleterious (D) for variants predicted to affect protein function.
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3.3.2

In vitro transport and protein expression
To assess the impact of these genetic variations on NTCP activity and

expression, transport assays and evaluation of NTCP protein expression and
localization were performed in transiently transfected HEK293T cells.
Stop codons for NTCP plasmids were mutated to express the 14 amino
acid V5 epitope tag for subsequent protein expression assays. Therefore, to
determine any difference in transport activities for TCA and rosuvastatin uptake,
transport by wild type (WT) NTCP expressing the stop codon and WT NTCP
expressing the V5 epitope were compared. Expression of the V5 epitope had no
measurable effect on NTCP-mediated transport of taurocholic acid and
rosuvastatin (Fig. 3.2).
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Figure 3.2. Determining the effect of the V5 epitope on substrate transport.
HEK293T cells transfected with the pEF-NTCP-Stop or pEF-NTCP-V5 plasmid were administered
5 µM TCA or 1 µM rosuvastatin and uptake was quantified at 5 min using liquid scintillation
spectroscopy or LC-MS/MS, respectively. A. TCA transport expressed as percentage of dose
administered. B. Rosuvastatin transport expressed as ratio of rosuvastatin uptake relative to d6rosuvastatin internal standard uptake. A standard curve was not used to determine concentration
of rosuvastatin uptake. Experiments were performed in duplicate on three experimental days, n=3
and results represent mean ± SEM. Statistical significance was determined using Student’s t
tests.
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After establishing no detectable difference between transport activity of
NTCP expressing the stop codon and NTCP expressing the V5 epitope, all
subsequent experiments were performed using constructs expressing the V5
epitope. To screen variants for their transport activity, uptake of 5 µM TCA and 1
µM rosuvastatin were determined (Figure 3.3).
Significantly increased transport of TCA was observed for two SLC10A1
variants, A3T and E342K (Fig. 3.3 A), which exhibited 127  10-17% of WT
NTCP activity (P < 0.05). Taurocholic acid transport was significantly reduced for
19 SLC10A1 variants (Fig. 3.3 A). Uptake by these variants ranged from 0 to
73% of WT NTCP TCA uptake activity (P < 0.05). Among these 19 variants,
robust reductions in TCA transport were observed for P73T, L138P, F234L,
S241F, R249W, R252S, and R252C (0-13  0-3% of WT NTCP uptake activity, P
< 0.0001, Fig. 3.3 A).
These same seven variants also showed marked reduction in rosuvastatin
transport, where 0-4  0-3% of WT rosuvastatin uptake activity was observed
(Fig. 3.3 B). Rosuvastatin transport was significantly increased for the T171I
variant, which displayed 194  17% of WT NTCP rosuvastatin uptake (P <
0.0001, Fig. 3.3 B).
One variant, G191R, displayed substrate specificity; transport of TCA was
comparable to WT NTCP activity (89  7%), however rosuvastatin transport was
significantly decreased to 8  2% of WT NTCP uptake (P < 0.0001).
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With regard to protein expression in HEK293T whole-cell lysates, three
distinct NTCP protein bands were observed. One band each at molecular
weights of approximately 32, 38, and 52 kDa were detected (Fig. 3.3 C).
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Figure 3.3. Substrate uptake and whole-cell NTCP protein expression of SLC10A1 variants
in HEK293T cells.
A. & B. Single timepoint substrate uptake in transfected HEK293T cells after 5 min incubation
with A. 5 µM TCA or B. 1 µM rosuvastatin. C. Whole-cell protein expression of NTCP from
transfected HEK293T lysates. Transport experiments were performed in duplicate on 3-4
experimental days and are expressed as mean percentage of wild type uptake ± SEM. Statistical
significance was assessed using one-way ANOVA with Dunnett’s multiple comparison tests, * P <
0.05, ** P < 0.01, *** P <0.0001.
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As NTCP exerts its function at the plasma membrane, cell surface
biotinylation and subsequent Western blotting were performed to determine the
extent of NTCP protein at the cell surface. Protein expression was quantified for
WT NTCP and select variants that displayed reductions in taurocholate and
rosuvastatin transport. The three-band pattern for NTCP expression was again
observed in whole-cell HEK293T lysates for WT NTCP and variants R21C, A64T,
and T258S (Fig. 3.5 A). For plasma membrane-enriched samples (Fig. 3.5 B),
the 52 kDa bands increased in intensity and the 32 and 38 kDa bands decreased
in intensity for NTCP, R21C, A64T, and T258S. This suggests that the 52 kDa
band represents NTCP protein expressed at the cell surface.
In contrast, no bands were observed at 52 kDa for the seven variants with
robust reductions in transport activity for both substrates. This was observed in
whole-cell (Fig. 3.5 A) and plasma membrane-enriched fractions (Fig. 3.5 B),
suggesting these variant proteins are not abundantly expressed at the cell
surface. Additionally, using immunofluorescence microscopy, plasma membrane
localization was detected for WT NTCP, whereas intracellular retention of NTCP
protein was observed for all variants with nearly undetectable transport activity
(Fig. 3.6).
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Figure 3.4. Whole-cell and plasma membrane expression of variant NTCP protein in
HEK293T cells
Variants with reduced transport activity: R21C A64T, and T258S. Variants with nearly
undetectable transport activity: P73T, L138P, F234L, S241F, R249W, R252S, and R252C. A.
NTCP protein expression in whole-cell HEK293T lysates. B. NTCP protein expression in plasma
membrane-enriched fractions of HEK293T cells, obtained using cell surface biotinylation..
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Figure 3.5. Immunofluorescence confocal microscopy of wild type and variant NTCP.
All variants in this figure displayed nearly absent transport for taurocholate and rosuvastatin.
DAPI was used to stain nuclei blue and Alexa-488 fluorophore was used to stain wild type and
variant NTCP fluorescent green. Scale bars represent 10 m and were obtained for WT NTCP,
and NTCP variants S241F and R252S. Scale bars are not available for variants P73T, L138P,
F234L, R249W, and R252C.
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The three band NTCP protein expression pattern is unique to our studies.
Previous in vitro studies consistently identify two protein bands for NTCP
expression. However, these studies typically use HeLa, HepG2, or HepaRG cell
lines (Ho et al., 2004; Appelman et al., 2017; Lee et al., 2018). The detected
molecular weight of NTCP protein bands in these studies range from 32-39 kDa
for the lower band and 45-65 kDa for the upper band. No additional studies
assessing NTCP protein expression in transiently transfected HEK293T cells
were identified upon literature search.
In human liver samples, NTCP protein migrates as a broad band of
approximately 56 kDa, which is reduced to 37 kDa upon deglycosylation
(Shneider et al., 1997). In HeLa cells, a band at 50 kDa was deglycosylated to 37
kDa (Ho et al., 2004). NTCP protein bands from HepG2 and HepaRG cells
treated with a deglycosylating agent shifted from 45-60 kDa to 32 kDa (Lee et al.,
2018). To elucidate whether the three band NTCP protein expression pattern
observed in our HEK293T cells was unique to HEK293T cells, we quantified WT
and variant NTCP protein expression in HeLa cells. Consistent with literature, we
observed a two-band pattern for NTCP in Hela cells (Fig. 3.7).
To determine whether the three bands in HEK293T cells represent
different extents of NTCP glycosylation, a deglycosylation assay was performed
in plasma membrane enriched HEK293T samples (Fig. 3.8). Deglycosylation
shifted the plasma membrane NTCP protein band from 52 kDa to protein streak
migrating around 38 kDa, and to a sharp band at 32 kDa.
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Figure 3.6. Whole-cell protein expression of NTCP in HeLa cells.
A. Lane 1 represents vector only control (pEF), lane 2 is WT NTCP, Lanes 3-4 are NTCP variant
proteins R21C and A64T with reduced transport activity, and lanes 5-6 are variants S241F and
F234L which show nearly abolished transport activity. Actin was used as the loading control for
this blot. B. Lane 1 represents vector only control (pEF), lane 2 is WT NTCP, Lanes 3-8 are
NTCP variant proteins L138P, F234L, S241F, R249W, R252S, and R252C which show nearly
abolished transport activity. A loading control was not performed for this blot; however, the
purpose of this blot is to indicate the two-band pattern of WT NTCP and the one band pattern
observed for loss of activity NTCP variants. This is in contrast to the three-band pattern observed
for WT NTCP and 2 band pattern observed for loss of activity variants in HEK293T cells (Fig. 3.3
C).
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Figure 3.7. Cell surface NTCP protein deglycosylation in HEK293T cells
Lane one (NTCP) represents the control sample, where the NTCP cell-surface fraction was not
treated with deglycosylating agent. Lane two (deglyc NTCP) represents an aliquot of this same
NTCP plasma membrane fraction treated with the deglycosylating agent, PNGase F.
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3.3.3

Transport kinetics
Transport kinetics were assessed for select variants to determine whether

variant activity is altered due to differences in affinity of NTCP for the substrate
(Km), rate of transport by NTCP (Vmax), or both. First, to determine the optimal
timepoint to conduct kinetic studies, time course uptake experiments were
performed. The objectives of these experiments were to determine timepoints at
which uptake is linear, which reflects that transport is not yet saturated. Uptake of
taurocholic acid and rosuvastatin occurred rapidly (Fig. 3.8). An incubation period
of 2 min was selected for subsequent kinetic studies.
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Figure 3.8. Determining linear substrate uptake timepoints for NTCP-mediated transport
Doses of A. 5 µM TCA (A) or B. 1 µM rosuvastatin were administered to HEK293T cells
expressing pEF-NTCP-V5. Uptake was quantified at 0, 2, 4, 6, 8, 10, 15, and 30 min. Studies
were conducted in duplicate on three experimental days and results are presented as mean ±
SEM.
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30

Three variants were selected for kinetic analysis based on the results from
the single time point substrate uptake assays. These include G191R, which
displayed substrate specificity (decreased rosuvastatin uptake but TCA uptake
similar to WT NTCP), and R21C and K52N, for which reduced uptake of TCA
and rosuvastatin were observed.
The Vmax for TCA uptake was significantly increased for NTCP G191R
relative to WT NTCP (P < 0.0001, Fig. 3.9 A). The Vmax for TCA uptake was
significantly reduced for NTCP R21C (P < 0.05, Fig. 3.9 A). For rosuvastatin
transport, Vmax values for NTCP R21C, NTCP K52N, and NTCP G191R were all
significantly decreased compared to WT NTCP (Fig. 3.9 B, P < 0.0001). No
significant differences were observed between WT and variant NTCP Km values
for TCA or rosuvastatin transport (Fig. 3.9).
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Figure 3.9. Transport kinetics for wild type and variant NTCP.
A. TCA transport kinetics after 2 min incubation with 0.5-100 M TCA. B. Rosuvastatin transport
kinetics after 2 min incubation with 1-200 M rosuvastatin. All experiments were performed in
duplicate on 3 experimental days and are expressed as mean ± SEM. Vmax and Km values were
determined by Michaelis-Menten nonlinear curve fitting using GraphPad Prism 6. Statistical
significance was assessed using one-way ANOVA with Dunnett’s multiple comparison tests, * P <
0.05, *** P < 0.0001.
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3.3.4

Determining the proximity of NTCP variants to amino acid
residues important in NTCP function
To assess whether loss of activity variants may affect amino acid residues

with important functions such as sodium- or bile acid-binding, variants were
mapped onto predicted two-dimensional and three-dimensional NTCP structures
(Figures 3.10-3.12). The number of transmembrane domains for NTCP remains
controversial, where some sources predict seven (Mareninova et al., 2005) and
others predict nine (Hallen et al., 2002) transmembrane domains. The seven
transmembrane model predicts sodium- and bile acid-binding sites are located
extracellularly. The nine transmembrane model predicts sodium- and bile acidbinding sites to be located intracellularly or within the membrane domain (Fig.
3.10 & 3.11).
None of the loss of activity variants directly affected amino acid residues
involved in post-translational modifications such as phosphorylation or
glycosylation (Fig. 3.10 & 3.11). Five of the loss of function and loss of plasma
membrane expression variants (F234L, S241F, R249W, R252S, and R252C)
were located within the putative bile acid-binding region of residues 221-274
(Mareninova et al., 2005) (Fig. 3.10-3.12). These variants were also in close
proximity to one of the putative Na+-binding residues, E257 (Fig. 3.10-3.12).
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Figure 3.10. Predicted topologies for NTCP with residues for TCA transport activity and
binding sites identified.
Residues involved in post-translational modifications and substrate binding are identified.
Residues mutated in this study and their corresponding transport activity for taurocholic acid are
also identified A. Predicted seven transmembrane model B. Predicted nine transmembrane
model.
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Figure 3.11. Predicted topologies for NTCP with residues for rosuvastatin transport
activity and binding sites identified.
Residues involved in post-translational modifications and substrate binding are identified.
Residues mutated in this study and their corresponding transport activity for rosuvastatin are also
identified A. Predicted seven transmembrane model B. Predicted nine transmembrane model.
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Figure 3.12. Predicted three dimensional structures for NTCP with loss of activity variants
identified.
Loss of activity and expression variants for A. taurocholic acid transport and B. rosuvastatin are
illustrated in red. Purple-coloured regions depict the predicted bile acid binding site (Mareninova
et al., 2005). Cyan regions are residues D115 and E257, critical for TCA uptake by rat NTCP and
putative sodium sensors (Zahner et al., 2003).
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For NTCP variants A64T and I279T, protein expression similar to WT
NTCP was detected, however transport of both TCA and rosuvastatin were
significantly decreased. To determine whether these variants may be within
important substrate binding regions of NTCP, A64T and I279T were mapped
onto the predicted 3D structure of NTCP. Both A64T and I279T are in close
proximity to residues important for sodium- and bile acid-binding (Figure 3.13).
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Figure 3.13. Predicted 3D structure of NTCP with identified binding sites and loss of
activity but not expression variants I279T and A64T.
Purple-coloured regions depict the predicted bile acid-binding site (Mareninova et al., 2005).
Cyan regions are residues D115 and E257, critical for TCA uptake by rat NTCP and putative
sodium sensors (Zahner et al., 2003). Red regions depict the seven variants from our study with
nearly undetectable transport activity and undetectable levels of protein expression at the plasma
membrane. Light green regions depict two NTCP variants, A64T and I279T, which show normal
protein expression yet significantly reduced transport of both TCA and rosuvastatin.
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To determine whether our loss of activity and plasma membrane
expression variants were located within amino acid residues that are
evolutionarily conserved, the human NTCP amino acid sequence was aligned
with sequences from rat and mouse NTCP orthologs, as well as the human
paralog ASBT. Six of the seven loss of activity and cell surface expression
variants (P73T, L138P, S235L, S241F, R252S, and R252C) are located at
residues conserved between a minimum of three of the four aligned sequences.
The only loss of activity and expression variant that is located at an amino acid
residue not conserved between species orthologs and protein paralogs is
R249W.
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Figure 3.14. Sequence alignment for human, mouse, and rat NTCP and human ASBT
Sequence alignment of NTCP (SLC10A1, UniProt: Q14973) to rat NTCP (rNtcp, P26435), mouse
NTCP (mNtcp, O08705), and human ASBT (SLC10A2, Q12908). Residues in cyan denote
putative sodium-binding sites, D114 and E257 (Zahner et al., 2003), which are conserved
between all species. Light blue and darker blue-coloured residues share 75% and 100%
sequence identity, respectively. The NTCP phosphorylation site, S226 (Anwer et al., 2005), is
coloured pink and is conserved by NTCP, rNtcp, and mNtcp. The seven variants identified in this
study to have loss of activity and loss of plasma membrane expression are coloured red: P73T,
L138P, F234L, S241F, R249W, R252S, R252C. The predicted bile acid-binding region spanning
NTCP residues 221-274 (Mareninova et al., 2005) is denoted by a purple box.
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3.3.5

Predictive performance of algorithms
Next, we compared in silico predicted function from a battery of seven in

silico tools to in vitro transport activities determined experimentally (Fig. 13.1513.17). Performance of in silico tools to predict reduced NTCP-mediated
transport of taurocholic acid and rosuvastatin was evaluated by determining
sensitivities, specificities, and area under the receiver operating characteristic
curves (AUCROC) (Table 3.5).
In silico tools SIFT and Mutation Assessor use evolutionary conservation
to generate predictions of genetic variation on protein function. PolyPhen-2 uses
evolutionary conservation and physicochemical properties of reference versus
mutant amino acids to predict effects on protein function. Among these three
algorithms, SIFT and Mutation Assessor predicted deleterious NTCP function for
TCA uptake with 100% sensitivity, which reflects the true positive rate (Fig. 13.15
& Table 3.5). Sensitivity of PolyPhen-2 to predict TCA transport by variant NTCP
was slightly lower at 86%. True negative rates, as reflected by specificities,
ranged from 46-50%. Overall performances to predict TCA uptake by variant
NTCP as reflected by AUCROC were 0.85, 0.69, and 0.87 for SIFT, PolyPhen-2,
and Mutation Assessor, respectively. For each of these three algorithms,
performance to predict decreased rosuvastatin transport by variant NTCP was
reduced relative to performance of TCA transport by variant NTCP. AUCROC
values reflective of rosuvastatin transport by variant NTCP were 0.72, 0.76, and
0.80 for SIFT, PolyPhen-2, and Mutation Assessor, respectively, and sensitivities
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and specificities ranged from 86-93% and 52-57%, respectively (Fig. 13.5 &
Table 3.5).
CADD, REVEL, and MetaLR are considered ensemble predictions
methods; they generate their predictions by aggregating predictive outputs from
various in silico tools. AUCROC values for CADD, REVEL, and MetaLR to predict
deleterious TCA uptake by NTCP were 0.78, 0.93, and 0.97, respectively (Fig.
3.16 & Table 3.5). CADD displayed 100% sensitivity and 50% specificity for
predicting reduced TCA transport (Fig. 3.16 & Table 3.5). Sensitivity and
specificity of REVEL to predict decreased TCA transport were 71% and 82%,
respectively. Sensitivity and specificity to predict decreased TCA transport were
43% and 96%, respectively (Fig. 3.16 & Table 3.5).
With regard to rosuvastatin transport by variant NTCP, CADD AUCROC
was 0.79, which was similar to predictive performance of CADD for TCA
transport. Sensitivity and specificity were 86% and 57%, respectively (Fig. 3.16 &
Table 3.5). Performances of REVEL and MetaLR to predict rosuvastatin transport
by variant NTCP were 0.84, which were lower than their AUCROC scores for TCA
transport. Sensitivity and specificity of REVEL were 57% and 90%, and
sensitivity and specificity were 29% and 100% for MetaLR (Fig. 3.16 & Table
3.5).
Performances of the ADME-optimized algorithm to predict TCA and
rosuvastatin uptake by variant NTCP were 0.87 and 0.78, respectively.
Sensitivities were 100% and 79% and specificities were 57% and 62% to predict
TCA and rosuvastatin uptake, respectively (Fig. 13.17 & Table 3.5).
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Overall, no algorithm was able to predict taurocholic acid and rosuvastatin
uptake with 100% accuracy (Fig. 3.15-3.17 and Table 3.5). Ranked performance,
for predicting variant NTCP uptake of TCA based on AUCROC was as follows:
MetaLR > REVEL > Mutation Assessor > ADME-optimized > SIFT > CADD >
PolyPhen-2. For predicting rosuvastatin uptake, ranked performance based on
AUCROC was as follows: MetaLR = REVEL > Mutation Assessor > CADD >
ADME-optimized > PolyPhen-2 > SIFT. Sensitivities (true positive rates) to
predict TCA uptake were 100% for SIFT, Mutation Assessor, CADD, and ADME,
and specificities (false positive rates) for these algorithms ranged from 46-59%.
No algorithm predicted rosuvastatin uptake with 100% sensitivity.
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Figure 3.15. Performance of in silico tools optimized for evolutionary conservation and
amino acid properties to predict in vitro NTCP variant transport activity
Variants were grouped by uptake activity in vitro, depicted as mean percentages of wild type
(WT) uptake along the x-axes. Uptake <25% is depicted in red, 25-75% in orange, and >75% in
green. In silico scores are plotted on the y-axes. True positives (accurate predictions) are
represented by red circles within the gray shaded areas. True negatives (accurate predictions)
are represented by green and orange circles that fall outside of gray area. False negatives
(inaccurate predictions) are depicted when red circles fall outside the gray area. False positives
(inaccurate predictions) are illustrated when green and orange circles fall within the gray area.
Threshold for deleterious scores by algorithm are A. SIFT (sorting intolerant from tolerant): < 0.05
B. PolyPhen-2: > 0.5, and C. Mutation Assessor: > 0.5. Mean prediction score per group is
indicated ± SEM.
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Figure 3.16. Performance of in silico tools optimized using outputs from multiple in silico
scoring tools to predict in vitro NTCP variant transport activity
Variants were grouped by uptake activity in vitro, depicted as mean percentages of wild type
(WT) uptake along the x-axes. Uptake <25% is depicted in red, 25-75% in orange, and >75% in
green. In silico scores are plotted on the y-axes. True positives (accurate predictions) are
represented by red circles within the gray shaded areas. True negatives (accurate predictions)
are represented by green and orange circles that fall outside of gray area. False negatives
(inaccurate predictions) are depicted when red circles fall outside the gray area. False positives
(inaccurate predictions) are illustrated when green and orange circles fall within the gray area.
Threshold for deleterious scores by algorithm are A. Combined Annotation-Dependent Depletion
(CADD): > 20, B. Rare Exome Variant Ensemble Learner (REVEL): > 0.5, C. Meta Logistic
Regression (MetaLR): > 0.5. Mean prediction score per group is indicated ± SEM.
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Figure 3.17. Performance of the ADME-optimised in silico tool to predict in vitro NTCP
variant transport activity
Variants were grouped by uptake activity in vitro, depicted as mean percentages of wild type
(WT) uptake along the x-axes. Uptake <25% is depicted in red, 25-75% in orange, and >75% in
green. In silico scores are plotted on the y-axes. True positives (accurate predictions) are
represented by red circles within the gray shaded areas. True negatives (accurate predictions)
are represented by green and orange circles that fall outside of gray area. False negatives
(inaccurate predictions) are depicted when red circles fall outside the gray area. False positives
(inaccurate predictions) are illustrated when green and orange circles fall within the gray area.
Scores were generated from the ADME-optimized prediction framework (Zhou et al., 2019).
Deleterious predictions: scores > 0.5. Mean prediction score per group is indicated ± SEM.
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Table 3.5. Performance of in silico tools to predict taurocholic acid and rosuvastatin
uptake.
TCA uptake
Predictive
performance
Algorithm
Category
Threshold (AUCROC)
SIFT
Functionality <0.05
0.85
PolyPhen-2
prediction
>0.5
0.69
Mutation Assessor
>0.5
0.87
CADD
Aggregate
>20
0.78
REVEL
scores
>0.5
0.93
MetaLR
>0.5
0.97
ADME
PGx optimized >0.5
0.87

Rosuvastatin uptake
Sensitivity Specificity
(%)
(%)
100
86
100
100
71
43
100

46
50
46
50
82
96
57

Predictive
performance
(AUCROC)
0.72
0.76
0.80
0.79
0.84
0.84
0.78

Sensitivity Specificity
(%)
(%)
86
79
93
86
57
29
79

52
57
57
57
90
100
62

Threshold values are expressed as arbitrary units and are indicative of scores that predict a
variant to be deleterious by each algorithm. Area under the receiver operating characteristic curve
(AUCROC) values were calculated using GraphPad Prism 6. Sensitivity and specificity were
calculated using the following equations:
Σ 𝑇𝑃
Σ 𝑇𝑁
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =
Σ 𝑇𝑃+Σ 𝐹𝑁

Σ 𝑇𝑁+Σ 𝐹𝑃
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3.4

Discussion

NTCP plays a central role in bile acid and rosuvastatin transport, as well
as HBV and HDV infection; thus, genetic variation in SLC10A1 may contribute to
disease and adverse drug events (Ho et al., 2004; Yan et al., 2012). However,
there is a paucity of information regarding effects of human SLC10A1 genetic
variation on NTCP function. Furthermore, next generation sequencing has
revealed a vast extent of rare genetic variants of unknown clinical significance
within the human genome. Prioritization of rare variants for functional study
based on the likelihood of altered protein function is therefore an important part
of streamlining their characterization. Our study was designed to determine
effects of rare, missense genetic variation in SLC10A1 on NTCP transport
activity and protein expression.
Of thirty-five previously uncharacterized NTCP variants, we identified
seven with nearly absent transport of the endogenous and drug substrates
taurocholic acid and rosuvastatin. These seven genetic variants produced the
following amino acid substitutions: P73T, L138P, F234L, S241F, R249W, R252S,
R252C. Although variant NTCP protein was detected in whole-cell lysates, their
expression was virtually undetectable at the plasma membrane, which likely
explains the loss of transport of both substrates. Amino acid sequence
alignments reveal that six of these seven residues are located in highly
conserved regions, indicating their relative importance in NTCP protein function.
Two variants, A3T and E342K showed modest but significant increases in
taurocholic acid. Nearly 2-fold higher rosuvastatin uptake was observed for the
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T171I variant. Interestingly, a substrate-specific effect was observed for the
G191R variant; this variation did not affect TCA uptake, however rosuvastatin
uptake was markedly reduced.
In silico tools were moderate to good predictors of in vitro taurocholic acid
transport. Four of the seven employed tools accurately predicted deleterious
activity for all of the seven of the loss of activity and loss of plasma membrane
expression variants. The ADME-optimized in silico tool was no better than other
tools for predicting uptake of rosuvastatin by variant forms of NTCP. These
results suggest that in silico predictions are not robust enough to replace
functional assessment of SLC10A1 genetic variation in vitro. Although the
ADME-optimized tool was developed using data for a variety of pharmacogenes,
including SLC10A2, further optimization for predicted function to transport a
specific class of drug by structure-function and drug binding studies may improve
predictions for substrate-specific functional effects.
Although statistically significant differences in activity were found for 19
variants, intrinsic variability typical of heterologous expression systems may
account for moderate changes in transport activity. Therefore, the most
conclusive findings of our study centralize around the variants that displayed <
25% wild type NTCP activity.
Genetic variation in SLC10A1 is dependent on ethnicity (Ho et al., 2004; Pan
et al., 2011). The most common missense variant, NTCP S267F, is present in
5.0-7.5% of East Asian populations, with a global MAF <1% (Ho et al., 2004; Pan
et al., 2011; Cunningham et al., 2019). This variant was reported to be protective
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against HBV and HDV infection and showed nearly abolished TCA uptake,
however transport of rosuvastatin was markedly increased (Ho et al., 2004; Ho et
al., 2006; Hu et al., 2016; An et al., 2018; Chuaypen et al., 2019).
Adding to the previous observation that the I279T variant was normally
expressed in vitro yet displayed reduced bile acid transport (Ho et al., 2004), we
now show significantly reduced rosuvastatin transport by this variant. In 2011,
Pan et al. reported decreased uptake of TCA and rosuvastatin, as well as
ethnicity-dependent allele frequencies for NTCP A64T (Pan et al., 2011).
Findings from our study add that both whole-cell and plasma membrane
expression of this variant are comparable to expression of WT NTCP. We
therefore speculate that decreased transport may be the result of decreased
substrate affinity or rate of translocation.
NTCP is glycosylated at residues N5 and N11, and plasma membrane
expression relies on glycosylation of at least one of these sites (Hagenbuch,
1997; Appelman et al., 2017). In vitro studies noted that the NTCP variant R252H
displayed insufficient glycosylation and lack of expression at the plasma
membrane (Vaz et al., 2015). Our results depict a pattern of three NTCP protein
bands in transiently transfected HEK293T cells, whereas our study and others
report a two band NTCP protein expression pattern in other cell lines. Our results
suggest that the lowest molecular weight protein band in HEK293T cells
represents fully deglycosylated NTCP protein. We therefore speculate that the
process of glycosylation may be differ in HEK293T cells relative to HeLa or
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HepG2 cells. This is supported by findings that cellular repertoires can produce
different glycosylation patterns (Goh and Ng, 2018).
Studies suggest the highest molecular weight NTCP protein band represents
fully mature glycosylated protein (Ananthanarayanan et al., 1994; Ho et al., 2004;
Appelman et al., 2017). This mature glycosylated form of protein is absent for the
seven variants that also display reduced transport of both substrates. Structural
changes induced by the variations may interfere with NTCP glycosylation,
leading to intrinsic instability and rapid degradation by proteases. Alternatively,
these variations may alter plasma membrane trafficking of NTCP protein. In
addition to glycosylation, NTCP undergoes a variety of post-translational
modifications that affect plasma membrane expression and substrate transport,
including phosphorylation and S-nitrosylation (Anwer et al., 2005; Schonhoff et
al., 2011; Ramasamy et al., 2013; Anwer and Stieger, 2014). Though none of the
genetic variants in our study directly affect residues important in posttranslational modifications, it is possible these variations induce structural
changes that interfere with modifications of these sites. Further studies will be
necessary to determine mechanisms altering plasma membrane expression of
these variants.
Biochemical studies predict NTCP to be a seven- or nine-transmembrane
domain protein. The seven transmembrane structure predicts extracellular Na+and bile acid-binding sites and an intracellular phosphorylation site, whereas the
nine-transmembrane model predicts intracellular localization of Na +- and bile acid
-binding sites (Hagenbuch et al., 1991; Hallen et al., 2002; Mareninova et al.,
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2005). These notions suggest that the seven transmembrane model is likely a
more accurate depiction of the membrane topology of NTCP. Interestingly, a
region recognized as crucial for bile acid-binding and transport spans amino
acids 221-274 of NTCP (Mareninova et al., 2005), the same region where five of
the seven loss of function variants identified by our study reside. Further,
mutagenesis studies show that residues S267 and C266 are required for bile
acid transport, and E257 is necessary for optimal sodium-binding (Saeki et al.,
2002; Zahner et al., 2003; Ho et al., 2004). When mapped onto the predicted 3D
structure of NTCP another putative sodium sensor, D115, is in close proximity to
the bile acid-binding region. Taken together, many of the loss of activity and
expression variants are located within a region integral to the physiological
function of NTCP, providing further support that these mutations are likely to play
a functional role.
Though we were able to successfully characterize 35 missense variants, this
is only a fraction of the 279 missense SLC10A1 variants that have been reported
to date in the Genome Aggregate Database (https://gnomad.broadinstitute.org,
accessed November 2019). One remaining challenge in functional
characterization of variants is that in vitro testing remains time and resource
consuming. High-throughput assays present an attractive solution to the
traditional low-throughput approach. These methodologies are conducted by
introducing a pooled library of genetic variants into cultured mammalian cells,
with each cell expressing a single genetic variation. Subsequently, phenotypic
assessment is carried out using protein abundance, stability, or toxicity assays
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(Starita et al., 2017; Weile and Roth, 2018). However, high-throughput
characterization remains technically challenging. Furthermore, these
methodologies are often inadequate to study protein localization and posttranslational modifications, which are highly relevant to the function of many
transporter proteins (Fowler and Fields, 2014; Starita et al., 2015; Ipe et al.,
2017). Accordingly, robust in silico algorithms with high predictive power are
becoming increasingly important to identify potential loss of activity rare variants.
One remaining limitation to this approach is that, for the most part, these
algorithms have been optimized to reflect effects related to physiological function.
Few in silico tools have been optimized with respect to drug transport or
metabolism, and predictions become even more complicated when variations
display substrate-dependent effects (Gulilat et al., 2019; Zhou et al., 2019).
Functionality predictions by algorithms chosen in this study display some
concordance. SIFT, Mutation Assessor, CADD, and ADME were 100% sensitive
at predicting TCA uptake. These algorithms generated deleterious predictions for
all seven loss of activity and loss of expression variants. Furthermore, four of
these seven variants were predicted deleterious by all seven algorithms. When
comparing prediction sensitivities for TCA uptake to prediction sensitivities for
rosuvastatin uptake, each algorithm predicted transport of the endogenous
substrate, TCA, with a higher degree of sensitivity. These data emphasize
complexities of applying in silico algorithms to predict pharmacogenetic effects,
as results can vary depending on the substrate.
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Results from the current study show that algorithms that portrayed high
sensitivity had low specificity, and vice versa. This is exemplified by MetaLR
which showed 100% specificity to predict TCA and rosuvastatin uptake, yet
sensitivities were limited to 50% and 29%, respectively. To optimize an algorithm,
it is important to consider the threshold used to define a deleterious variant
(Berrar and Flach, 2012). In our study, variants were defined as deleterious with
a threshold of < 25% wild type NTCP activity, which is lower than the < 50%
activity threshold used for the ADME-optimized algorithm (Zhou et al., 2019).
Using this < 50% activity threshold, specificity of ADME to predict TCA uptake
increases from 57% to 66%, and sensitivity and specificity to predict rosuvastatin
uptake increase from 79% to 83% and 62% to 76%, respectively. This highlights
the importance of selecting the threshold that classifies a variant as deleterious.
The ideal threshold will give the best compromise between sensitivity and
specificity (Berrar and Flach, 2012).
In conclusion, we identified seven previously uncharacterized, rare, missense
SLC10A1 variants with reduced transport activity for NTCP substrates
taurocholic acid and rosuvastatin, likely subsequent to their inability to traffic or
be retained at the plasma membrane. We also identified one variant that
maintained taurocholic acid uptake but for which rosuvastatin transport was
nearly absent. The in vivo relevance of these genetic variations remains unclear,
however we expect that homozygous carriers of these loss of activity variants
would display hypercholanemia as observed for variant carriers of NTCP S267F
(Vaz et al., 2015; Deng et al., 2016; Liu et al., 2017; Qiu et al., 2017). We reveal
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that currently available in silico algorithms do not adequately predict variant
NTCP activity, thus in vitro functional assessment remains an important first step
in determining which variants may be of clinical importance. These findings
suggest that further optimization of in silico prediction tools is required to
enhance their applicability for classifying rare variants as deleterious or tolerated.
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4

Evaluating serum bile acid composition, bile acid gene
expression, and rosuvastatin disposition in Slc10a1-/mice
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4.1

Introduction

In addition to their well-known roles in digestive processes, bile acids are
important signaling molecules that modulate bile acid synthesis and transport
within the enterohepatic system. Bile acids are synthesized in hepatocytes,
secreted into bile, and released into the duodenum to facilitate solubilization of
lipids and xenobiotics for nutrient absorption. Bile acids are efficiently circulated
throughout the enterohepatic system by plasma membrane-bound uptake and
efflux transport proteins in enterocytes and hepatocytes (Dawson et al., 2009).
Due to their detergent properties, excessive extracellular or intracellular
accumulation of bile acids, known as hypercholanemia and cholestasis,
respectively, can mediate toxicity by breaking down cellular membranes.
Additionally, different bile acids have different capacities to mediate toxicity;
cholic acids are more toxic to lipid membranes than are muricholic acids (Li and
Dawson, 2019).
Bile acid homeostasis is controlled by nuclear receptor signaling. Bile
acids are ligands for nuclear receptors including the farnesoid X receptor (FXR),
the pregnane X receptor (PXR), and the vitamin D receptor (VDR). Additionally,
bile acids indirectly activate the constitutive androstane receptor (CAR). These
nuclear receptors are ligand-activated transcription factors that regulate
transcription of genes involved in bile acid synthesis, transport, and detoxification
(Chiang, 2013). Genetic variation in bile acid transporters and the resulting
dysregulation of nuclear receptor signaling have been linked to a variety of
cholestatic and metabolic conditions (Kosters and Karpen, 2008).
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Sodium taurocholate co-transporting polypeptide (NTCP; SLC10A1) is a
key hepatic bile acid uptake transporter with preference for conjugated bile acids
(Dawson et al., 2009). In humans, homozygous missense mutations in SLC10A1
have been associated with vitamin D deficiency and persistent serum
hypercholanemia, with bile acid concentrations reaching as high as 1531 µM
(normal range: 0-16µM) (Vaz et al., 2015; Deng et al., 2016; Liu et al., 2017; Qiu
et al., 2017).
Two independent mouse lines in which the Slc10a1 gene was targeted
have been generated (Slijepcevic et al., 2015; Mao et al., 2019). The first study
reported a surprising bimodal phenotype in Slc10a1-/- mice; serum bile acid
concentrations were highly elevated and bile acid transporter expression was
altered in 30-35% of adult Slc10a1-/-mice. The remaining mice displayed
physiological serum bile acid concentrations and expression of bile acid
transporters comparable to control animals (Slijepcevic et al., 2015).
The second study of Slc10a1-/- mice observed a similar hypercholanemic
phenotype in some animals aged four and eight weeks, noting important
differences in expression of hepatic genes that control bile acid synthesis,
transport, and detoxification. Following mice over time, investigators reported that
serum bile acid concentrations decreased with age. Furthermore, hepatic bile
acid transporter gene expression tended to normalize to levels seen in control
animals by 20 months of age. Importantly, however, some mice remained
hypercholanemic even at 20-month age mark (Mao et al., 2019). Authors also
quantified serum bile acids in NTCP-deficient humans over time and noted that
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bile acid concentrations are highest within the first three months of life and
typically decline over time. However, some NTCP-deficient humans also
remained hypercholanemic, with bile acid concentrations over 100 µM in certain
individuals seven years of age (Mao et al., 2019).
In addition to its central role in bile acid uptake, NTCP is also capable of
drug transport and may be important in hepatic uptake of rosuvastatin (Ho et al.,
2006). Statins are a common class of lipid-lowering drugs. Their primary
therapeutic effect is lowering cholesterol. This is achieved by inhibiting the ratelimiting enzyme in hepatic cholesterol synthesis, 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase. Rosuvastatin is a commonly prescribed,
hydrophilic statin that is minimally metabolized in the liver. Hepatic disposition of
rosuvastatin is therefore highly dependent on transporters (Stancu and Sima,
2001). Further, increased plasma concentrations of statin in the blood has been
linked to increased risk of statin-induced myopathy (Link et al., 2008; DeGorter et
al., 2013). Studies in human hepatocytes have identified OATP1B1, OATP1B3,
OATP2B1, and NTCP as rosuvastatin transporters (Ho et al., 2006). Genetic
polymorphisms in OATP transporters explain some of the variability seen in
plasma rosuvastatin concentrations (DeGorter et al., 2013). However, the
remaining unexplained variability in rosuvastatin concentrations in the plasma
may contribute to adverse events. Investigation into additional factors influencing
statin disposition will help maximize their safety and efficacy (Link et al., 2008).
Despite recent advancements in studying mouse models of NTCP
deficiency, information regarding differences between normocholanemic and
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hypercholanemic phenotypes induced by Slc10a1 disruption remains limited.
Moreover, although the impact of OATP deficiency on rosuvastatin disposition
has been evaluated in a variety of OATP-null mouse models (Chen et al., 2008;
Zaher et al., 2008; van de Steeg et al., 2010; DeGorter et al., 2012; Medwid et
al., 2019), the relative importance of NTCP to rosuvastatin disposition has not yet
been elucidated in vivo.
This study was designed to evaluate serum bile acid composition and
hepatic, ileal, and renal mRNA levels in a third, independent Slc10a1-/- mouse
model. Additionally, this study aimed to assess the role of Slc10a1 gene
disruption on hepatic rosuvastatin disposition in mice.
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Methods & Materials

4.2
4.2.1

Materials

Rosuvastatin, d6-rosuvastatin, and d5-Taurocholic acid were purchased from
Toronto Research Chemicals (Toronto, ON). All other chemicals, unless
otherwise stated, were obtained from Millipore-Sigma (St. Louis, MO).

4.2.2

Animal use approval

All animal experiments were approved by the University of Western Ontario
Animal Care Committee (Protocol No. 2015-011), according to regulations and
guidelines of the Canadian Council on Animal Care. Approval is listed in
Appendix C.

4.2.3

Liver-specific targeted disruption of Slc10a1 in C57BL/6
mice

The approach used to disrupt the mouse Slc10a1 gene is depicted in Figure 4.1.
A targeting vector designed by the Mouse Biology Program and UC Davis (Davis,
CA) was injected into C57BL/6 embryos, where homologous recombination
resulted in the insertion of a LoxP site between exons 1 and 2, and insertion of a
neomycin cassette followed by a second LoxP site between exons 2 and 3.
Selection of embryos with the integrated target vector was performed using
diptheria toxin A (DTA). Floxed mice were mated with mice expressing Cre
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recombinase driven by the liver-specific Albumin promoter, B6.Cg-Tg(Albcre)21Mgn/J (The Jackson Laboratory, stock number 003574). Exon 2 of
Slc10a1 was replaced by the PGK-NEO cassette located in the targeting vector
to generate Slc10a1-/- mice.
Mice homozygous for the LoxP-flanked Slc10a1 gene were mated with
mice homozygous for the liver-specific Cre transgene to generate Slc10a1-/- mice.
Heterozygous Slc10a1+/- mice were generated by crossing mice heterozygous for
the LoxP flanked Slc10a1 gene with mice homozygous for the liver-specific Cre
transgene. Mice homozygous for the LoxP-flanked Slc10a1 gene mated with
animals that do not express the Cre transgene were used as wild type control
animals and will be hereafter referred to as controls.
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Generation of a conditional allele to knock-out the Slc10a1 gene

3 4

1 2Slc10a1.
Figure 4.1. Liver-specific targeted disruption
A schematic of the wild type (wt) mouse Slc10a1 gene and the targeting vector for disruption of
the mouse Slc10a1 gene. PGK-DTA: Diptheria Toxin A driven by the phosphoglycerate kinase
(PGK) promoter, used for negative selection; PGK-NEO: neomycin selection cassette driven by
the PGK promoter. Black horizontal arrows represent LoxP sites for Cre recombinase recognition.
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4.2.4

Quantification of serum total bile acids by colorimetric assay

Immediately following isoflurane overdose, blood was collected from mice using
cardiac puncture and was incubated at room temperature for 15 min to allow for
clotting. Blood was then centrifuged for 10 min at 2,000 x g and 4°C. The
supernatant was used to measure bile acids in the serum immediately or was
stored at -20°C for bile acid quantification within 3 months of sample collection.
Total serum bile acids were quantified following the protocol for the Total Bile
Acids Assay Kit (Diazyme Laboratories Inc., Poway, CA).

4.2.5

Quantification of serum individual bile acids by LC-MS/MS

Individual serum bile acids were quantified using ultra-high-performance liquid
chromatography tandem mass spectrometry (UHPLC-MS/MS). On the day of
measurement, samples were thawed at 4°C and 50 µL were transferred to clean
microcentrifuge tubes. Calibration curves were prepared in 1:1 (v/v)
methanol:acetonitrile supplemented with various concentrations of bile acids:
cholic acid (CA), deoxycholic acid (DCA), taurocholic acid (TCA),
taurodeoxycholic acid (TDCA), α and β muricholic acids (αMCA, βMCA), tauro-αmuricholic acid (TαMCA) and tauro-β-muricholic acid (TβMCA). The internal
standard (IS) solution was composed of TCA-d5 in 1:1 (v/v) MeOH:ACN. One
hundred µL of ice-cold IS solution were added to each mouse blood and
standard curve sample. Samples were mixed at 1400 RPM in a shaker placed at
4°C for 15 min. To induce protein precipitation, samples were incubated at -20°C
for 20 min followed by centrifugation at 18,000 x g at 4°C for 15 min. The
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supernatants were collected for UHPLC-MS/MS analysis, and samples were kept
at 4°C prior to column injection. Analytes were separated by ultra-highperformance liquid chromatography (Agilent 1290 Infinity LC Injector; Agilent,
Santa Clara, CA) using a Kinetex 2.6 µm C18 100Å Reversed Phase LC Column,
50 x 3 mm (Phenomenex, Torrance, CA) following sample injection (40 µL per
sample). A mobile phase of 2mM ammonium acetate in 9:1 H2O:ACN (v/v)
adjusted to pH 4.15 (A) and equal parts ACN:C3H8O:H2O (1:1:1) (B) was used
with an elution gradient of 10% B at a flow rate of 0.5 mL/min from 0-1 min, 1070% B at 0.6 mL/min from 1-9 min, 70-80% B at 0.5 mL/min from 9-10 min, and
80-10% B at 0.5 mL/min from 10-12 min, with a wash period at 10% B from 1215 min at a flow rate 0.5mL/min. The heated electrospray ionization source of the
triple quadrupole mass spectrometer (Finnigan TSQ Quantum Ultra; Thermo
Fisher Scientific) was operated in negative mode (4500V, 350°C) with collision
energies listed in Table 4.1. Sheath gas pressure was set to 45 psi, auxiliary gas
pressure was 15 psi, and capillary temperature was 350°C. Multiple reaction
monitoring was performed using mass-to-charge ratio transitions and retention
times are listed in Table 4.1. Calibration curves were linear with concentrations
between 0 and 50 µM. Interday accuracy and precision were 18.5% and 22.1%
respectively. The lower limits of quantification were between 10 and 50 nM.
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Table 4.1. Bile acid mass spectrometry parameters
Parent mass
Product mass
CE
RT
(g/mol)
(g/mol)
(eV)
(min)
DCA
391.285
Parent quantified
10
6.65
αMCA
407.280
Parent quantified
10
4.96
βMCA
407.300
Parent quantified
10
5.02
CA
407.370
Parent quantified
10
5.80
TDCA
498.280
80.11
80
4.71
TαβMCA
514.300
80.11
80
3.20
TCA
514.380
80.11
80
3.85
TCA-d5
519.420
80.11
80
3.20
CE: collision energy (eV: electron volts), RT: retention time (minutes)
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4.2.6

Quantification of mRNA in mouse tissues

Liver, kidney, and terminal ileum sections were isolated from mice immediately
following isoflurane overdose. RNA was extracted using TRIzol reagent (Life
Technologies, Carlsbad, CA). RNA was reverse transcribed to cDNA using
random hexamers (Multiscribe; Applied Biosystems, Foster City, CA).
Quantitative polymerase chain reaction using SYBR Green (7500 system;
Applied Biosystems) was used to determine relative mRNA levels of genes
involved in bile acid disposition, including synthesis enzymes and transporters.
Target mRNA levels were normalized to those of 18S ribosomal RNA using
TaqMan reagents (Applied Biosystems). Primer sequences are listed in Table
4.2.
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Table 4.2. Primers used for qPCR
Mouse Gene
Slc10a1
Slc10a2
Slco1a1
Slco1a4
Slco1b2
Abcb1a
Abcb11
Abcc2
Abcc3
Abcc4
Slc51a
Slc51b
Nr0b2
Fgf15
Cyp7a1
Cyp8b1
Cyp27a1

Protein
NTCP
ASBT
OATP1A1
OATP1A4
OATP1B2
MDR1A (P-gp)
BSEP
MRP2
MRP3
MRP4
OSTα
OSTβ
SHP
FGF15
CYP7A1
CYP8B1
CYP27A1

Forward Primer
5'-GGCTTCCTGATGGGCTACATT-3'
5'-CCATGGGGTATCTTCGTGGG-3'
5'-GTGCATACCTAGCCAAATCACT-3'
5'-CCCAGAGCTCTCCAGTTTTG-3'
5'-TGGGCATTGGGAGTATTCTGA-3'
5'-CTCTTTGACTCGGGAGCAGAA-3'
5'-CTGCCAAGGATGCTAATGCA-3'
5'-CTGAGTGCTTGGACCAGTGA-3'
5'-CTGGGTCCCCTGCATCTAC-3'
5'-GAACAAGCAAGGTGCACTGA-3'
5'-CACTGGCTCAGTTGCCATTT-3'
5'-GCAAACAGAAATCGAAAGAAGC-3'
5'-CGATCCTCTTCAACCCAGATG-3'
5'-GCCATCAAGGACGTCAGCA-3'
5'-AACAACCTGCCAGTACTAGATAGC-3'
5'-GCCTTCAAGTATGATCGGTTCCT-3'
5'-CTGCGTCAGGCTTTGAAACA-3'
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Reverse Primer
5'-AGAGTTGGACGTTTTGGAATCC-3'
5'-GTTCCCGAGTCAACCCACAT-3'
5'-CCAGGCCCATAACCACACA-3'
5'-TCCCATGTTGTTCTTCTGATTG-3'
5'-CCAGGTGTATGAGTTGGACCC-3'
5'-CGGAAACAAGCAGCATAAGAAA-3'
5'-CGATGGCTACCCTTTGCTTCT-3'
5'-CAAAGTCTGGGGGAGTGTGT-3'
5'-GCCGTCTTGAGCCTGGATAAC-3'
5'-TGCATCAAACAGCTCCTGAC-3'
5'-GCATACGGCATAAAACGAGGT-3'
5'-TCTGGCAGAAAGACAAGTGAT-3'
5'-AGGGCTCCAAGACTTCACACA-3'
5'-CTTCCTCCGAGTAGCGAATCAG-3'
5'-GTGTAGAGTGAAGTCCTCCTTAGC-3'
5'-GATCTTCTTGCCCGACTTGTAGA-3'
5'-TCGTTTAAGGCATCCGTGTAGA-3'

4.2.7

Mouse necropsy

Five male Slc10a1-/- mice that failed to thrive were euthanized at ages 4-6 weeks
due to hunched posture, reduced locomotion, and occasional blood in the urine.
Veterinary pathologists examined them to determine potential causes of failure to
thrive. Tissues examined by histology included kidneys, heart, lung, esophagus,
trachea, small intestine, large intestines, stomach, liver, thyroid gland,
gallbladder, urinary bladder, bone marrow, skeletal muscle, uterus, testicle, and
spleen.

4.2.8

Rosuvastatin studies

Control and Slc10a1-/- mice were fasted 16 hr prior to oral gavage of rosuvastatin
(10 mg/kg body weight) dissolved in 1x PBS. Mice were sacrificed 2 hr after
rosuvastatin administration, blood was collected via cardiac puncture, and livers
were harvested. The concentrations of rosuvastatin in serum and liver were
determined using an adapted LC-MS/MS described below (DeGorter et al.,
2012). Livers were diluted in acetonitrile (1:1 w/v) containing the internal standard
d6-rosuvastatin. Livers were homogenized using a VeriSonic ultrasonic tissue
homogenizer using ten, one-second pulses at eight watts at room temperature.
The homogenates were centrifuged for 20 min at 10,000 x g at 4°C. Proteins in
serum samples were precipitated by the addition of acetonitrile (1:1 v/v)
containing the internal standard d6-rosuvastatin diluted to a final concentration of
20 ng/mL and centrifuged for 20 min at 10,000 x g at 4°C. A volume of 100 µL
supernatant from serum or liver samples was added to a volume of 200 µL
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0.05% formic acid (1:2 dilution (v/v) and analyzed by LC-MS/MS. Solutes were
separated by reversed-phase chromatography using a TLX2 high-performance
liquid chromatography system (Thermo Fisher Scientific). A 50 µL aliquot of the
diluted serum or liver sample containing internal standard was injected onto a
Hypersil GOLD C18 column (50 × 3 mm, 5 μm; Thermo Fisher Scientific) and
analytes were separated using a 0.05% formic acid and acetonitrile solvent
gradient from a ratio of 70:30 v/v to 10:90 v/v. After electrospray ionization,
positive mode mass spectrometric detection was carried out using the TSQ
Vantage triple quadrupole mass spectrometer (Thermo Fisher Scientific) with a
HESI II probe (Thermo Fisher Scientific). Mass-to-charge transitions were 482.1
→ 258.2 m/z for rosuvastatin and 488.0 → 264.3 m/z for d6-rosuvastatin.
Calibration curves were created with blank mouse serum and blank mouse liver
homogenates from wild type C57BL/6 mice, with rosuvastatin concentrations in
the linear range between 100 to 2000 ng/mL for liver samples, and 1 to 100
ng/mL for serum samples. Interday accuracy and precision were 5.8% and 8.9%,
respectively, and the lower limit of quantitation was 1 ng/mL.

4.2.9

Statistics

Mann-Whitney tests were used to determine statistical differences between two
groups where normal distribution was not observed. Student’s t tests were used
to determine statistical differences between two groups where normal distribution
was observed. One-way ANOVA with Tukey’s multiple comparison tests were
used to determine statistical differences between three groups. Serum bile acids
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and mRNA levels for control, normocholanemic Slc10a1-/-, and hypercholanemic
Slc10a1-/- mice were quantified in four- to six-week old mice (n=4-5 male mice
per group). Rosuvastatin studies and associated qPCR were conducted in tenweek-old mice (n=3-5 male mice per group). LC-MS/MS measurements for
individual bile acids and rosuvastatin were performed once per mouse sample,
and results are presented as mean ± SD. Total bile acid measurements were
performed in duplicate and quantitative PCR was performed in triplicate; these
results are presented as mean ± SEM. All statistical analyses were conducted
using GraphPad Prism 6 (La Jolla, CA) and statistical significance was deemed
at P < 0.05..
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4.3
4.3.1

Results
Mouse phenotype

Relative mRNA levels were quantified to infer the extent of Slc10a1 gene
transcription in these mice. Relative to control animals, Ntcp (Slc10a1) mRNA
levels were reduced 2-fold in heterozygous Slc10a1+/- mice (P < 0.0001, Fig. 4.2)
and >15 fold in homozygous Slc10a1-/- mice (P < 0.0001, Fig. 4.2).
In Slc10a1-/- mice, a bimodal phenotype was observed. Overall,
approximately 45% of Slc10a1-/- mice failed to thrive beginning at four weeks of
age and died by seven weeks of age (Fig. 4.3). Between the ages of four and
eight weeks, these mice appeared lethargic as subjectively observed by reduced
locomotion and hunched posture. These mice also appeared dehydrated by
reduced ability of skin to return to normal shape after pinching, and blood was
detected in urine of some of these mice. No discernable pattern was observed in
survival of these mice based on the breeding pair or litter. In some litters, all
Slc10a1-/- mice would survive. In other litters, 15-100% of Slc10a1-/- mice would
fail to thrive and succumb by seven weeks of age. This is the first report of
mortality in a subset of Slc10a1-/- mice.
Five male mice that appeared hunched with reduced locomotion,
dehydration, and blood in urine were euthanized between the ages of four and
six weeks for preliminary necropsies. Findings indicated that these Slc10a1-/mice were small for their age, with thin bodies and slightly jaundiced body
cavities. Gallbladders were enlarged, bile ducts were not prominent, and
compression of the gallbladder did not release bile into the duodenum. This
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usually occurs subsequent to obstruction or from a congenital lack of a portion of
the ductal wall, known as cholangiectasis. Bilirubin was found in the urine which
may indicate diseased liver. Upon histological analysis, mice were found to have
hyperplasia of the gallbladder, tubular degeneration in the kidneys, and bile acid
depositions in the kidney resulting in bile cast nephropathy. Bile acid deposits
were also observed in the bile canaliculi of the liver. Some hepatocyte swelling
and necrosis were observed. Low body fat and may reflect decreased nutritional
absorption. Subcutaneous administration of saline reversed this failure to thrive
phenotype in mice. In mice that appeared lethargic and dehydrated between the
ages of four and seven weeks, daily subcutaneous saline injections allowed mice
to recover from this morbid phenotype and survive passed eight weeks of age.
The full necropsy reports for these mice can be found in Appendix B. No
abnormal phenotype was observed in heterozygous or control animals.
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Relative expression

1.5

a
1.0

Control (n=5)
Slc10a1+/- (n=5)
Slc10a1-/- (n=5)

b
0.5

c
0.0

Ntcp

Figure 4.2. Relative mRNA levels in the livers of floxed control mice, Slc10a1+/- mice, and
Slc10a1-/- mice.
Hepatic Ntcp (Slc10a1) mRNA expression was determined using qPCR. Experiments were
performed in triplicate and results are presented as mean ± SEM (n=5 mice per group).
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Figure 4.3. Mouse survival over the first eight weeks of life
Control mice: n=20. Slc10a1-/- mice: 0-3 weeks of age, n=20; 3-5 weeks of age, n=19; 5-6 weeks
of age, n=18; 6-7 weeks of age, n=17; 7-8 weeks of age, n=13; 8-9 weeks of age, n=11.
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Altered bile acid signaling may result in nutrient malabsorption at the
intestinal level. Body weights of control and Slc10a1-/- mice were recorded
weekly until eight weeks of age and are reported in Figure 4. Consistent with
previous studies (Slijepcevic et al., 2015; Mao et al., 2019), between three and
seven weeks of age, body weights for all Slc10a1-/- mice in our study were
significantly reduced relative to controls (Fig. 4.4, P < 0.05). This was observed in
Slc10a1-/- mice irrespective of phenotype, occurring in mice that failed to thrive
and also in Slc10a1-/- mice that survived past eight weeks of age. For mice that
survived, their body weights normalized with body weights of control mice by 8
weeks of age (Fig. 4.4).
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B.
Week
1
2
3
4
5
6
7
8

Weight (grams ± SD)
Control (n=6) Slc10a1-/- (n=7-9)
4.8 ± 0.8
4.5 ± 0.2
6.0 ± 1.2
7.2 ± 0.3
11.3 ± 2.0
8.8 ± 0.3
16.1 ± 2.5
11.1 ± 0.2
18.8 ± 2.1
10.5 ± 0.2
20.2 ± 2.0
11.8 ± 2.3
21.2 ± 1.9
15.7 ± 3.6
21.8 ± 2.0
19.8 ± 3.2

Figure 4.4. Weekly mouse body weights from week one to week eight
Control mice: n=6, Slc10a1-/- mice: n=9 mice for weeks 1-6 and n=7 mice for weeks 7 & 8.
Statistical significance was determined using Mann Whitney tests, * P < 0.05, ** P < 0.001, *** P
< 0.0001, **** P < 0.0001.
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4.3.2

Serum total bile acid concentrations
To determine potential differences in bile acid disposition in mice four to

six weeks of age, total serum bile acid concentrations were quantified. Mean
serum bile acid concentrations for control mice were within the normal
physiological range (<16µM) at 3.5 ± 1.3 µM, which were significantly lower than
mean serum bile acid concentrations for Slc10a1-/- mice (249.0 ± 79.2 µM, P =
0.0056, Fig. 4.5 A). Similar to the two published Slc10a1-/- mouse models, a
bimodal bile acid phenotype was observed in our Slc10a1-/- mice (Fig. 4.5 A). For
the remainder of this study, Slc10a1-/- mice were divided into subgroups based
on total bile acid concentrations (Fig. 4.5 B). Total serum bile acids for Slc10a1-/normocholanemic mice were 16.2 ± 5.8 µM and were not significantly different
than controls. Total serum bile acids for Slc10a1-/- hypercholanemic mice were
435.3 ± 55.0 µM, highly elevated relative to both control and Slc10a1-/normocholanemic mice (P < 0.0001, Fig. 4.5 B).
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Figure 4.5. Total serum bile acid concentrations
A. Total serum bile acids in control (n=4) and Slc10a1-/- mice (n=9), showing a bimodal bile acid
phenotype in Slc10a1-/- mice. Results are presented as mean ± SEM. Statistical significance was
determined using Mann-Whitney test, * P < 0.05. B. Total serum bile acid concentrations in mice
divided by subpopulations: control (n=4), Slc10a1-/- normocholanemic (n=4) and Slc10a1-/hypercholanemic (n=5) mice. Results are presented as mean ± SEM and statistical significance
was determined by one-way ANOVA with Tukey’s multiple comparison tests, statistical
differences between a and b: P < 0.0001.
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4.3.3

Serum conjugated and unconjugated bile acids
Composition of the bile acid pool can be indicative of disruptions in

specific bile acid genes and can provide insight into the relative toxicity profiles of
bile acids within the serum. To investigate potential differences in the
composition of circulating bile acid pools in mice four-to-six weeks of age,
concentrations of individual bile acid species were quantified in the sera (Figure
4.6).
Hypercholanemic mice had significantly elevated taurocholic acid (TCA)
concentrations in the serum (282.8 ± 170.5 µM) relative to normocholanemic (1.6
± 1.2 µM) and control (0.3 ± 0.1 µM) mice (Fig. 4.6 A & C, P < 0.019). Apparent
differences in additional conjugated species TαβMCA and TDCA did not reach
statistical significance (P < 0.081 and P < 0.25, respectively). None of the
quantified unconjugated bile acid were significantly different between groups
(Fig. 4.6 B).
To further determine the relative composition of unconjugated and
conjugated bile acids in the sera, unconjugated and conjugated species are
represented as percentage of the total bile acid pool in Figure 7. The sums of
unconjugated bile acids αMCA, βMCA, CA, and DCA in the sera of mice were
not significantly different between groups and ranged from 1.6 - 17.0 ± 0.5 - 17.6
µM per group. The sum of conjugated bile acids TαβMCA, TCA, and TDCA was
significantly elevated in Slc10a1-/- hypercholanemic mice (275.3 ± 187.2 µM)
relative to Slc10a1-/- normocholanemic (2.9 ± 2.4 µM) and control mice (0.5 ± 0.1
µM) (P < 0.016, Fig. 4.7). These elevations in conjugated bile acids in
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hypercholanemic mice altered the overall ratio of unconjugated to conjugated bile
acids. Serum bile acids in control and normocholanemic mice were ~20-25%
conjugated species, whereas bile acids were 94% conjugated in
hypercholanemic mice (Fig. 4.7).
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Serum bile acid concentration (µM ± SD)
Control
(n=4)
αMCA
βMCA
CA
DCA
TαβMCA
TCA
TDCA

0.5 ± 0.5
0.3 ± 0.2
0.5 ± 0.2
0.3 ± 0.2
0.1 ± 0.0
0.3 ± 0.1
0.1 ± 0.0

Slc10a1 -/Slc10a1-/normocholanemic hypercholanemic
(n=4)
(n=5)
4.4 ± 4.2
10.1 ± 11.3
1.5 ± 1.3
1.0 ± 1.0
1.1 ± 1.0
1.6 ± 1.2
0.2 ± 0.2

1.5 ± 1.8
2.5 ± 3.0
9.2 ± 7.9
1.1 ± 1.1
25.2 ± 23.2
242.8 ± 170.5
7.3 ± 9.7

Figure 4.6. Individual serum bile acid concentrations
A. Conjugated bile acids species. B. Unconjugated bile acid species: C. Concentrations of each
bile acid organized by group. Results are presented as mean ± SD (n=4-5 mice per group) and
statistical significance was determined using one-way ANOVA with Tukey’s multiple comparison
test, statistical differences between a and b: P < 0.02.
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A.

D.

24 ± 6%

Significance (P value)
Unconjugated
Conjugated

Unconjugated
1.6 ± 0.5 µM

76 ± 6%

Conjugated
0.5 ± 0.1 µM

Control (n=4)
B.

21 ± 15%

Control vs.
Slc10a1-/normocholanemic

ns (0.23)

ns (> 0.99)

Control vs.
Slc10a1-/hypercholanemic

ns (0.32)

* (0.015)

Slc10a1-/normocholanemic
-/vs. Slc10a1
hypercholanemic

ns (0.94)

* (0.016)

Unconjugated
17.0 ± 17.6 µM

79 ± 15%

Conjugated
2.9 ± 2.4 µM

Slc10a1-/normocholanemic (n=4)
C.

6 ± 5%

Unconjugated
14.2 ± 11.9 µM
94 ± 5%

Conjugated
275.3 ± 187.2 µM

Slc10a1-/hypercholanemic (n=5)

Figure 4.7. Percentages of unconjugated and conjugated bile acids
A-C. Unconjugated bile acids represent the sum of αMCA, βMCA, CA, and DCA. Conjugated bile
acids represent the sum of TαβMCA, TCA, and TDCA. D. Summary of statistical differences
between groups. Results are presented as mean ± SD (n=4-5 mice per group) and statistical
significance was assessed using one-way ANOVA with Tukey’s multiple comparison test, * P <
0.05.
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To assess the relative toxicity of the serum bile acid pools in four- to sixweek-old mice, compositions of cholic acid-derived species and muricholic acidderived species were determined. Cholic acid species are more toxic whereas
muricholic acids are more hydrophilic and less toxic (Chiang, 2017).
The sums of muricholic acids in the sera of mice ranged from 0.9 - 29.1 ±
0.1 - 22.8 µM and were not significantly different between groups (Fig. 4.8).
However, the sum of cholic acids was significantly elevated in Slc10a1-/hypercholanemic mice (260.4 ± 182.7 µM) relative to Slc10a1-/- normocholanemic
(2.2 ± 3.6 µM) and control mice (1.2 ± 0.4 µM) (P < 0.020, Fig. 4.8). These
elevations in cholic acids in hypercholanemic mice alter the ratio of muricholic
acids to cholic acids. Cholic acids dominate the bile acid pool in hypercholanemic
mice (89%), in contrast to normocholanemic and control mice, whose bile acid
compositions were 29 and 56% cholic acid species, respectively (Fig. 4.8 A-C).
These results suggest that hypercholanemic mice may have more toxic bile acid
species in their sera than do control and normocholanemic mice.
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260.4 ± 182.7 µM
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Figure 4.8. Percentages of muricholic acid and cholic acid species
A-C. Muricholic acids (MCAs) represent the sum of αMCA, βMCA, and TαβMCA. Cholic acids
(CAs) represent the sum of CA, DCA, TCA, and TDCA. D. Summary of statistical differences
between groups. Results are presented as mean ± SD (n=4-5 mice per group) and statistical
significance was assessed using one-way ANOVA with Tukey’s multiple comparison test, * P <
0.05.
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4.3.4

Relative mRNA levels of hepatic bile acid uptake
transporters
Serum hypercholanemia may be the result of reduced uptake of bile acids

into hepatocytes. Therefore, expression levels of hepatic genes involved in bile
acid uptake were evaluated in four- to six-week-old mice.
Relative mRNA levels of Ntcp were significantly reduced in both
normocholanemic and hypercholanemic Slc10a1-/- mice (Fig. 4.9 B, P < 0.0001).
Hepatic mRNA expression of Oatp1b2 was unchanged between groups (Fig. 9
C). Expression levels of Oatp1a1 were significantly decreased in
hypercholanemic mice relative to normocholanemic and control mice (P < 0.033,
Fig. 4.9 D); Oatp1a1 mRNA was nearly undetectable in all hypercholanemic
mice. Relative mRNA levels of Oatp1a4 were increased ~15-fold in
hypercholanemic mice relative to normocholanemic and control mice (P <
0.0030, Fig. 4.9 E).
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Figure 4.9. Relative mRNA expression of bile acid uptake transporters in the liver
A. Localization of uptake transporters at the basolateral membrane of hepatocytes. Expression of
B. Na+-taurocholate co-transporting polypeptide (Ntcp), and C-E. Organic anion transporting
polypeptide (Oatp) isoforms 1b2, 1a1, and 1a4. Results are presented as mean ± SEM (n=4-5
mice per group) and statistical significance was determined using one-way ANOVA with Tukey’s
multiple comparison tests, statistical differences between a, b, and c: P < 0.04.
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4.3.5

Relative mRNA levels of bile acid efflux transporters
Expression of transporter genes that export bile acids into the bile

canaliculi were also assessed in four- to six-week-old mice. The main canalicular
membrane bile acid efflux transporter is bile salt export pump (BSEP), whereas
multidrug resistance-associated protein 2 (MRP2) plays a more minor role and
transports mainly sulfated bile acids.
Relative to control and normocholanemic mice, Bsep mRNA levels were
reduced approximately 2 to 3-fold in hypercholanemic mice (Fig. 4.10 B, P < 0.01
and P < 0.0001, respectively). Normocholanemic mice displayed increased
mRNA levels of Bsep compared to controls (Fig. 4.10 B, P < 0.01). No detectable
differences were observed in Mrp2 mRNA levels between groups (Fig. 4.10 C).
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Figure 4.10. Relative mRNA expression of canalicular efflux transporters in the liver
A. Localization of efflux transporters at the bile canalicular membrane of hepatocytes. Expression
of B. Bile salt export pump (Bsep), and C. Multidrug resistance-associated protein 2 (Mrp2).
Results are presented as mean ± SEM (n=4-5 mice per group). Statistical significance was
determined using one-way ANOVA with Tukey’s multiple comparison test, statistical differences
between a, b, and c: P < 0.01.

152

Under physiological conditions, basolateral efflux transporters organic
solute transporters α and β (OSTαβ) and multidrug resistance-associated protein
4 (MRP4) are not highly expressed in the liver. However, both OSTαβ and MRP4
can become upregulated upon dysregulated nuclear receptor signaling arising
from pathology (Boyer et al., 2006; Slitt et al., 2007).
In hypercholanemic Slc10a1-/- mice, both Ostβ and Mrp4 mRNA levels
were significantly higher than what were detected for normocholanemic and
control mice (Fig. 4.11 B & C, P < 0.05). Levels of Ostα mRNA were
undetectable in all liver samples.
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Figure 4.11. Relative mRNA expression of basolateral efflux transporters in the liver
A. Localization of efflux transporters at the basolateral membrane of hepatocytes. Expression of
B. Organic solute transporter β (Ostβ) and C. Multidrug resistance-associated protein 4 (Mrp4).
Results are presented as mean ± SEM (n=4-5 mice per group) and statistical significance was
determined using one-way ANOVA with Tukey’s multiple comparison test, statistical differences
between a and b,P < 0.05.
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4.3.6

Relative mRNA levels of hepatic bile acid synthesis genes
In addition to differences in hepatic transporter genes, disruption of

Slc10a1 may alter bile acid synthesis. Relative mRNA levels of the three main
hepatic bile acid synthesis genes, Cyp7a1, Cyp8b1, and Cyp27a1, and of the
transcriptional repressor of bile acid synthesis, small heterodimer partner (Shp),
were quantified in mice four to six weeks of age.
Relative mRNA levels of Shp and Cyp7a1 decreased and increased,
respectively, in hypercholanemic mice compared to normocholanemic mice
compared to normocholanemic mice (P = 0.011, Fig. 4.12 C and P = 0.042, Fig.
4.12 B). No significant differences in Shp or Cyp7a1 mRNA levels were detected
between control and hypercholanemic mice. Further, no differences were
observed in Cyp8b1 or Cyp27a1 mRNA levels between groups (Fig. 4.12 D-E).
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Figure 4.12. Relative mRNA levels of bile acid synthesis genes in the liver
A. Bile acid synthesis occurs through CYP7A1 (rate-limiting enzyme), CYP8B1 (responsible for
cholic acid (CA) synthesis, and CYP27A1 (involved in synthesis of CA and chenodeoxycholic acid
(CDCA). Bile acid-mediated activation of the nuclear receptor farnesoid X receptor (FXR) induces
the production of the transcription factor small heterodimer partner (SHP), which indirectly
represses Cyp7a1. Relative mRNA expression of B. Cyp7a1, C. Shp, D. Cyp8b1, and E.
Cyp27a1. Results are presented as mean ± SEM (n=4-5 mice per group) and statistical
significance was determined using one-way ANOVA with Tukey’s multiple comparison test,
statistical differences between a, and b: P < 0.05.
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4.3.7

Relative mRNA levels of bile acid genes in the ileum
Aside from the important role of the liver in bile acid synthesis and

transport, the terminal ileum is responsible for the majority of active bile acid
reuptake in the intestine. Thus, the effects of Slc10a1 disruption on mRNA levels
in the terminal ileum were assessed in four- to six-week-old mice.
Relative mRNA levels of the bile acid uptake transporter apical sodiumdependent bile acid transporter (Asbt) were not significantly different between
groups (Fig. 4.13 B). Levels of multidrug resistance-associated protein 3 (Mrp3)
were reduced in hypercholanemic mice relative to control and normocholanemic
mice (P < 0.0085, Fig. 4.13 C). No detectable differences were observed in Ostα
mRNA levels between groups. However, Ostβ expression was increased in
hypercholanemic mice relative to control mice (P = 0.048, Fig. 4.13 D & E).
Bile acid activation of FXR in ileocytes induces Shp and Fgf15, which
signal to repress bile acid uptake and synthesis in enterocytes and hepatocytes.
Although Shp and Fgf15 mRNA levels appear higher in hypercholanemic mice
relative to controls and normocholanemic mice, there were no significant
differences detected between groups (Fig. 4.13 F & G).
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Figure 4.13. Relative mRNA levels of transporters and repressors of bile acid synthesis
and uptake in the ileum
A. Bile acid uptake from the intestinal lumen occurs through apical sodium-dependent bile acid
transporter (ASBT), and efflux into blood occurs through multidrug resistance-associated protein
3 (MRP3) and organic solute transporter αβ (OSTαβ). Bile acid-mediated activation of the nuclear
receptor farnesoid X receptor (FXR) induces the production of the transcription factor small
heterodimer partner (SHP) and the hormone fibroblast growth factor 15 (FGF15), which repress
bile acid uptake and synthesis. B-G. Relative mRNA expression of B. Asbt, C. Mrp3 D. OSTα, E.
Ostβ, F. Shp, and G. Fgf15. Results are presented as mean ± SEM (n=4-5 mice per group) and
statistical significance was determined using one-way ANOVA with Tukey’s multiple comparison
test, statistical differences between a and b: P < 0.05.
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4.3.8

Relative mRNA levels of bile acid transporter genes in the
kidney
Bile acids are minimally excreted in the urine under physiological

conditions, however hypercholanemia can increase renal filtration and excretion
(Alnouti, 2009). Furthermore, our hypercholanemic mice displayed signs of
dehydration and blood in urine, which could be indicative of kidney damage.
Relative mRNA levels of bile acid transporters in the kidney were therefore
assessed in four- to six-week-old mice.
Relative mRNA levels of the uptake transporter Asbt were significantly
reduced in hypercholanemic mice relative to normocholanemic mice (Fig. 4.14 B,
P < 0.012). However, no significant differences were detected in relative mRNA
levels for uptake transporters Oatp1a1 and Oatp1a4 (Fig. 4.14 C & D). No
significant differences were observed between groups for mRNA levels of efflux
transporters Mrp2 and Mrp4, which export bile acids from renal cells into the
filtrate for urinary excretion. Relative mRNA levels of efflux transporters Ostα,
Ostβ, and Mrp3, which favour secretion of bile acids from renal cells back into the
blood, were significantly increased in hypercholanemic mice relative to
normocholanemic and control mice (Fig. 4.14 G-I, Ostα and Ostβ: P < 0.001,
Mrp3: P < 0.05).
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Figure 4.14. Relative mRNA levels of bile acid transporters in the kidney
A. Bile acid filtration at the kidney. Bile acids are excreted into the tubule lumen for urinary
excretion by multidrug resistance-associated proteins 2 and 4 (MRP2 and MRP4). From the
lumen, bile acids can be reabsorbed into proximal tubule cells by apical sodium-dependent bile
acid transporter (ASBT) and organic anion transporting polypeptides (OATP1A1 and OATP1A4).
Bile acids are exported back into the blood by organic solute transporters αβ (OSTαβ) and MRP3.
B-I. Relative mRNA expression of B. Asbt, C. Oatp1a1 D. Oatp1a4, E. Mrp2, F. Mrp4, and G.
Mrp3, H. Ostα, I. Ostβ Results are presented as mean ± SEM (n=4-5 mice per group) and
statistical significance was determined using one-way ANOVA with Tukey’s multiple comparison
test, statistical differences between a, and b: P < 0.05.
.
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4.3.9

Hepatic uptake of rosuvastatin
In human hepatocytes, NTCP is responsible for ~35% of rosuvastatin

uptake (Ho et al., 2006; Bi et al., 2013). To determine the effect of Slc10a1
disruption on hepatic uptake of rosuvastatin, a single dose of 10 mg/kg
rosuvastatin was administered to ten-week-old mice by oral gavage. Two hours
after rosuvastatin administration, mice were euthanized; blood was collected via
cardiac puncture, and livers were harvested.
Serum rosuvastatin concentrations were 25.6 ± 13.7 ng/mL and 19.0 ±
10.6 ng/mL in Slc10a1-/- and control mice, respectively (Fig. 4.15 A). Liver
rosuvastatin concentrations were 861.9 ± 279.6 ng/g and 1028 ± 511.2 ng/g in
Slc10a1-/- and control mice, respectively (Fig. 4.15 B). No significant differences
were observed in serum or liver concentrations of rosuvastatin between the two
mouse genotypes (Figure 4.15 A & B). The liver-to-serum concentration ratios,
which are important determinants of reliance on hepatic transport processes,
were not significantly different, at 42.8 and 60.3 in Slc10a1-/- mice and control
animals, respectively (Fig. 14,5 C, P = 0.34).
To determine whether Slc10a1-/- disruption affected bile acid transporter
expression in these mice, mRNA levels for hepatic transporters were evaluated.
Aside from the expected difference in Ntcp mRNA expression (P = 0.0040, Fig.
4.16 A), no significant differences were observed in hepatic uptake or efflux
transporters between ten-week-old control and Slc10a1-/- mice (Fig. 4.16 A & B).
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Figure 4.15. Hepatic disposition of orally administered rosuvastatin (10mg/kg) in control
and Slc10a1-/- mice.
A. Concentrations of rosuvastatin in serum, expressed as ng/mL. B. Concentrations of
rosuvastatin in liver, expressed as ng rosuvastatin per g liver tissue. C. Liver-to-serum ratio of
rosuvastatin, an important indicator of rosuvastatin uptake by hepatic transporters. Results are
presented as mean ± SD (n=5 mice per group) and statistical differences were determined using
Student’s t tests.
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Figure 4.16. Hepatic mRNA expression of bile acid uptake and efflux transporters in tenweek-old mice
A. Bile acid uptake transporter at the basolateral membrane of hepatocytes. B. Bile acid efflux
transporters at the canalicular (Bsep, Mrp2) and basolateral (Mrp3 and Ostβ) membranes of
hepatocytes. Results are presented as mean ± SEM (n=3 mice per group) and statistical
differences were assessed using Student’s t tests.
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4.4

Discussion

NTCP (encoded by gene SLC10A1) is the key bile acid uptake transporter
on the basolateral membrane of hepatocytes (Dawson et al., 2009) and may be
important for the hepatic uptake of rosuvastatin (Ho et al., 2006; Bi et al., 2013).
However, limited information exists regarding bile acid dynamics and gene
expression in mouse models of Slc10a1 disruption, and hepatic uptake of
rosuvastatin has not been evaluated in Slc10a1-/- mice. This study assessed
serum bile acid composition, mRNA expression in the liver, ileum, and kidney,
and hepatic uptake of rosuvastatin in Slc10a1-/- mice.
A bimodal bile acid phenotype was observed in our Slc10a1-/- mice.
Approximately 55% of Slc10a1-/- mice exhibited decreased body weights from
three to seven weeks of age, which normalized with control body weights by
eight weeks of age. Serum bile acids were not significantly elevated in these
mice, no additional phenotypic traits were observed, and gene expression was
comparable to what was observed in control mice. Conversely, serum
hypercholanemia was observed in approximately 45% of Slc10a1-/- mice, and
these mice failed to thrive passed seven weeks of age.
Mendelian frequencies were not observed in the proportions of
hypercholanemic and normocholanemic mice in any given litter, suggesting that
disruption of Slc10a1-/- is associated with incomplete penetrance. Reduced
penetrance is also observed in the inherited bile acid condition Familial
Hypercholanemia. Three individuals homozygous for mutations in the TJP2
gene, which is important in tight junction formation between hepatocytes and
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cholangiocytes of the bile ducts, were unaffected by this genetic deficiency.
However, their siblings suffered from fat malabsorption, rickets, and deficiency of
vitamin K subsequent to reduced bile acids in the intestinal lumen (van Mil et al.,
2005).
Mice that failed to thrive displayed striking elevations in conjugated and
cholic acid species. The prototypical NTCP substrate, taurocholic acid, was
highly elevated in hypercholanemic Slc10a1-/- mice. Increased cholic acid
species in mouse serum may suggest greater toxicity in the bile acid pools of
hypercholanemic Slc10a1-/- mice. However, hepatic concentrations of bile acids
were not quantified, and mRNA expression of the Cyp8b1, the precursor to cholic
acid synthesis, was no different between control and hypercholanemic mice.
Therefore, it remains unclear whether the hepatic composition of bile acids is
also dominated by cholic acid species. Regardless of the composition of serum
bile acids in these mice, the extent of hypercholanemia likely results in bile acid
spillover into the kidney in these mice. The decreased mRNA expression of
uptake transporter genes and increased mRNA expression of efflux transporter
genes in the kidney are indicative of elevated bile acids in the kidney (Slitt et al.,
2007).
Our findings of reduced survival in hypercholanemic mice are inconsistent
with previous reports of Slc10a1-/- mice, where mortality was not observed
(Slijepcevic et al., 2015; Mao et al., 2019). As serum bile acid concentrations in
our hypercholanemic mice were comparable or even lower than concentrations
observed in the alternative studies, it remains unclear why our mice were unable
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to thrive. However, the enlarged gallbladders, bile deposits in bile canaliculi, and
lack of prominent bile ducts in hypercholanemic mice suggest disruption of
gallbladder emptying. This would decrease bile acid levels within the intestinal
lumen, limiting food emulsification and decreasing absorption of vital nutrients.
Numerous changes in mRNA expression levels of bile acid transporters
and synthesis genes were observed in hypercholanemic Slc10a1-/- mice relative
to normocholanemic Slc10a1-/- mice and controls. Hepatic mRNA levels of
Cyp7a1, Oatp1a4, Ostβ, and Mrp4, were increased, whereas Oatp1a1, Bsep and
Shp were decreased in hypercholanemic mice. The rodent transporter OATP1A1
is important in hepatic bile acid uptake transport in mice, especially in the
absence of NTCP (Slijepcevic et al., 2015). Levels of Oatp1a1 mRNA were
nearly undetectable in our hypercholanemic mice. Consistent with reports from
Slijepcevic et al., we speculate that hypercholanemia results from absence of
OATP1A1 and NTCP in these mice. Simulations by Cravetto et al. showed that
reduced hepatic extraction of bile acids is likely the most important contributor to
elevated serum bile acids (Cravetto et al., 1988).
The major nuclear receptor involved in bile acid homeostasis is FXR (Li
and Chiang, 2013). Nuclear receptors PXR and CAR also act as complementary
pathways for bile acid homeostasis and detoxification, especially in cases of
disrupted FXR signaling (Schuetz et al., 2001; Guo et al., 2003; Wagner et al.,
2005). Hepatic nuclear receptors are regulated by the fasted and fed states.
Activity of FXR and VDR is reduced during the fasted state, whereas activity of
PXR and CAR is enhanced in the fasted state (Ding et al., 2006; Wieneke et al.,
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2007; Grasfeder et al., 2009; Preidis et al., 2017; Aatsinki et al., 2019). Relative
mRNA expression of genes in our hypercholanemic mice reflected changes that
occur during fasting; levels of hepatic mRNA for direct FXR target genes Bsep
and Shp were decreased in hypercholanemic mice. Furthermore, consistent with
PXR activation in the fasted state, Oatp1a1 mRNA was reduced and Oatp1a4
was increased in hypercholanemic mice. The increase in Mrp4 mRNA observed
in livers of our hypercholanemic mice may be the result of increased activity of
CAR. Significantly decreased mRNA levels of Mrp3 in the ileum are consistent
with reduced VDR activity in the fasted state.
In our hypercholanemic mice, significantly elevated mRNA levels of the
major bile acid synthesis gene Cyp7a1 are consistent with reduced expression of
its repressor, Shp. However, these observations are inconsistent with the trends
of mRNA expression of Shp and Fgf15 observed in the ilea of our
hypercholanemic mice. One possible explanation is increased retention of bile
acids in ileocytes, which has been reported in cases where intestinal cells sense
low levels of bile acids within the intestinal lumen. The cells react by conserving
intracellular stores of bile acids (Hofmann, 2003; Lanzini et al., 2003), which
would explain enhanced Shp and Fgf15 mRNA levels. However, recent studies
have also indicated enterocytes can sense high serum bile acid concentrations,
resulting in induction of FGF15/19 signaling (Slijepcevic et al., 2017). To
determine the bases for these inconsistencies, further evaluation of serum
FGF15 concentrations and FGF15 signaling at the hepatocyte is warranted.
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In mice ten weeks of age, no significant differences were observed in the
serum or liver concentrations of rosuvastatin, nor in the serum-to-liver ratio of
rosuvastatin in Slc10a1-/- mice. Expression of mRNA levels for hepatic
transporters were no different between ten-week-old control and Slc10a1-/- mice.
Although serum bile acids were not quantified in these mice, the absences of
differences in transporter expression suggest these mice were normocholanemic.
Important species differences in hepatic uptake of bile acids should be
considered when interpreting findings from mouse models. Human OATP1B1
and OATP1B3 are hepatocyte-specific transporters that are highly expressed in
the liver and possess a single murine ortholog, OATP1B2 (Roth et al., 2012). In
addition, OATP1A1 and OATP1A4 localize to the basolateral membrane of
mouse hepatocytes (Geier et al., 2007), however the human ortholog, OATP1A2,
is not abundant in human hepatocytes (Lee et al., 2005).
In the context of bile acid uptake, murine OATP1A1 is an important rodent
bile acid transporter and shares a similar substrate profile with NTCP (Hata et al.,
2003). Although the repression of Oatp1a1 in hypercholanemic mice cannot be
directly translated to humans, findings may still be indicative of overall hepatic
nuclear receptor signaling during hypercholanemia. This is supported by clinical
studies describing vitamin D deficiency in individuals with homozygous loss of
function genetic variation in SLC10A1 (Vaz et al., 2015; Deng et al., 2016; Liu et
al., 2017; Qiu et al., 2017).
In the context of rosuvastatin uptake, murine OATP1A1 and OATP1A4 act
along with OATP1B2 to mimic the hepatic uptake functions of human OATP1B1
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and OATP1B3 (Iusuf et al., 2012). Previous studies in mouse models of OATP
deficiency have found that murine isoforms of OATP1A and OATP1B are
important in hepatic rosuvastatin uptake in mice (DeGorter et al., 2012; Iusuf et
al., 2013). Importantly, in Oatp1a/1b-/- mice, systemic concentrations of
rosuvastatin were ~8-fold higher in Oatp1a/1b-/- mice compared to controls,
however hepatic concentrations were unchanged between groups. This suggests
that in the event of OATP1A/1B deficiency, there are additional hepatic uptake
transporters with lower affinity for rosuvastatin that can maintain some degree of
hepatic rosuvastatin uptake. The presence of OATP1A isoforms in mouse
hepatocytes but not human hepatocytes is a major species difference that could
negate a potential relevance of NTCP to rosuvastatin transport in mice. The
absence of OATP1A isoforms in human hepatocytes likely provides a more
important role for NTCP in statin disposition in humans. This is especially true in
the context of genetic deficiency or pharmacological inhibition of OATPs, which is
relatively common. Evidence suggests that NTCP is important in the hepatic
uptake of pravastatin in humans, another hydrophilic statin (Lu et al., 2016).
Taken together, hypercholanemic Slc10a1-/- mice display hepatic gene
expression that is consistent with nuclear receptor activity observed in the fasted
state. This is supported by enlarged gallbladders and lack functional bile ducts,
which may decrease bile acid concentrations in the intestinal lumen. Additionally,
transporter expression and bile casts in the kidneys of hypercholanemic mice
suggest that excessive renal accumulation of bile acids may lead to their demise.
Failure of adequate compensatory bile acid uptake via OATP1A1 may represent
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the basis for profound hypercholanemia observed in a subset of Slc10a1-/- mice.
Despite differences in hepatic uptake transporters between mice and humans,
our findings of likely altered hepatic nuclear receptor signaling in the liver merit
investigation in humans. In terms of pharmacotherapy, NTCP does not appear
important in hepatic rosuvastatin uptake in mice, however the relevance of NTCP
to human hepatic rosuvastatin disposition should be investigated.
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Figure 4.17. Hypothesized alterations in nuclear receptor signaling in our hypercholanemic
Slc10a1-/- mice
The major findings in our hypercholanemic mice are reduced Oatp1a1, Bsep, and Shp
expression, along with elevated Oatp1a4 and Mrp4 expression. These changes are consistent
with upregulated PXR and CAR and downregulated FXR observed in the fasted state. Together
with reduced body weights, enlarged gallbladders, and serum hypercholanemia, it is likely that
reduced bile acids in the lumen of the intestine diminishes nutrient absorption in hypercholanemic
Slc10a1-/- mice, resulting in fasted state gene expression in the liver.
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5

Investigating sex-related effects of Slc10a1 disruption in
mice on serum bile acids and hepatic bile acid gene
expression
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5.1

Introduction

Bile acids are synthesized from catabolism of cholesterol in the liver and
therefore mediate an important route for cholesterol turnover. Key enzymes
involved in bile acid synthesis include CYP7A1, CYP8B1, and CYP27A1. Bile
acid synthesis is negatively regulated by bile acid signaling. Bile acids bind to
ligand-activated nuclear receptors, which elicit transcriptional repression of genes
involved in synthesis and cellular uptake and efflux of bile acids. This process is
integral to maintain bile acid homeostasis; when disrupted, accumulation of bile
can be toxic to cells (Boyer, 2013). Plasma membrane-bound proteins that
mediate the cellular uptake and efflux of bile acids, known as bile acid
transporters, control bile flow throughout the enterohepatic system. Disruption of
these transporters can alter bile acid disposition, resulting in bile acid-mediated
pathologies including hepatic cholestasis and serum hypercholanemia (Dawson
et al., 2009).
Despite wide-spread knowledge of sex-related differences in bile acid
synthesis (Phelps et al., 2019), transport (Klaassen and Cheng, 2005), and
detoxification (Alnouti and Klaassen, 2011), many studies are conducted solely in
male subjects. Specifically, studies in bile acid transporter-deficient mice have
largely reported results from male mice (van de Steeg et al., 2010; Csanaky et
al., 2011; Zhang et al., 2012; Slijepcevic et al., 2015; Slijepcevic et al., 2017).
These biases in medical research have implications on understanding
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pathogenesis of disease and response to pharmacological treatments (Holdcroft,
2007).
NTCP (SLC10A1) is an important bile acid and drug transporter localized
to the basolateral membrane of hepatocytes. NTCP has long been considered
the key hepatic bile acid uptake transporter and is essential to maintain
conjugated bile acid uptake into hepatocytes (Dawson et al., 2009). Genetic
disruption of SLC10A1 in humans and mice has been associated with serum
hypercholanemia and differential expression of bile acid transporters (Slijepcevic
et al., 2015; Mao et al., 2019). Studies in Slc10a1-/- mice suggest that serum
hypercholanemia may persist in females more so than males (Mao et al., 2019).
However, detailed sex-associated characterization of differences in bile acid
composition and hepatic gene expression have not been evaluated in Slc10a1-/mice.
Further, expression of drug metabolizing enzymes and drug and bile acid
transporters, including NTCP, is sexually dimorphic (Cheng et al., 2005; Yang et
al., 2012). Notwithstanding the growing evidence for a role of biological sex in
bile acid regulation, limited information exists regarding potential sex differences
in bile acid synthesis, composition, and transport in the context of SLC10A1
disruption. Therefore, our study analyzed sex-associated differences in serum
bile acid composition and hepatic bile acid synthesis and transporter gene
expression in Slc10a1-/- mice.
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Methods & Materials

5.2
5.2.1

Materials

Taurocholic acid and d5-taurocholic acid were purchased from Toronto Research
Chemicals (Toronto, ON). All other chemicals, unless otherwise stated, were
obtained from Millipore-Sigma (St. Louis, MO).

5.2.2

Animal use approval

All animal experiments were approved by the University of Western Ontario
Animal Care Committee (Protocol No. 2015-011), according to regulations and
guidelines of the Canadian Council on Animal Care. Approval is listed in
Appendix C.

5.2.3

Liver-specific targeted disruption of Slc10a1 in C57BL/6
mice

Liver-specific targeted disruption of Slc10a1 in C57BL/6 mice using the Albcre/LoxP method was performed as described in Chapter 4.2.3.

5.2.4

Quantification of serum total bile acids by colorimetric assay

Quantification of serum total bile acids was performed as previously described in
Chapter 4.2.4
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5.2.5

Quantification of serum individual bile acids by LC-MS/MS

Quantification of serum individual bile acids by LC-MS/MS was performed as
previously described in Chapter 4.2.4.

5.2.6

Quantification of hepatic mRNA expression by qPCR

Quantification of hepatic mRNA levels was performed as previously described in
Chapter 4.5.6.

5.2.7

Control, normocholanemic, and hypercholanemic mice

In keeping with previous studies (Slijepcevic et al., 2015; Mao et al., 2019), and
with observations in Chapter 4 of this thesis, we observed serum
normocholanemic and hypercholanemic populations within our Slc10a1-/- mice.
For the entirety of this study, our Slc10a1-/- mice are grouped as
normocholanemic (total bile acids < 35 µM) or hypercholanemic (total serum bile
acids >35 µM).

5.2.8

Statistics

Unpaired, two-tailed, Student’s t tests were used to determine statistical
differences between two groups. Student’s t tests were therefore employed to
determine sex differences within control, normocholanemic Slc10a1-/-, and
hypercholanemic Slc10a1-/- groups. One-way ANOVA with Tukey’s multiple
comparisons tests were used to determine statistical significance between three
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groups. Therefore, one-way ANOVA with Tukey’s tests were employed to
determine differences between control, normocholanemic Slc10a1-/-, and
hypercholanemic Slc10a1-/- mice of the same biological sex. Statistical
significance was deemed at P < 0.05. Studies were conducted using 3-9 mice
per group. All statistical analyses were conducted using GraphPad Prism 6 (La
Jolla, CA).
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5.3
5.3.1

Results
Total serum bile acids

To determine whether total serum bile acids were elevated in
hypercholanemic mice regardless of biological sex, mice were grouped by sex
and by genotype and phenotype. Serum total bile acids were elevated in
hypercholanemic Slc10a1-/- mice relative to control and normocholanemic mice,
irrespective of sex (P < 0.0001, Fig. 5.1 A & B). In males, serum total bile acids
were 1.8 ± 0.7 µM in control mice, 12.3 ± 3.7 µM in normocholanemic mice, and
435.3 ± 55.0 µM in hypercholanemic mice. In female animals, serum total bile
acid concentrations were 3.8 ± 1.1 µM in controls, 25.3 ± 4.4 µM in
normocholanemic mice, and 495.2 ± 20.6 µM in hypercholanemic mice,
respectively. Total serum bile acids were not significantly different between
control and normocholanemic mice, regardless of sex.
Studies in multiple strains of wild type mice observe that serum bile acid
concentrations are higher in females relative to males (Turley et al., 1998; Phelps
et al., 2019). To assess whether this trend is maintained in Slc10a1-/- mice,
differences were evaluated between males and females of the same genotype
and phenotype (Fig. 5.1 C). Total serum bile acid concentrations were higher in
female normocholanemic Slc10a1-/- mice relative to male normocholanemic
Slc10a1-/- mice (25.3 ± 4.4 versus 12.3 ± 3.7, P = 0.047, Fig. 5.1 C). No sexrelated differences were observed in total serum bile acids in control and
hypercholanemic Slc10a1-/- mice.
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Figure 5.1. Total serum total bile acid concentrations grouped by biological sex
Evaluating serum total bile acids between genotype and phenotype for A. Male mice (n=5-9 mice
per group) B. Female mice (n=5-8 mice per group). Results are presented as mean ± SEM.
Statistical differences were determined using one-way ANOVA with Tukey’s tests. Statistical
significance between a and b: P < 0.0001. C. Evaluating sex-related differences within genotype
and phenotype groups. Bile acid measurements in five control male mice were <0.1µM therefore
do not appear on the graphs. Experiments were performed in triplicate and results are presented
as mean ± SEM and statistical differences were determined using Student’s t tests, * P < 0.05.
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5.3.2

Individual serum unconjugated bile acids
To elucidate sex-associated differences in the effects of Slc10a1

disruption on bile acid profiles in our mice, individual serum unconjugated bile
acids were quantified.
No detectable differences in individual serum unconjugated bile acids
were observed between control and normocholanemic mice, regardless of sex
(Fig. 5.2 A & B). In hypercholanemic male mice, cholic acid was significantly
elevated relative to control and normocholanemic mice (9.2 ± 7.9 µM versus 0.1
± 0.1 µM and 0.3 ± 0.4 µM respectively, P < 0.016, Fig. 5.2 A). Although cholic
acid appears elevated in hypercholanemic female mice relative to controls and
normocholanemic animals, differences did not reach significance (13.4 ± 14.0 µM
versus 0.4 ± 0.3 µM and 0.4 ± 0.4 µM respectively, P < 0.17, Fig. 5.2 B). No
additional differences were observed for individual unconjugated bile acids
between control, normocholanemic, and hypercholanemic mice of the same sex.
Sex differences were assessed for individual unconjugated bile acids in
animals of the same genotype/phenotype. In control mice, deoxycholic acid was
significantly elevated in females (0.5 ± 0.2 µM) compared with males (0.2 ± 0.2
µM) (P = 0.0026 Fig. 5.2 C). Deoxycholic acid was also higher in female
normocholanemic mice relative to male normocholanemic mice (1.0 ± 0.3 versus
0.3 ± 0.2 µM, P = 0.024, Fig 5.2 C). No sex-related differences were observed in
unconjugated bile acids of hypercholanemic mice (Fig. 5.2 C).
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Figure 5.2. Individual unconjugated serum bile acid concentrations grouped by sex
Comparing unconjugated bile acid species alpha muricholic acid (αMCA), beta muricholic acid
(βMCA), cholic acid (CA), and deoxycholic acid (DCA) between genotype/phenotype for A. Males
(n=5-6 mice per group). B. Females (n=3-5 mice per group). Results are presented as mean ±
SEM. Statistical differences were determined using one-way ANOVA with Tukey’s tests and
statistical significance between a and b: P < 0.02. C. Evaluating sex-related differences within
genotype/phenotype. Results are presented as mean ± SD. Statistical differences were
determined using Student’s t tests, * P < 0.05, ** P < 0.01.
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5.3.3

Individual serum conjugated bile acids
As NTCP is the major hepatic conjugated bile acid transporter, effects of

Slc10a1 disruption on serum conjugated bile acid concentrations were evaluated.
In male mice, serum TαβMCA concentrations were significantly elevated
in hypercholanemic animals relative to control and normocholanemic mice (25.2
± 23.2 µM versus 0.03 ± 0.03 µM and 0.4 ± 0.6 µM respectively, P < 0.022, Fig.
5.3 A). Although serum tauro-alpha and tauro-beta muricholic acid (TαβMCA)
concentrations appeared higher in female hypercholanemic mice relative to
female control and normocholanemic mice, differences did not reach significance
(P < 0.14). Serum taurocholic acid (TCA) concentrations were significantly
elevated in hypercholanemic mice regardless of biological sex. In male
hypercholanemic mice, serum TCA concentrations were 242.8 ± 170.5 µM,
compared to 0.2 ± 0.1 µM and 1.6 ± 2.4 µM in male control and
normocholanemic mice (P < 0.036, Fig. 5.3 A). In female hypercholanemic mice,
serum TCA concentrations were 251.5 ± 97.7 µM, compared to 0.4 ± 0.3 µM and
6.4 ± 6.7 µM in female control and normocholanemic mice, respectively (P <
0.0008, Fig. 5.3 B). Taurodeoxycholic acid concentrations were not significantly
different between males or females of different genotypes and phenotypes.
Sex differences were assessed for individual unconjugated bile acids in
animals of the same genotype/phenotype. No significant sex-associated
differences were observed for individual serum conjugated bile acids (Fig. 5.3 C).
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Figure 5.3. Individual conjugated serum bile acid concentrations grouped by sex
Comparing conjugated bile acid species tauro-alpha and tauro-beta muricholic acids (TαβMCA),
taurocholic acid (TCA), taurodeoxycholic acid (TDCA) between genotype/phenotype for A. Males
(n=5-6 mice per group). B. Females (n=3-5 mice per group). Results are presented as mean ±
SEM. Statistical differences were determined using one-way ANOVA with Tukey’s tests, and
statistical significance between a and b: P < 0.02. C. Evaluating sex-related differences within
genotype and phenotype groups. Results are presented as mean ± SD. Significant differences
were determined using Student’s t tests, * P < 0.05. Taurine-conjugated αMCA and βMCA
(TαMCA and TβMCA) are separate bile acids, however their concentrations were pooled as their
mass-to-charge (m/z) ratios and retention times during mass spectrometry detection were
indistinguishable, therefore they are represented together as TαβMCA.
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5.3.4

Overall serum unconjugated and conjugated bile acid
profiles
Based on total and individual bile acid measurements, our

hypercholanemic Slc10a1-/- mice have larger total bile acid pools than control,
which appears to be mainly attributed to a rise in conjugated bile acids in the
serum. To evaluate the relative abundance of conjugated bile acids in the sera,
percentages of conjugated and unconjugated bile acid species were determined.
Serum bile acid compositions of control mice were 30-38 ± 5-16%
conjugated (Fig. 5.4 A & B), whereas bile acids in normocholanemic mice were
slightly more conjugated at 52-71 ± 17-32% (Fig. 5.4 C & D). The bile acid pools
in the sera of hypercholanemic Slc10a1-/- mice dominated by conjugated species
(94 ± 4-5%, Fig. 5.4 E & F).
Differences in overall concentrations of unconjugated bile acids were
determined by comparing the sums of αMCA, βMCA, CA, and DCA. Overall
unconjugated bile acid concentrations were elevated in male hypercholanemic
Slc10a1-/- mice relative to control and normocholanemic males (14.2 ± 11.9 µM
versus 0.6 ± 0.4 µM and 1.2 ± 0.7 µM respectively, P = 0.016, Fig. 5.4 A, C, D &
Table 5.1). No significant differences were detected in overall unconjugated bile
acids between control, normocholanemic, and hypercholanemic females.
Differences in overall concentrations of conjugated bile acids were
determined by comparing the sums of TαβMCA, TCA, and TDCA. Overall
conjugated bile acids were markedly higher in hypercholanemic mice, reaching
significance in male and female groups. In males, conjugated bile acids in
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hypercholanemic mice were 275 ± 187.2 µM, compared to 0.3 ± 0.1 µM and 2.9
± 4.0 in control and normocholanemic animals (P < 0.0028, Fig. 5.4 A, C, E &
Table 5.1). In females, overall conjugated bile acids were 279.4 ± 109.2 µM in
hypercholanemic mice compared to 0.5 ± 0.3 µM and 9.2 ± 9.4 µM in control and
normocholanemic animals respectively (P < 0.009, Fig. 5.4 B, D, F & Table 5.1).
No significant differences were observed between control and normocholanemic
mice of either sex.
With regard to sex-associated differences, no differences in overall
conjugated or unconjugated bile acids were observed between male and female
Slc10a1-/- mice, regardless of bile acid phenotype (Table 5.2). In control mice,
female unconjugated bile acids were significantly elevated relative to males (0.5
± 0.3 µM versus 0.3 ± 0.1 µM respectively, P = 0.034, Table 5.2). No sex
differences in conjugated bile acids were observed in control mice (Table 5.2).
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94 ± 4%
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279.4 ±109.2 µM
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Figure 5.4. Overall serum unconjugated and conjugated bile acids
Unconjugated bile acids represent the sum of αMCA, βMCA, CA, and DCA. Conjugated bile acids
represent the sum of TαβMCA, TCA, and TDCA. Percentages were derived from the mean
micromolar concentrations of bile acids in the serum of mice ± SD (denoted in the graph
legends), n=3-6 mice per group.
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Table 5.1. Statistical differences in serum unconjugated and conjugated bile acid species
Males

Significance (P value)
Unconjugated
Conjugated

Females

Significance (P value)
Unconjugated
Conjugated

Control vs.
Slc10a1-/normocholanemic

ns (0.99)

ns (0.99)

Control vs.
Slc10a1-/normocholanemic

ns (0.99)

ns (0.98)

Control vs.
Slc10a1-/hypercholanemic

* (0.016)

** (0.0028)

Control vs.
Slc10a1-/hypercholanemic

ns (0.11)

*** (0.00020)

** (0.0022)

Slc10a1-/normocholanemic
vs. Slc10a1 -/hypercholanemic

ns (0.19)

*** (0.00090)

Slc10a1-/normocholanemic
vs. Slc10a1 -/hypercholanemic

* (0.016)

Statistical differences were determined using one-way ANOVA with Tukey’s tests, ns: not
significant

Table 5.2. Sex-related differences in unconjugated and conjugated serum bile acids
Males vs. Females
Control
Slc10a1-/- normocholanemic
Slc10a1-/- hypercholanemic

Significance (P value)
Unconjugated
Conjugated
* (0.034)
ns (0.066)
ns (0.055)
ns (0.15)
ns (0.64)
ns (0.97)

Statistical differences were determined using Student’s t tests, ns: not significant
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5.3.5

Overall serum muricholic acid and cholic acid profiles
Muricholic acids are more hydrophilic bile acid species, are less toxic, and

are weak agonists or antagonists of the master regulator of bile acid synthesis,
farnesoid X receptor (FXR) (Sayin et al., 2013). Cholic acid species are more
toxic and are more potent activators of FXR (Wang et al., 1999). The effects of
Slc10a1 disruption on serum muricholic acid and cholic acid species were
therefore evaluated.
The serum bile acid pools of control and normocholanemic mice were
composed of 22-35 ± 2-18% muricholic acids (Fig. 5.4 A-D). Serum bile acids of
hypercholanemic mice comprised 8-11 ± 6-7% muricholic acid species (Fig. 5.4
E & F). Bile acid pools of hypercholanemic mice were therefore dominated by
cholic acid species (89-92 ± 6-7%, Fig. 5.4 E & F).
Differences in overall concentrations of muricholic acids were determined
by comparing the sums of αMCA, βMCA, and TαβMCA. Differences in overall
concentrations of cholic acids were determined by comparing the sums of CA,
TCA, and TDCA. In females and males, no significant differences were observed
for concentrations of muricholic or cholic acids in control compared to
normocholanemic mice (Fig. 5.5 A-D & Table 5.3). In males, overall
concentrations of muricholic acids and cholic acids were significantly higher in
hypercholanemic mice (29.1 ± 22.8 µM and 260.4 ± 187.2 µM) compared to
control (0.4 ± 0.3 µM and 0.6 ± 0.2 µM) and normocholanemic mice (1.2 ± 0.7
µM and 2.9 ± 3.3 µM) (P < 0.0086, Fig. 5.5 & Table 5.3). In females, muricholic
acids and cholic acids were elevated in hypercholanemic mice (26.0 ± 21.2 µM
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and 272.6 ± 113.8 µM) relative to control (0.8 ± 0.4 µM and 1.4 ± 0.7 µM) and
normocholanemic mice (2.5 ± 2.2 µM and 9.0 ± 7.6 µM, Fig. 5.5). These
differences were significant (P < 0.035 Fig. 5.5 & Table 4.3) with the exception of
the differences in muricholic acids between female normocholanemic and
hypercholanemic, which did not reach significance (P = 0.088).
The only sex-related difference observed when comparing concentrations
of muricholic acids and cholic acids by genotype and phenotype was the
significantly higher cholic acid concentrations in female control mice relative to
male controls (1.4 ± 0.7 versus 0.6 ± 0.2 µM, P = 0.030, Table 5.4).
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0.4 ± 0.3 µM
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36 ± 5%
64 ± 5%

Control male (n=5)
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0.8 ± 0.4 µM
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1.4 ± 0.7 µM

Control female (n=5)
D.

C.

37 ± 18%
63 ± 18%

22 ± 2%

MCAs
1.2 ± 0.7 µM
CAs
2.9 ± 3.3 µM

78 ± 2%

Male Slc10a1-/normocholanemic (n=6)

Female Slc10a1-/normocholanemic (n=3)

E.

F.

11 ± 6%

89 ± 6%

MCAs
2.5 ± 2.2 µM
CAs
9.0 ± 7.6 µM

MCAs
29.1 ± 22.8 µM
CAs
260.4 ± 182.7 µM

Male Slc10a1-/hypercholanemic (n=5)

8 ± 7%

92 ± 7%

MCAs
26.0 ± 21.2 µM
CAs
272.6 ± 113.8 µM

Female Slc10a1-/hypercholanemic (n=5)

Figure 5.5. Overall serum muricholic acid species (MCAs) and cholic acid species (CAs)
Muricholic acid species are derived from muricholic acid and, in our study, represent the sum of
αMCA, βMCA, and TαβMCA. Cholic acid species are derived from cholic acid and represent, in
our study, the sum of CA, DCA, TCA, and TDCA. Percentages were derived from the mean
micromolar concentrations of bile acids ± SD, which are denoted in the graph legends.
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Table 5.3. Statistical differences in overall serum muricholic acid and cholic acid species
Males

Significance (P value)
Muricholic acids Cholic acids

Females

Significance (P value)
Muricholic acids Cholic acids

Control vs.
Slc10a1-/normocholanemic

ns (0.99)

ns (0.99)

Control vs.
Slc10a1-/normocholanemic

ns (0.98)

ns (0.99)

Control vs.
Slc10a1-/hypercholanemic

** (0.0086)

** (0.0036)

Control vs.
Slc10a1-/hypercholanemic

* (0.035)

*** (0.00040)

** (0.0028)

Slc10a1-/normocholanemic
vs. Slc10a1 -/hypercholanemic

ns (0.088)

** (0.0014)

Slc10a1-/normocholanemic
vs. Slc10a1 -/hypercholanemic

** (0.0074)

Statistical differences were determined using one-way ANOVA with Tukey’s tests, ns: not
significant

Table 5.4. Sex-related differences in overall serum muricholic acid and cholic acid
Males vs. Females
Control
Slc10a1-/- normocholanemic
Slc10a1-/- hypercholanemic

Significance (P value)
Muricholic acids
Cholic acids
ns (0.095)
* (0.030)
ns (0.17)
ns (0.10)
ns (0.83)
ns (0.90)

Statistical differences were determined using Student’s t tests, ns: not significant
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5.3.6

Hepatic bile acid synthesis gene expression
Different bile acid pool composition could be due to differential expression

of bile acid synthesis genes. In the liver, CYP7A1 is the rate-limiting enzyme for
bile acid synthesis. Bile acid synthesis is repressed through negative feedback,
where bile acid-binding to FXR induces production of small heterodimer partner
(SHP). Small heterodimer partner is a transcription factor that inhibits Cyp7a1
gene transcription (Chiang, 2009). Hepatic mRNA levels of genes involved in bile
acid synthesis were assessed to determine potential differences between mouse
groups.
No significant differences were observed in hepatic mRNA levels of
Cyp7a1 or Shp when comparing control and normocholanemic Slc10a1-/- mice
irrespective of sex (Fig. 5.6 A-D). In hypercholanemic mice, Cyp7a1 was
increased ~90-fold in male hypercholanemic mice relative to male control and
male normocholanemic mice, however this difference did not reach significance
(P < 0.068, Fig. 5.6 A). Levels of Cyp7a1 were not different in female
hypercholanemic mice relative to female control and female normocholanemic
mice (Fig. 5.6 C). Expression of Shp mRNA was significantly decreased in both
male and female hypercholanemic mice relative to control mice of the same sex
(P < 0.023, Fig. 5.6 B & D). Relative to normocholanemic mice, Shp mRNA was
decreased in male and female hypercholanemic mice. This difference was
significant in female mice (P = 0.025, Fig. 5.6 D) however did not reach
significance in males (P = 0.070, Fig. 5.6 B).
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Sex-related differences were observed between male and female
hypercholanemic mice. Levels of Cyp7a1 mRNA were increased and Shp mRNA
levels were decreased in male hypercholanemic mice relative to female
hypercholanemic mice (P < 0.016, Fig. 5.6 E & F). Although Cyp7a1 and Shp
mRNA levels appeared elevated in female relative to male mice in control and
normocholanemic groups, no significant sex-associated differences were
detected (Fig. 5.6 E & F).

200

P = 0.068

A.

B.

P = 0.067
128

1.5

16

Male control (n=3)

8

Male Slc10a1-/normocholanemic (n=3)

4
2

Male Slc10a1-/hypercholanemic (n=5)

1
0.5

Relative expression

D.

2.0
1.5

Female control (n=3)
Slc10a1-/-

Female
normocholanemic (n=3)
Female Slc10a1-/hypercholanemic (n=5)

1.0
0.5
0.0

Cyp7a1

E.

P = 0.070

ab
1.0

Male control (n=3)
Male Slc10a1-/normocholanemic (n=3)

0.5

b

1.5

Male Slc10a1-/hypercholanemic (n=5)

Shp

a
a

1.0

Female control (n=3)
0.5

b
0.0

Female Slc10a1-/normocholanemic (n=3)
Female Slc10a1-/hypercholanemic (n=5)

Shp

*

128

Relative expression

a

0.0

Cyp7a1

2.5

C.

Relative expression

32

Relative expression

Relative expression

64

64

Male control (n=3)
Female control (n=3)

32
16

Male Slc10a1-/- normocholanemic (n=3)

8

Female Slc10a1-/- normocholanemic (n=3)

4

Male Slc10a1-/- hypercholanemic (n=5)

2

Female Slc10a1-/- hypercholanemic (n=5)

1
0.5

F.

Cyp7a1

Relative expression

4

Male control (n=3)
Female control (n=3)

3

Male Slc10a1-/- normocholanemic (n=3)

2

Female Slc10a1-/- normocholanemic (n=3)
Male Slc10a1-/- hypercholanemic (n=5)

1

**
0

Female Slc10a1-/- hypercholanemic (n=5)

Shp

Figure 5.6. Hepatic mRNA expression of bile acid synthesis gene Cyp7a1 its
transcriptional repressor Shp
A. & B. Relative mRNA levels in male mice for A. Cyp7a1 and B. Shp. C. & D. Relative mRNA
levels in female mice for C. Cyp7a1 and D. Shp. Experiments were performed in triplicate and
results are presented as mean ± SEM, n=3-5 mice per group. Statistical differences were
detected using one-way ANOVA with Tukey’s tests, and statistical significance between a and b:
P < 0.05. E. & F. Sex-associated differences within genotype and phenotype groups for E.
Cyp7a1 expression. F. Shp expression. Experiments were performed in triplicate and results are
presented as mean ± SEM, n=3-5 mice per group. Statistical differences were determined using
Student’s t tests, * P = 0.016, ** P = 0.0010.

201

Within the liver, CYP8B1 is responsible for production of cholic acid, and
CYP27A1 is involved in the production of both cholic acid and muricholic acids
(Chiang, 2009). To elucidate whether differences in expression of these
synthesis genes may contribute to increased cholic acid species in the serum of
hypercholanemic mice, hepatic mRNA levels of Cyp8b1 and Cyp27a1 were
quantified.
In male and female hypercholanemic mice, Cyp8b1 mRNA levels were
significantly reduced relative to normocholanemic males and females (P < 0.019,
Fig. 5.7 A & C). Although Cyp8b1 levels in hypercholanemic mice also appear
decreased relative to Cyp8b1 levels in control mice, these differences did not
reach significance (P = 0.053, Fig. 5.7 A & C). Expression of Cyp27a1 mRNA
was significantly increased in hypercholanemic male mice relative to male control
and normocholanemic mice (P < 0.0004, Fig. 5.7 B). In female hypercholanemic
mice, the opposite was observed. Levels of Cyp27a1 were decreased in female
hypercholanemic mice relative females of different genotypes and phenotypes.
This decrease was significant relative to normocholanemic females (P = 0.011,
Fig 5.7 D), however the decrease in Cyp27a1 mRNA observed between female
hypercholanemic relative to female control mice did not reach significance (P =
0.050).
When assessing sex-related differences, both Cyp8b1 and Cyp27a1 were
significantly decreased in female hypercholanemic mice relative to male
hypercholanemic mice (P = 0.0060 & P < 0.0001 respectively, Fig. 5.7 E & F). No
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sex-associated differences were detected in control or normocholanemic mice
(Fig. 5.7 E & F).
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Figure 5.7. Hepatic mRNA expression of bile acid synthesis genes Cyp8b1 and Cyp27a1
A. & B. Relative mRNA levels in male mice for A. Cyp8b1 and B. Cyp27a1. C. & D. Relative
mRNA levels in female mice for C. Cyp8b1 and D. Cyp27a1. Experiments were performed in
triplicate and results are presented as mean ± SEM, n=3-5 mice per group. Statistical differences
were detected using one-way ANOVA with Tukey’s tests, and statistical significance between a
and b: P < 0.05. E. & F. Sex-associated differences within genotype and phenotype groups for E.
Cyp8b1 expression. F. Cyp27a1 expression. Experiments were performed in triplicate and results
are presented as mean ± SEM, n=3-5 mice per group. Statistical differences were determined
using Student’s t tests, * P = 0.0060, ** P < 0.0001.
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5.3.7

Hepatic expression of hepatic bile acid uptake transporters
Altered serum bile acid profiles may also be attributed to differential

expression of genes involved in hepatic uptake of bile acids. Therefore, we
determined expression of hepatic genes involved in bile acid uptake into the liver.
As expected, Ntcp mRNA levels were significantly decreased in
normocholanemic and hypercholanemic Slc10a1-/- mice relative to controls (P <
0.044, Fig. 5.8 A & C). No significant differences were observed in hepatic
expression of Oatp1b2 between mice of different genotypes & phenotypes for
either sex (Fig. 5.8 B & D). No sex associated differences were observed for
Oatp1b2 expression within genotype and phenotype groups (Fig. 5.8 E). Within
the hypercholanemic group, Ntcp mRNA expression was significantly decreased
in females relative to males (P = 0.021, Fig. 5.8 F).
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Figure 5.8. Hepatic mRNA expression of bile acid uptake transporter genes Ntcp and
Oatp1b2
A. & B. Relative mRNA levels in male mice for A. Ntcp and B. Oatp1b2. C. & D. Relative mRNA
levels in female mice for C. Ntcp and D. Oatp1b2. Experiments were performed in triplicate and
results are presented as mean ± SEM, n=3-5 mice per group. Statistical differences were
detected using one-way ANOVA with Tukey’s tests and statistical significance between a and b:
P < 0.05. E. & F. Sex-associated differences within genotype and phenotype groups for E. Ntcp
expression. F. Oatp1b2 expression. Experiments were performed in triplicate and results are
presented as mean ± SEM, n=3-5 mice per group. Statistical differences were determined using
Student’s t tests, * P = 0.021.
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Levels of the hepatic bile acid uptake transporter gene Oatp1a1 mRNA
were virtually undetectable in male and female hypercholanemic mice. The
reduced expression of Oatp1a1 mRNA was significant for male hypercholanemic
mice relative to male controls and normocholanemic mice (P < 0.034, Fig. 5.9 A),
however the observed decrease in Oatp1a1 mRNA in female hypercholanemic
mice relative to female control and normocholanemic mice did not reach
significance (P < 0.18, 0.036, Fig. 5.9 C). Levels of Oatp1a4 mRNA were
significantly higher in male hypercholanemic mice relative to male control and
normocholanemic animals (P < 0.010, Fig. 5.9 B). In female mice, the opposite
trend was observed; Oatp1a4 mRNA levels were decreased in hypercholanemic
mice relative to control and normocholanemic animals, however these
differences did not reach significance (P < 0.078, Fig. 5.9 D).
No detectable sex-related differences were observed for Oatp1a1 mRNA
expression within genotype and phenotype groups (Fig. 5.9 E). In control
normocholanemic mice, Oatp1a4 expression was higher in females than males.
This sex difference was significant in control animals (P = 0.011, Fig. 5.9 F),
however it did not reach significance for nomocholanemic animals (P = 0.19, Fig.
5.9 F). The opposite was observed in hypercholanemic mice; Oatp1a4 mRNA
expression was significantly higher in males relative to females (P = 0.0015, Fig.
5.9 F).
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Figure 5.9. Hepatic mRNA expression of bile acid uptake transporter genes Oatp1a1 and
Oatp1a4
A. & B. Relative mRNA levels in male mice for A. Oatp1a1 and B. Oatp1a4. C. & D. Relative
mRNA levels in female mice for C. Oatp1a1 and D. Oatp1a4. Experiments were performed in
triplicate and results are presented as mean ± SEM, n=3-5 mice per group. Statistical differences
were detected using one-way ANOVA with Tukey’s tests and statistical significance between a
and b: P < 0.04. E. & F. Sex-associated differences within genotype and phenotype groups for E.
Oatp1a1 expression and F. Oatp1a4 expression. Experiments were performed in triplicate and
results are presented as mean ± SEM, n=3-5 mice per group. Statistical differences were
determined using Student’s t tests, * P = 0.011, ** P = 0.0015.
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5.3.8

Hepatic expression of hepatic bile acid efflux transporters
Hepatic bile acid efflux is also an important determinant to bile acid

enterohepatic circulation and can affect serum bile acid concentrations.
Differences in mRNA levels for transporters involved in hepatic bile acid efflux
were therefore assessed.
With respect to canalicular efflux transporters, no significant differences
were observed in Bsep mRNA levels between male control, normocholanemic,
and hypercholanemic mice (Fig. 5.10 A). However, decreased Bsep mRNA
levels were observed in hypercholanemic females relative to female control and
normocholanemic mice (P = 0.0009, Fig. 5.10 C). Levels of Mrp2 mRNA were
decreased in male and female hypercholanemic mice relative to control and
normocholanemic animals of the same sex. These differences were significant (P
< 0.05) with the exception of the reduced Mrp2 expression observed between
male hypercholanemic and control animals, which did not reach significance (P =
0.055, Fig. 5.10 B).

209

E.
Relative expression

5

3

*

2

****

1
0

F.

*

4

Bsep

Relative expression

3

2

1

**
0

Mrp2

Figure 5.10. Hepatic mRNA expression of canalicular bile acid efflux transporter genes
Bsep and Mrp2
A. & B. Relative mRNA levels in male mice for A. Bsep and B. Mrp2. C. & D. Relative mRNA
levels in female mice for C. Bsep and D. Mrp2. Experiments were performed in triplicate and
results are presented as mean ± SEM, n=3-5 mice per group. Statistical differences were
detected using one-way ANOVA with Tukey’s tests and statistical significance between a and b:
P < 0.05. E. & F. Sex-associated differences within genotype and phenotype groups for E. Bsep
expression and F. Mrp2 expression. Experiments were performed in triplicate and results are
presented as mean ± SEM, n=3-5 mice per group. Statistical differences were determined using
Student’s t tests, * P < 0.042, ** P = 0.0014, **** P < 0.0001.
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Efflux transporters on the basolateral membranes of hepatocytes are also
indicative of bile acid signaling and dynamics and can influence serum bile acid
concentrations. In male hypercholanemic mice, although Mrp3 mRNA appeared
increased relative to male control and male normocholanemic mice, these
differences did not reach significance (p = 0.39, Fig. 5.11 A). Conversely, Mrp3
mRNA was nearly undetectable in livers of hypercholanemic female mice. Levels
of Mrp3 mRNA were significantly reduced in hypercholanemic female mice
relative to female control mice (P = 0.010, Fig 5.11 C), however this reduction did
not reach significance relative to control females (P = 0.056, Fig. 5.11 C).
Expression of Ostα was assessed, however mRNA levels were undetectable in
all animals. No detectable differences were observed in expression of Ostβ in
male mice between genotype and phenotype groups (Fig. 5.11 B). However,
Ostβ mRNA levels were significantly increased in female hypercholanemic mice
relative to female control and normocholanemic animals (P < 0.0048, Fig. 5.11
D).
With respect to sex-associated differences within genotype and phenotype
groups, no significant differences were observed for Mrp3. Although Mrp3 mRNA
levels appear reduced in female hypercholanemic mice relative to male
hypercholanemic mice, this difference did not reach significance (Fig 5.11 E).
Sex differences were observed in Ostβ mRNA levels, which were higher in
female mice with respect to males of the same genotype and phenotype. These
increases were significant in control and hypercholanemic animals (P < 0.0089,
Fig. 5.11 F), however significance was not reached for differences for Ostβ
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mRNA levels between male and female normocholanemic mice (P = 0.14, Fig.
5.11 F).
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Figure 5.11. Hepatic mRNA expression of basolateral bile acid efflux transporter genes
Mrp3 and Ostβ
Expression of Ostα was assessed but levels were undetectable in all mice. A. & B. Relative
mRNA levels in male mice for A. Mrp3 and B. Ostβ. C. & D. Relative mRNA levels in female mice
for C. Mrp3 and D. Ostβ. Experiments were performed in triplicate and results are presented as
mean ± SEM, n=3-5 mice per group. Statistical differences were detected using one-way ANOVA
with Tukey’s tests and statistical significance between a and b: P < 0.01. E. & F. Sex-associated
differences within genotype and phenotype groups for E. Mrp3 expression and F.
Ostβ.expression. Experiments were performed in triplicate and results are presented as mean ±
SEM, n=3-5 mice per group. Statistical differences were determined using Student’s t tests, ** P =
0.0089, *** P = 0.0005
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5.4

Discussion

Our study evaluated sex-dependent effects of Slc10a1 disruption on
serum bile acid composition and expression of hepatic bile acid synthesis and
transport genes. We found that Slc10a1 disruption results in excess serum
conjugated bile acids and increases the abundance of both muricholic and cholic
acid species in male and female hypercholanemic mice. No key differences were
detected in overall bile acid composition between sexes. Expression of Oatp1a1
mRNA was nearly undetectable in livers of male and female hypercholanemic
mice. Sex-related differences within control and normocholanemic Slc10a1-/mouse groups are consistent with previous studies. In contrast, the sex
differences in mRNA expression observed within hypercholanemic Slc10a1-/mice are opposite to what is reported in literature for wild type mice.
In wild type mice, serum bile acid concentrations are elevated in females
(Uchida et al., 1983; Turley et al., 1998), which has been attributed to increased
Cyp7a1 expression in female animals (Schwarz et al., 2001). However, in our
study, decreased hepatic mRNA levels of bile acid synthesis genes in female
hypercholanemic mice suggests repression of bile acid synthesis. Interestingly,
the opposite was observed in hypercholanemic male animals, who displayed
significant elevations in Cyp7a1 and Cyp27a1 mRNA levels. Despite these
differences, reduced mRNA levels of the transcriptional repressor Shp were
observed in both male and female hypercholanemic mice. It is therefore unlikely
that Shp is responsible for the differential Cyp7a1 and Cyp27a1 mRNA levels
observed between male and female hypercholanemic mice.
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We observed a shift toward cholic acid species in the sera of male and
female hypercholanemic mice relative to control and normocholanemic mice.
However, mRNA levels of the bile acid synthesis enzyme Cyp8b1 were reduced
in male and female hypercholanemic mice relative to normocholanemic and
control animals. Thus, it is unlikely that the observed increase in cholic acids is
due to increased Cyp8b1 activity within the liver. The bile acid most highly
elevated in sera of hypercholanemic mice was taurocholic acid, which is not
surprising as TCA is the prototypical substrate of NTCP (Greupink et al., 2012).
The striking increase in serum TCA concentrations in hypercholanemic mice is
most likely a result of reduced hepatic uptake of conjugated bile acids in these
animals. Contrary to findings by Mao et al., who observed persistently elevated
conjugated bile acids in some female hypercholanemic Slc10a1-/- mice relative to
hypercholanemic males (Mao et al., 2019), no sex differences in serum
conjugated bile acid concentrations were observed in our hypercholanemic
Slc10a1-/- animals.
Hepatic mRNA levels of many bile acid transporters were elevated in
female control and normocholanemic mice relative to males of their respective
genotypes and phenotypes. These sex related differences were significant for
Oatp1a4 and Bsep and Ostβ. This is consistent with previous studies, which
indicate increased Bsep, Oatp1a4, and Ostβ expression in wild type female mice
relative to males (Cheng et al., 2005; Sheng et al., 2017). Sexually dimorphic
expression of these transporters is likely the result of differences in hormonal
signaling (Cheng et al., 2006). Interestingly, sex associated differences in hepatic
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bile acid gene expression in our hypercholanemic mice are opposite to what is
was observed in our control and normocholanemic mice and to what is reported
in literature. Levels of hepatic Cyp7a1, Cyp27a1, Oatp1a4, and Bsep mRNA
were significantly lower in livers of female relative to male hypercholanemic mice.
This was not the case for Ostβ, although it remains unclear why female biased
Ostβ is maintained in hypercholanemic mice whereas female biased expression
of hepatic Cyp7a1, Cyp27a1, Oatp1a4, and Bsep are not.
Further studies will be necessary to elucidate exact pathways regulating
these sex differences in gene expression. One possible hypothesis involves the
interplays between bile acid signaling, the gut microbiome, sex hormones, and
nuclear receptor activity. A symbiotic relationship is observed between bile acids
and the gut microbiome. Bile acids modulate the gut microbiota through direct
antimicrobial effects, which alters the composition of the gut microbiome (Begley
et al., 2005). Alternatively, microbiota metabolize bile acids and, in doing so,
contribute to FXR regulation (Inagaki et al., 2006). In mice, sex differences have
been reported in the gut microbiome composition and in FXR signaling, which
has been associated with sex differences in hepatic bile acid gene expression
(Sheng et al., 2017).
Taken together, the likely reduction in bile acids in the intestine of
Slc10a1-/- mice may disrupt microbial composition and FXR signaling in a sexdependent manner. An elegant study by Weger et al. evaluated gene expression
in conventional and germ free mice and noted that the abolition of the gut
microbiome induced a feminized gene expression pattern in livers of germ free
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animals (Weger et al., 2019). Authors found that altered gut microbiomes in germ
free mice resulted in disrupted sex and growth hormone signaling, which are
imperative in establishing sexually dimorphic hepatic gene expression (Weger et
al., 2019). This hypothesis is supported by Mao et al.’s observation of
upregulated Sult2e1 the major estrogen sulfotransferase, in livers of male
hypercholanemic Slc10a1-/- mice (Mao et al., 2019).
Despite our observations of differences in bile acid synthesis and
transporter genes, similar overall phenotypes were observed for male and female
hypercholanemic mice. As Oatp1a1 mRNA levels are nearly absent in both male
and female hypercholanemic mice, we suggest that the inability of OATP1A1 to
compensate for absence of NTCP remains the driving factor for serum
hypercholanemia is Slc10a1-/- mice, regardless of biological sex.
In contrast to mice, bile acid concentrations in humans are generally
higher in males (Trottier et al., 2011; Xiang et al., 2012; Frommherz et al., 2016).
This is also reflected in human pathology by female-dominant gallstone formation
(Fisher and Yousef, 1973; Bennion et al., 1978) and hormonal induction of
cholestasis in genetically predisposed women (Wagner et al., 2009; Dixon and
Williamson, 2016). Additionally, biological sex, rather than CYP7A1 or OATP1B1
genotype, was identified as the most important determinant of bile acid synthesis
and composition in humans (Xiang et al., 2009).
Humans with inactive NTCP develop serum hypercholanemia and striking
elevations in conjugated bile acids. These elevations are most prominent in early
life (Vaz et al., 2015; Deng et al., 2016; Liu et al., 2017; Qiu et al., 2017), which
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corresponds with the hypercholanemic phenotype observed in our juvenile
Slc10a1-/- mice. Studies have not assessed sex differences in human cases of
NTCP deficiency, likely due to the rare nature of NTCP deficiency. However, the
sex differences in mRNA expression of important bile acid synthesis and
transport genes observed in our hypercholanemic mice suggest altered hormonal
and nuclear receptor signaling, which warrant further investigation in humans.
Importantly, many of these bile acid transporters are also central to drug
disposition and response (Giacomini et al., 2010), therefore disruptions in their
expression or function may alter drug disposition or predispose individuals to
adverse drug events.
In conclusion, we identified normocholanemic and hypercholanemic serum
bile acid phenotypes in male and female Slc10a1-/- mice. We determined that
biological sex does not influence bile acid pool composition in Slc10a1-/- mice,
regardless of normocholanemic or hypercholanemic phenotype. We observed
that sex-associated differences in mRNA levels of bile acid synthesis and
transport genes in control and normocholanemic mice reflect what is reported in
literature. Importantly, however, many of the sex related differences observed in
our hypercholanemic mice were opposite to what is found in wild type mice. Sexrelated differences in hepatic gene expression in NTCP-deficient humans should
be investigated to determine potential clinical relevance of our findings.
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6

Summary, future directions & conclusions

Aim 1
The primary aim of this chapter was to characterize the transport activity
and expression of missense human genetic variants of SLC10A1 in vitro. The
secondary objective was to use this data to determine whether seven in silico
prediction tools accurately predicted our observed in vitro NTCP transport
activity. We hypothesized that genetic variation would decrease transport activity
and expression of variant NTCP. We also hypothesized that predictions made by
in silico tools would reflect in vitro taurocholic acid transport, and that the ADMEoptimized tool would be the best predictor of rosuvastatin transport by variant
NTCP.
Of thirty-five previously uncharacterized NTCP variants, we identified
seven with nearly absent transport of the endogenous and drug substrates
taurocholic acid and rosuvastatin. These seven genetic variants produced the
following amino acid substitutions: P73T, L138P, F234L, S241F, R249W, R252S,
R252C. Although variant NTCP protein was detected in whole cell lysates, their
expression was virtually undetectable at the plasma membrane. Their absence at
the plasma membrane likely explains their loss of substrate transport. Sequence
alignments show that six of seven residues that were affected are located within
highly conserved regions, indicating their relative importance in the protein
function. Furthermore, in the case of these variants, mutant amino acid residues
have different properties than the original amino acid residue, which suggests
they may disrupt protein structure or function. Two variants, A3T and E342K,

223

showed modest but significant increases in taurocholic acid. Nearly 2-fold higher
rosuvastatin uptake was observed for the T171I variant. Interestingly, the G191R
variant show a substrate-specific effect; this variation did not affect TCA uptake,
however rosuvastatin uptake was markedly reduced. This may indicate that this
region or residue is important in rosuvastatin binding, whereas it is not important
in taurocholic acid binding.
In silico tools were moderate to good predictors of in vitro taurocholic acid
transport. Four of the seven employed tools accurately predicted deleterious
activity for all of the seven loss of activity and loss of plasma membrane
expression variants. The ADME-optimized in silico tool was no better than other
tools for predicting uptake of rosuvastatin by variant forms of NTCP. These
results suggest that in silico predictions are not robust enough to replace
functional assessment of SLC10A1 genetic variation in vitro.
Caveats of these in vitro characterization methodologies include the
laborious nature of experiments relative to the number of rare variants revealed
by next-generation sequencing. Novel, high-throughput methodologies that
characterize function and expression of thousands of variants show promise for
replacing these low throughput approaches (Matreyek et al., 2018). Additionally,
although we can infer that reduced activity is the result of reduced plasma
membrane expression, the exact mechanisms of decreased plasma membrane
expression remain unclear. Understanding the cellular localization of the variant
proteins that are not expressed at the plasma membrane could provide evidence
into the mechanisms of reduced trafficking or stability of these proteins.
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Currently, the appeal of using in silico functional predictions is to rank
variants from large datasets, such as next-generation sequencing data, for
functional characterization. One approach that may increase the utility of current
in silico prediction tools could be to generate predictions from multiple tools and
rank variants based on the number of tools that predict deleteriousness. Further
optimization of algorithms will be required to increase confidence of their
predictions.
A challenge of employing in silico tools to predict protein function is their
relevance in terms of drug disposition. With the exception of few novel tools
optimized using experimental data from drug studies, predictions are often based
on data relevant to the endogenous function of a protein. Optimization for
relevance to drug transport or metabolism is particularly challenging for multiple
reasons, including substrate specificity. One approach could be to optimize a
prediction tool based on known or predicted binding sites for a particular class of
drug.
Taken together, these results identify previously uncharacterized genetic
variants in human SLC10A1 that result in altered taurocholic acid and
rosuvastatin transport in vitro. The loss of function variants are likely the most
directly transferrable findings from this study, as homozygous loss of function
variation in SLC10A1 is associated with serum hypercholanemia and may disrupt
nutrient homeostasis. However, the variant that displays gain of rosuvastatin
transport could be beneficial in humans on rosuvastatin therapy, owing to the
potential increase in hepatic accumulation of rosuvastatin.
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Next steps involve defining the roles of these genetic variants in vivo, and
in particular, in human subjects. The variants characterized in this study are rare,
with global minor allele frequencies less than 0.5%, which explains why such
variants have not been previously characterized. However, frequencies of certain
genetic variants in SLC10A1 are higher in Asian populations (Ho et al., 2004;
Pan et al., 2011), reaching upwards of 7.5% minor allele frequency. Therefore,
the relevance of our findings may be of greater importance in individuals of Asian
descent. The most frequent and widely characterized NTCP variant, p.S267F,
was shown to have nearly abolished taurocholic acid transport in vitro (Ho et al.,
2004), yet a 4-fold gain of rosuvastatin transport relative to wild type (Ho et al.,
2006). These in vitro findings translate to humans homozygous for the p.S267F
variant as serum conjugated hypercholanemia (Liu et al., 2017) and increased
hepatic uptake of pravastatin (Lu et al., 2016), respectively. Our in vitro findings
represent an important step in identifying variants of potential clinical importance,
and future studies should evaluate the effects of these variations on bile acid
dynamics and rosuvastatin transport in human subjects. A summary of how in
silico and in vitro assays contribute to overall functional characterization of
important human genetic variants is displayed in Figure 6.1 (Russell and
Schwarz, 2020).
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Figure 6.1. Rare genetic variant discovery and characterization: from next-generation
sequencing to in vivo clinical relevance
First, next-generation sequencing is used to identify rare variants. This is done by sequence
mapping, which helps discover variants by comparing the patient sequencing data to that of a
reference genome. Using this approach, many rare variants of unknown clinical significance are
identified. Subsequent to this, we can employ in silico tools to help predict the function of these
rare variants, and low-throughput and high-throughput in vitro assays can be used to help
elucidate functional effects of these genetic variants. Ultimately, this can help inform which
variants should be tested in vivo for potential clinical relevance. Overall, the goal is to help identify
rare genetic factors that might contribute to disease and drug response (Russell and Schwarz,
2020).
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Aim 2
The primary objective of this chapter was to elucidate the effects of
genetic disruption of Slc10a1 in mice on serum bile acids and bile acid synthesis
and transporter gene expression. The secondary objective of this chapter was to
determine hepatic uptake of rosuvastatin in Slc10a1-/- mice. We hypothesized
that Slc10a1 disruption would result in conjugated serum hypercholanemia due
to a lack of compensatory hepatic bile acid uptake by non-NTCP transporters.
We also hypothesized that disruption of Slc10a1 would result in significantly
reduced hepatic uptake of rosuvastatin.
A bimodal bile acid phenotype was observed in our Slc10a1-/- mice, which
was not surprising given that two independent research groups also noted this
finding (Slijepcevic et al., 2015; Mao et al., 2019). In our study, bile acid
concentrations in the serum were >25-fold higher than physiological
concentrations in approximately 45% of Slc10a1-/- mice. The enlarged
gallbladders, bile deposits in bile canaliculi, and lack of prominent bile ducts in
hypercholanemic mice suggest disruption of gallbladder emptying. This would
decrease bile acid levels within the intestinal lumen, limiting food emulsification
and decreasing absorption of nutrients, which may explain persistent reductions
in body weights in these mice. The fasted state has been associated with
increased activity of important hepatic nuclear receptors PXR and CAR, and
decreased activity of FXR and VDR. Altered mRNA levels of bile acid genes in
our hypercholanemic Slc10a1-/- mice are consistent with these alterations in
nuclear receptor signaling (Fig. 6.2).
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Figure 6.2. Hypothesized alterations in nuclear receptor signaling in our hypercholanemic
Slc10a1-/- mice
The major findings in our hypercholanemic mice are reduced Oatp1a1, Bsep, and Shp
expression, along with elevated Oatp1a4 and Mrp4 expression. These changes are consistent
with upregulated PXR and CAR and downregulated FXR observed in the fasted state. Together
with reduced body weights, enlarged gallbladders, and serum hypercholanemia, it is likely that
reduced bile acids in the lumen of the intestine diminishes nutrient absorption in hypercholanemic
Slc10a1-/- mice, resulting in fasted state gene expression in the liver.
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Our hypothesis of serum conjugated hypercholanemia was therefore
supported in this subset of Slc10a1-/- mice. The virtual absence of hepatic
Oatp1a1 mRNA, an important bile acid transporter in rodents, supports the
hypothesis that OATP1A1 is an important compensatory pathway in Slc10a1-/mice exhibiting profound hypecholenemia. Bile casts in the kidneys, increased
renal expression of bile acid efflux transporters, and decreased renal expression
of bile acid uptake transporters were observed in these mice. These findings
suggest enhanced renal elimination of bile acids subsequent to accumulation of
bile acids in the serum, which may result in kidney toxicity. It is important to note
that a developmental defect in the formation of the bile duct system of
hypercholanemic mice cannot be ruled out. This is supported by bile cast
formation in the bile canaliculi, some hepatocyte swelling and necrosis, unformed
bile ducts, and markedly enlarged gallbladders. Although we did not directly
evaluate formation of the bile ducts in the present thesis, SLC10A1 has been
identified as a master regulator of genes in the liver (Yang et al., 2010) and its
disruption could impair proper formation of the biliary system.
Implications of this fasted phenotype in hypercholanemic Slc10a1-/- mice
may be important in humans. In humans, serum hypercholanemia is most
prominent in NTCP-deficient pediatrics (Vaz et al., 2015). Additionally, our
hypothesis of upregulated PXR and CAR in hypercholanemic mice due to fasting
could be important in humans with homozygous loss of function genetic variation
in SLC10A1, although this remains to be tested. PXR and CAR are particularly
important in drug metabolism (Wang et al., 2012), thus if these findings translate
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to humans, NTCP deficient individuals may be susceptible to altered
pharmacokinetics and pharmacodynamics for may drugs in clinical use. Such
individuals may require an enhanced dose of drug due to rapid drug metabolism
and inactivation. Conversely, for prodrugs, enhanced PXR or CAR-mediated
metabolism to the active drug could render an individual more susceptible to
toxicity or adverse drug events.
It remains unclear why only ~45% of Slc10a1-/- mice display this fastedlike phenotype. The remaining 55% of mice appear moderately affected in early
life, as observed by decreased body weights. However, their body weights
normalize with those of control mice by eight weeks of age. A potential
explanation for these major phenotypic differences is reduced maternal care in
early life. This is supported by the notion that hypercholanemic mice are able to
survive to ten weeks when hydrated with saline injections. It remains to be seen
whether these mice would survive long-term, and if so, whether their
hypercholanemia and altered gene expression would persist.
This aim relied on evaluating mRNA expression of bile acid genes
determine potential disruption of pathways in bile acid signaling. Although mRNA
is a good first step in understanding which genes might be affected, additional
methods are necessary to further validate these findings. Protein expression is
an important indicator of bile acid transporter function. Additionally, hepatic
concentrations of bile acids could assist in evaluating the extent of nuclear
receptor activation in these animals. Furthermore, quantification and serum
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biomarkers of bile acid synthesis and signaling would enhance our understanding
of disruptions in bile acid physiology in Slc10a1-/- mice.
For our secondary objective, our hypothesis of decreased hepatic
rosuvastatin uptake in Slc10a1-/- was not supported by our results. Liver-to-serum
concentrations of rosuvastatin were no different in ten-week-old Slc10a1-/- mice
relative to age-matched controls. Although we did not quantify serum bile acids in
these mice, these studies were conducted in ten-week-old mice. Our
hypercholanemic mice did not naturally survive passed seven weeks of age,
therefore we speculate that the Slc10a1-/- mice in the rosuvastatin study were
normocholanemic. Hepatic bile acid transporter mRNA expression in ten-weekold mice was no different in Slc10a1-/- mice relative to controls, providing further
evidence that these mice were normocholanemic. Normocholanemia.
The major limitations of extrapolating these results in the context of
humans are species differences in rosuvastatin uptake transporters when
comparing mice and humans. The presence of OATP1A isoforms in mouse
hepatocytes but not human hepatocytes is a major species difference that may
reduce the relevance of NTCP to rosuvastatin disposition in mice. Future studies
could co-administer an NTCP inhibitor and rosuvastatin in Oatp1a/1b-/- mice to
determine whether hepatic uptake of rosuvastatin is maintained by additional
transporters. Ultimately, studies should be performed in humans to determine
whether rosuvastatin disposition is affected by inhibition of NTCP. Studies in
humans with the p.S267F NTCP variation, which displays gain of statin transport
relative to wild type, showed that this variant enhanced systemic clearance of
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pravastatin, which is another hydrophilic statin (Lu et al., 2016). These results
provide the basis to hypothesize that pharmacological inhibition or genetic
deficiency in NTCP will alter hepatic uptake of rosuvastatin in humans.
In mice, OATP1A isoforms and OATP1B2 appear important for
rosuvastatin disposition, whereas NTCP and OATP2B1 do not (DeGorter et al.,
2012; Iusuf et al., 2013; Medwid et al., 2019). To determine the importance of
NTCP to rosuvastatin transport in humans, clinical studies using coadministration
of rosuvastatin and a selective inhibitor of the important rosuvastatin
transporters, OATP1B1 and OATP1B3, will be required. It is likely that genetic
deficiency or pharmacological inhibition of NTCP alone will not be clinically
important to rosuvastatin disposition in humans, as OATP1B1 and OATP1B3 will
maintain hepatic rosuvastatin uptake. However, the role of NTCP in rosuvastatin
uptake into hepatocytes may become more important in genetic deficiency of
hepatic OATPs or their pharmacological inhibition. Furthermore, as NTCP
inhibitors are becoming important in treating hepatitis B and D, and further
therapeutic indications relative to select forms of cholestasis or metabolic
conditions are being evaluated, this may enhance the incidence of drugtransporter interactions involving NTCP and OATPs.

Aim 3
The objective of this aim was to examine sex-related differences in serum
bile acid composition and hepatic bile acid gene expression in Slc10a1-/- mice.
Our first hypothesis was that mRNA expression of bile acid synthesis genes
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would be elevated in female mice, resulting in increased serum bile acid
concentrations. We also hypothesized that sex differences in bile acid transporter
expression observed in wild type mice would be conserved in our Slc10a1-/- mice.
Our results did not support these hypotheses.
Overall, serum bile acid pool concentrations did not significantly differ
between males and females. Sexual dimorphisms in bile acid synthesis and
transporter mRNA expression in control and normocholanemic mice were
consistent with literature (Cheng et al., 2005; Sheng et al., 2017). However, sexassociated expression of bile acid synthesis and transport genes in
hypercholanemic mice were largely opposite of what was expected. Expression
of Cyp7a1, which has been linked to increased bile acid synthesis in female mice
(Schwarz et al., 2001), was increased in male hypercholanemic mice rather than
female hypercholanemic mice. Additionally, Oatp1a4 and Bsep are femaledominant genes, which was reflected in our control and normocholanemic mice.
However, Oatp1a4 and Bsep mRNA levels were significantly reduced in female
hypercholanemic mice relative to male hypercholanemic mice. These findings
suggest potentially dysregulated hormonal signaling in our hypercholanemic
mice, resulting in feminization of liver gene expression in hypercholanemic males
and defective sexual dimorphism in hypercholanemic females.
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Figure 6.3. Female-dominant gene expression in healthy and hypercholanemic mice
In healthy, C57BL/6 mice and additional strains of mice, there is female-dominant expression of a
variety of genes, including Cyp7a1, Oatp1a4, and Bsep. When tested in our Slc10a1-/- mice,
opposite sexual dimorphism was observed in our mice with hypercholanemia. Livers of female
hypercholanemic Slc10a1-/- mice show patterns consistent with male sex hormone expression,
whereas livers of male hypercholanemic Slc10a1-/- mice appear feminized by the increased
expression of female-dominant genes. Although not tested directly in this thesis, potential
explanations may involve altered bile acids within the intestine, which affect the gut microbiome
and hormonal signaling.
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Despite these differences, Oatp1a1 mRNA was nearly undetectable in
female and male hypercholanemic mice. Similarities in bile acid composition and
concentrations, alongside virtually absent Oatp1a1 mRNA, suggest that the sex
differences in bile acid synthesis and transporter genes are not inherently
important for the development of hypercholanemia in Slc10a1-/- mice.
Although we speculate that reduced bile acids in the intestinal lumen may
affect FXR and sex hormone signaling, additional studies are necessary to
confirm this. Concentrations of estrogens and androgens should be measured in
the serum and liver of these animals to determine potential alterations in sex
hormones. Additionally, replicating hepatic concentrations of bile acids in
hypercholanemic males and females and assessing the activation of estrogen
and androgen receptors by these bile acid pools could reveal potential sex
differences in bile acid signaling.
A high degree of variability was observed in serum bile acid
concentrations and in mRNA levels of certain bile acid genes for mice within the
same group. As the number of mice per group was relatively low (n=3-6 for the
majority of comparisons), this variability could hinder potential significant
differences in findings. Studies in larger cohorts of mice may be of more benefit
to determine statistical differences.
Sex related differences have not been reported in human cases of NTCP
deficiency, however there is a paucity of data surrounding NTCP deficient
humans. In an aging study, Mao et al. determined that certain female Slc10a1-/mice remain hypercholanemic at 20 months of age, whereas this was not
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observed in male Slc10a1-/- mice. Our findings of sex-related differences in
hepatic mRNA expression of bile acid and drug transporters in Slc10a1-/- mice
warrant studies to determine whether these changes translate to humans. The
altered gene expression we see in these mice involve a variety of genes
important in additional physiological functions, including drug metabolism.

6.1

Conclusions

The hypothesis of this study was that genetic variation in SLC10A1 would
decrease bile acid and rosuvastatin transport. Our hypothesis was both
supported and refuted by in vitro data, where some variants are gain of function
and others show loss of function to transport taurocholic acid or rosuvastatin. Our
in vivo studies show that disruption of SLC10A1 in mice reduced bile acid uptake
and altered expression of a variety of important bile acid and drug disposition
genes in a subset of Slc10a1-/- mice. Our findings in Slc10a1-/- mice also suggest
that NTCP is not important for hepatic rosuvastatin uptake in mice.
NTCP is recognized as an important hepatic bile acid uptake transporter
that is also capable of in vitro transport of rosuvastatin and integral to hepatitis B
and D uptake into the liver (Ho et al., 2006; Dawson et al., 2009; Yan et al.,
2012). Evidence suggests genetic variation in SLC10A1 and pharmacological
inhibition of NTCP mediate serum hypercholanemia and may potentiate
malnutrition subsequent to altered bile flow (Vaz et al., 2015; Deng et al., 2016;
Liu et al., 2017; Qiu et al., 2017; Blank et al., 2018). Bioinformatic analysis of
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gene pathways in human liver samples have identified SLC10A1 as a master
regulator of gene expression for cytochrome P450 and bile acid synthesis
enzymes (Yang et al., 2010). These important functions have heightened the
interest in understanding effects of SLC10A1 disruption on bile acid homeostasis
and pharmacotherapy.
The studies in this thesis contribute to a better understanding of molecular
changes observed in NTCP deficiency. Ultimately, these findings will provide the
basis for subsequent evaluation of genetic deficiency and pharmacologic
modulation of human NTCP and associated impacts on bile acid dynamics,
nuclear receptor signaling, and substrate drug response.
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Appendices

Appendix A. Supplemental data

Serum bile acids and gene array data for female Slc10a1-/- mice
Description of female mice used in this study: One hypercholanemic KO mouse
with low body weight, lethargy, hunched posture, and blood in urine was treated
with subcutaneous fluids every two days for one week, from the age of five to six
weeks postnatal. The condition of this mouse objectively improved, observed by
increased body weight and increased locomotion. At 9 weeks of age, the total
serum bile acid concentration for this mouse was 97µM. This mouse was
deemed hypercholanemic and was sacrificed alongside a normocholanemic
Slc10a1-/- mouse that survived 9 weeks without subcutaneous intervention whose
total serum bile acid concentration was 12µM. Additionally, three age-matched
controls were sacrificed. RNA was extracted from livers of these five mice for
subsequent gene array analysis by the Affymetrix GeneChip 2.0 at Robarts
Research Institute. Bile acid concentrations and gene expression are presented
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Appendix A. Figure 1. Total serum bile acid concentrations in 4-6-week-old control (n=3) and
normocholanemic (n=1) and hypercholanemic (n=1) Slc10a1-/- mice.
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Appendix A Figure 2. Individual serum bile acid concentrations in 4-6-week-old control (n=3)
and normocholanemic (n=1) and hypercholanemic (n=1) Slc10a1-/- mice.
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Appendix A. Figure 3. Gene transcript levels for Cyp2a genes in three control, one
normocholanemic Slc10a1-/- mouse (KO normocholanemic), and one hypercholanemic Slc10a1-/mouse (KO Hypercholanemic) determined by liver gene array.
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Appendix A. Figure 4. Gene transcript levels for Cyp3a genes in three control, one
normocholanemic Slc10a1-/- mouse (KO normocholanemic), and one hypercholanemic Slc10a1-/mouse (KO Hypercholanemic) determined by liver gene array.
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Appendix A. Figure 5. Gene transcript levels for Cyp4a genes in three control, one
normocholanemic Slc10a1-/- mouse (KO normocholanemic), and one hypercholanemic Slc10a1-/mouse (KO Hypercholanemic) determined by liver gene array.
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Appendix A. Figure 6. Gene transcript levels for additional Cyp genes in three control, one
normocholanemic Slc10a1-/- mouse (KO normocholanemic), and one hypercholanemic Slc10a1-/mouse (KO Hypercholanemic) determined by liver gene array.
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Appendix A. Figure 7. Gene transcript levels for Sult genes in three control, one
normocholanemic Slc10a1-/- mouse (KO normocholanemic), and one hypercholanemic Slc10a1-/mouse (KO Hypercholanemic) determined by liver gene array.
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Appendix B. Mouse necropsy reports
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Oct. 25, 2017
Necropsy report
Description: 2 juvenile male mice are presented live for necropsy and subsequently euthanized by
isofluorane gas. Both are hunched, but ambulatory. Hair coat and skin are apparently normal. Teeth are
aligned and show no malocclusion. Each mouse will be described below under ‘small’ and ‘large’ which
denotes their relative size.
Sm all: The thymus is not apparent. The gall bladder is moderately distended and filled with
green/brown clear fluid. The common bile duct is not prominent. The stomach is filled with ingesta and
the intestines are filled with digesta with formed fecal material in the distal colon. There are no
significant lesions of the major organs including the liver, spleen, kidney, adrenal glands, stomach, and
intestines. There are likewise no significant lesions of the heart, lung, and brain. Body fat is minimal,
but there is no apparent serous atrophy.
Large: The thymus is present. The gall bladder is markedly enlarged and filled with clear green to black
fluid. The gall bladder extends approximately 3mm beyond the edge of the right medial lobe. The
common bile duct is not prominent. The stomach is filled with ingesta and the intestines are filled with
digesta with formed fecal material in the distal colon. Similar to the small mouse, there are no
significant lesions of the major organs including the liver, spleen, kidney, adrenal glands, stomach, and
intestines. There are likewise no significant lesions of the heart, lung, and brain. Body fat is minimal,
but there is no apparent serous atrophy.
Preliminary diagnosis: Cholangiectasis
Interpretation: Consistent with reported previous findings, the gall bladder is enlarged. There are no
secondary gross abnormalities that would suggest an ongoing severe pathologic process, such as
inflammation. Lymph nodes are not prominent, which supports a non-reactive state. The
gastrointestinal system contains abundant ingesta and digesta, which indicates robust appetite and
digestive capability. The underconditioned state (low body fat) could reflect possible previous negative
energy balance (i.e. off feed), conditions that prevents adequate nutritional absorption and/or a
catabolic state. The reason for ill-thrift and hunched posture is not yet clear.
Thank you for the opportunity to necropsy the two mice. Please don’t hesitate to contact me with any
questions or comments.
Patti Kiser, MS, DVM, PhD
Assistant Professor
Western University
Department of Pathology and Laboratory Medicine
Schulich School of Medicine & Dentistry
DSB4039
London ON N6A 3K7
Phone: 519-661-2111 Ext. 85351
Email: pkiser@uwo.ca
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Oct. 26, 2017
Necropsy report
Description: A female juvenile mouse is presented live for necropsy and subsequently euthanized by
isofluorane gas. Similar to the mice necropsied on October 25th, 2017, this mouse is hunched, but
ambulatory. Hair coat and skin are apparently normal. Teeth are aligned.
The thymus is present. The gall bladder is moderately enlarged and filled with clear green to black fluid.
The common bile duct is not prominent. Compression of the gall bladder does not release bile into the
duodenum. The stomach is filled with ingesta and the intestines are partially, but uniformly filled with
digesta with formed fecal material in the distal colon. Similar to the previous necropsied mice, there are
no significant lesions of the major organs including the liver, spleen, kidney, adrenal glands, stomach,
and intestines. There are likewise no significant lesions of the heart, lung, and brain.
Preliminary diagnosis: Cholangiectasis
Interpretation: Consistent with the previous necropsies, the gall bladder is enlarged. Likewise, there
are no secondary gross abnormalities that would suggest an ongoing severe pathologic process. Bile
duct patency is difficult to test in small animals such as the mouse. The reason for ill-thrift and hunched
posture is not yet clear.
Thank you for the opportunity to necropsy the mouse. Please don’t hesitate to contact me with any
questions or comments.
Patti Kiser, MS, DVM, PhD
Assistant Professor
Western University
Department of Pathology and Laboratory Medicine
Schulich School of Medicine & Dentistry
DSB4039
London ON N6A 3K7
Phone: 519-661-2111 Ext. 85351
Email: pkiser@uwo.ca
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Oct. 30, 2017
Necropsy report
Description: A 4 week old male mouse is presented live for necropsy and subsequently euthanized by
isofluorane gas. Similar to the mice necropsied on October 25 and 26, 2017, this mouse is hunched, but
ambulatory. Subjectively, the mouse is more mobile than previous mice. Hair coat and skin are
apparently normal. Teeth are aligned.
The thymus is present. The gall bladder is markedly enlarged, extending approximately 3mm from the
edge of the right medial lobe, and filled with clear green to black fluid. The common bile duct is not
prominent. The stomach is filled with ingesta and the intestines are partially, but uniformly filled with
digesta with formed fecal material in the distal colon. Similar to the previous necropsied mice, there are
no significant lesions of the major organs including the liver, spleen, kidney, adrenal glands, stomach,
and intestines. There are likewise no significant lesions of the heart, lung, and brain.
Preliminary diagnosis: Cholangiectasis
Interpretation: Consistent with the previous necropsies, the gall bladder is enlarged. Likewise, there
are no secondary gross abnormalities that would suggest an ongoing severe pathologic process.
Histopathology may be helpful for assessing microscopic lesions. After fresh tissue harvesting for
research purposes, organs were collected and infused with formalin when appropriate (intestines, lungs,
heart). These tissues were placed in fixative for future trimming.
Thank you for the opportunity to necropsy the mouse. Please don’t hesitate to contact me with any
questions or comments.
Patti Kiser, MS, DVM, PhD
Assistant Professor
Western University
Department of Pathology and Laboratory Medicine
Schulich School of Medicine & Dentistry
DSB4039
London ON N6A 3K7
Phone: 519-661-2111 Ext. 85351
Email: pkiser@uwo.ca
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Society of Pharmacology & Therapeutics, Canadian Society for Pharmaceutical
Sciences, and Canadian Chapter for Controlled Release Society in Toronto,
Canada, May 22-25, 2018
William Mahon Oral Presentation Award, presented by the Canadian Society of
Pharmacology & Therapeutics at the 2016 Safety Pharmacology
Society/Canadian Society of Pharmacology & Therapeutics/Japanese Safety
Pharmacology Society Joint Meeting in Vancouver, Canada, September 18-21,
2016
Publications:
Russell LE, Zhou Y, Lauschke VM, Kim RB. 2020. In vitro functional
characterization and in silico prediction of rare genetic variation in the bile acid
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and drug transporter, Na+-taurocholate co-transporting polypeptide (NTCP,
SLC10A1). Mol Pharm 17(4):1170-81.
Russell LE and Schwarz UI. 2020. Variant discovery using next-generation
sequencing and its future role in pharmacogenetics. Pharmacogenomics
21(7):471-86.
Russell LE & Schleiff MA, Gonzalez E, Bart AG, Broccatelli F, Durmus S,
Hartman JH, Humphreys WG, Lauschke VM, Martin I, Nichols C, Nwabufo C,
Prasad B, Scott EE, Segall M, Takahashi R, Taub ME and Sodhi JK. 2020.
Advances in the Study of Drug Metabolism – Symposium Report of the 12th
Meeting of the International Society for the Study of Xenobiotics (ISSX). Drug
Metab Rev 52(3):395-407.
Abstracts presented as oral presentations at conferences:
“Genetic variation in the hepatic bile acid and drug transporter, NTCP:
expression, transport, and in silico functional prediction”, London Health
Research Day, London, Canada, April 30, 2019
“Function & expression of rare genetic variants in bile acid and drug transporter
NTCP”, Drug Safety and Effectiveness Cross-Disciplinary Training Program
Annual Symposium, Toronto, Canada, April 10-12, 2019
“In vitro characterization of genetic variation in the bile acid transporter NTCP”
Canadian Society of Pharmacology & Therapeutics Annual Meeting, Halifax,
Canada, June 14- 16, 2017
“Elucidating the impact of genetic variation in bile acid transporters on bile acid
and xenobiotic transport”, 2016 Safety Pharmacology Society/Canadian Society
of Pharmacology & Therapeutics/Japanese Safety Pharmacology Society Joint
Meeting, Vancouver, Canada, September 18-21, 2016
Abstracts presented as poster presentations at conferences:
“In vitro characterization and in silico prediction of rare genetic variants in bile
acid and drug transporter, NTCP”. Physiology & Pharmacology Annual Research
Day, Western University, London, Canada, November 5, 2019
“In vitro functional characterization of rare genetic variants in bile acid and drug
transporter, NTCP”, International Society for the Study of Xenobiotics (ISSX)
12th International Meeting, Portland, Oregon, USA, July 28-31, 2019
“Investigating the mechanisms of bile acid-mediated organ toxicity in Ntcp
(Slc10a1) knockout mice”, Physiology & Pharmacology Annual Research Day,
Western University, London, Canada, November 6, 2018
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“Investigating the effect of the gut microbiome on pharmacokinetics”, Genentech
Intern Poster Day, South San Francisco, August 8, 2018
“Investigating the mechanisms of bile acid-mediated organ toxicity in Ntcp
(Slc10a1) knockout mice”, Joint Meeting of Canadian Society of Pharmacology &
Therapeutics, Canadian Society for Pharmaceutical Sciences, and Canadian
Chapter for Controlled Release Society, Toronto, Canada, May 22-25, 2018
“In silico prediction of functional genetic variation in the hepatic bile acid
transporter NTCP”, Joint Drug Safety & Effectiveness Cross-Training Program
and the International Society for Pharmacoepidemiology, Toronto, Canada, April
22-25, 2018
“In silico prediction of functional genetic variation in the hepatic bile acid
transporter NTCP”, Physiology & Pharmacology Research Day, Western
University, London, Canada, November 7, 2017
“The functional role of genetic variation in the bile acid transporter NTCP”,
London Health Research Day, London, Canada, March 28, 2017
“Elucidating the physiological impact of genetic variation in bile acid
transporters”, Physiology & Pharmacology Research Day, Western University,
London, Canada, November 1, 2016
Invited seminar presentations:
“Epigenetic regulation of bile acid transport”, Clinical Pharmacology Journal Club,
Western University, London, Canada, March 26, 2020 *Cancelled due to COVID19
“Biomarkers of Hepatic Drug Transporter Function: Improving Drug Development
and Patient Therapy”, Drug Safety & Efficacy Cross Disciplinary Training
Program Objective Structured Knowledge Translation Experience, Online, March
24, 2020
“Phosphorylation, bile acid homeostasis, and primary biliary cirrhosis”, Clinical
Pharmacology Journal Club, Western University, London, Canada April 18, 2019
“Effective use of genomic data & applications for drug therapy”, Drug Safety &
Efficacy Cross Disciplinary Training Program Objective Structured Knowledge
Translation Experience, Online presentation, March 22, 2019
“Investigating the effect of the gut microbiome on pharmacokinetics: Genentech
summer internship”, Clinical Pharmacology Grand Rounds, Western University,
London, Canada, October 31, 2018
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Discussing the journal article “FXR Agonists OCA and CDCA Increase Bile Acid
Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and
Mechanisms”, by Guo et al., Clinical Pharmacology Journal Club, Western
University, London, Canada, March 22, 2018
“Elucidating the effects of genetic variation in hepatic bile acid & drug uptake
transporter, NTCP”, Clinical Pharmacology Grand Rounds, Western University,
London, Canada, March 7, 2018
Related Work Experience:
Genentech Summer Intern, June – September 2018
Research internship in the department of Drug Metabolism and
Pharmacokinetics at Genentech, South San Francisco, USA.
Research project: determining the role of the gut microbiome on the
pharmacokinetics and metabolism of two Genentech compounds in rodent
models of gut microbiome depletion
Experience using Phoenix Win-Nonlin, antibiotic-induced knockdown of gut
microbiome in mice and rats, germ-free mice, microsomal stability assays,
aerobic and anaerobic stool culture incubations, LC/MS
Teaching Assistantships:
Physiology & Pharmacology 4980E: Seminar & Research Project, 2018 – 2020
A major laboratory project in Physiology or Pharmacology, which emphasizes
experimental design, instrumentation, collection/analysis of data and
communication of experimental results by oral, poster, and written presentations
Responsibilities: attend classes, presentations for class workshops, assist in
developing research skills among students, grade assignments, administrative
duties
Pharmacology 3620: Human Pharmacology & Therapeutic Principles, 2016 –
2018
Full year systems-based pharmacology course that examines drugs used to treat
diseases that affect various organs of the body
Responsibilities as teaching assistant: Attend classes, answer student questions
pertaining to course material, perform course review sessions, proctor exams
Pharmacology 2060: Introductory Pharmacology & Therapeutics, Jan. – Apr.
2016
Online course to assist in understanding fundamentals of drug action
Responsibilities: Answer student questions pertaining to lecture material, proctor
exams

259

